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Pumilio (Pum) is a sequence-specific RNA-binding protein (RBP) that recognizes 
Pum Response Elements (PREs) in the 3'UTR of target mRNAs. Pum represses an 
extensive network of mRNAs to control embryogenesis, stem cell maintenance, fertility, 
and neurological function in Drosophila. Moreover, Pum orthologs have roles in cancer, 
neurodegeneration, ataxia, and epilepsy. Given these crucial functions, the primary goal 
of my thesis research has been to identify the mechanisms of mRNA regulation by Pum. 
Pum accelerates degradation of target mRNAs, and this activity is primarily caused by 
three repression domains (RDs) in the protein's N terminus. The RDs are unique to Pum 
and its orthologs, and can function autonomously when directed to a reporter mRNA. 
Each Pum RD causes repression and mRNA degradation, and I found that their activity 
requires the Ccr4-Not (CNOT) deadenylase complex. The Not1 scaffold and Pop2 
deadenylase subunits of CNOT are crucial for Pum RD-mediated repression. Moreover, 
Pop2's catalytic activity is necessary to rescue RD function, indicating that Pum RDs 
require the deadenylation activity of CNOT. Our biochemical data reveal that multiple 
regions of Pum recruit CNOT to target mRNAs, including the three N-terminal RDs, and 
the C-terminal RNA-binding domain. Consistent with this model, the ability of Pum to 
accelerate decay of target mRNAs requires CNOT. I also observed that decapping factors 
participate in repression by the Pum N terminus. Together, the data reveal that Pum 
utilizes multiple mRNA decay pathways to repress target mRNAs. Ongoing work includes 
studying the relevance of the RDs in vivo during embryogenesis using transgenic flies 
with deletions in one or more RD. 
These mechanistic insights into Pum repression may shed light on its 
combinatorial regulation with other RBP partners, such as Nanos (Nos). We previously 
showed that Pum and Nos bind cooperatively to RNA, thereby strengthening repression 
of mRNAs. In collaboration with Traci Hall at NIEHS and Zachary Campbell at UT Dallas, 
we reported the structure and specificity of the Pum-Nos-RNA complex. Nos binds Pum 
and nucleotides upstream of the PRE, strengthening its RNA binding and repression 
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activities. I contributed to the validation of Nos-Pum contacts through mutagenesis, and 
cell-based experiments demonstrating that Nos can expand Pum’s target repertoire and 
confer repression to canonically weak PREs. To expand on our molecular studies of Pum 
and Nos, we also integrated transcriptome-wide analyses and bioinformatics predictions 
to assess their global impacts on gene regulation. Taken together, these findings support 
the potential for pervasive, dynamic post-transcriptional control by these RBPs both 




CHAPTER 1  
Post-Transcriptional Gene Regulation 
 
Portions of this chapter were adapted from Post-transcriptional mechanisms in 
Endocrine regulation, Chapter 1 (by Arvola et al. 2016): “Mechanisms of post-
transcriptional gene regulation” (Springer publishing); co-authors included Elizabeth 
Abshire, Jennifer Bohn and Dr. Aaron Goldstrohm. 
 
1. Post-transcriptional gene regulation 
The same genomic sequence is present in every cell of an organism, but this 
information is utilized with many permutations to diversify cell types and functions. When 
a gene is transcribed from the DNA genome to messenger RNA (mRNA), it is subject to 
many layers of processing and quality control, including co-transcriptional capping and 
splicing, coating with RNA binding proteins (RBPs), polyadenylation, nuclear export, 
cytoplasmic localization, translation and decay, with all of these steps being themselves 
subject to regulation. Post-transcriptional regulation (PTR) encompasses these steps. 
 
1.1 Nuclear mRNA processing and export 
The life of an mRNA begins in the nucleus, where it transcribed from genomic DNA 
by RNA polymerase II (RNAP II). Transcribed mRNAs are then subject to splicing and 
modification, followed by export from the nucleus to the cytoplasm for translation. Nuclear 
mRNA processes will be described in this section. All of these events are crucial to the 
eventual expression of the encoded protein.  
 
1.1.1 Splicing: mechanism and regulation 
Splicing can occur either co- or post-transcriptionally, removing non-coding introns 
from the transcript and splicing together the exons that make up the coding sequence and 
5’ and 3’ untranslated regions (UTRs). This conserved process is catalyzed by the 
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spliceosome, a large, dynamic ribonucleoprotein complex made up of over 100 proteins 
in metazoans, and several small nuclear RNAs (snRNAs) [1]. U2 and U6 snRNAs confer 
catalysis through coordination of metal ions and positioning the 3' and 5' exons, while U5 
aids in positioning the 5' exon and 5' splice site selection [2]. Other RNA and protein 
cofactors provide additional structural support and sequence recognition. The 
spliceosome transitions through at least six different conformations, with varying cofactor 
composition; these transitions are facilitated by ATP-dependent helicases. Splicing 
catalysis occurs through two transesterification reactions and can be broken down into 
two steps: branching and ligation. In the branching step, the intron lariat structure is 
formed through nucleophilic attack of branch point adenosine 3'OH on the 5' splice site 
guanosine phosphate. The 5' and 3' exons are then joined through ligation, releasing the 
intron lariat [2]. 
Proper splicing can be crucial to the eventual expression of the mRNA, as mis-
spliced mRNAs can be targets of nonsense-mediated decay (NMD), a process 
potentiated through the presence of a premature stop codon [3, 4]. Splicing encompasses 
different layers of regulation by many protein cofactors, which can vary between tissues 
and cellular contexts. The SR family of proteins is one example, which coat mRNA to help 
regulate splicing and nuclear export [5]. SR protein can stimulate splicing through 
recognition of exonic splicing enhancers and recruitment of the spliceosome, but can also 
function as suppressors through binding intronic regions; moreover, SR protein function 
is diversified through other interacting RNA binding proteins (RBPs).  Adding yet another 
layer of regulation, SR protein function is modulated through phosphorylation by SR 
protein kinases [5]. 
 
1.1.2 Alternative splicing 
It is estimated that more than 90% of all human genes are in some way subject to 
alternative splicing, which generates transcript variants [6]. This can occur through exon 
skipping or inclusion, intron retention, or utilization of alternative splice sites, which can 
be caused by splice site or enhancer element mutations, and/or altered expression of 
trans-acting splicing factors. While the majority of these events will lead to mRNA 
destruction via NMD, it is estimated that over a third will lead to different protein isoforms 
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[6]. Alternative splicing is relevant to many disease states, including muscular dystrophy 
and cancer, as these aberrant protein isoforms can result in loss- or gain-of-function 
consequences.  
Spinal Muscular atrophy is one example of a loss-of-function consequence through 
alternative splicing of the Survival Motor Neuron (SMN) mRNA [7]. The SMN1 and SMN2 
genes encode identical proteins; however, SMN2 mRNA undergoes exon skipping and 
generates a truncated, less stable protein isoform. In one form of SMA, SMN1 is lost 
through deletion or mutation, thus SMA patients only generate the less functional SMN2 
protein. SMA has been successfully targeted by antisense oligo (ASO) therapy, in which 
ASOs target a splicing inhibitory element SMN2 mRNA to prevent exon skipping and yield 
full-length functional protein to mitigate the effects of SMN1 loss [7].  
Alternative splicing can also promote certain cancers. One way this can happen is 
through the tumorigenic effects of splicing factors that are abberantly under- or over-
expressed in different cellular contexts [8]. Several hnRNPs have been linked to cancer 
in promoting alternative splicing to generate oncogenic isoforms, such as pyruvate kinase 
muscle isozyme M2 (PKM2), while hnRNP K may function as a tumor suppressor in acute 
myeloid leukemia (AML). SR proteins are also thought to play roles as oncogenes by 
promoting expression of mRNA isoforms that are associated with cancer [8].  
 
1.1.3 mRNA modifications: the cap and poly(A) tail 
Two non-templated modifications enable subsequent mRNA processes and are 
thus important for the expression of most mRNAs. The first is the 7-methylguanosine 
(m7G) nucleotide cap at the 5′ end of the transcript, which is added to the mRNA co-
transcriptionally via a 5'-5' triphosphate linkage through three enzymatic steps: 5' 
triphosphate hydrolysis of the nascent RNA (yielding diphosphate), addition of guanosine 
monophosphate, and N7 methylation of the terminal guanine [9]. The m7G cap is crucial 
for the closed loop formation in cap-dependent translation initiation, as well as serving as 
a barrier to 5'-3' mRNA degradation; both of these processes will be discussed later in 
this chapter.  
The 3′ ends of all mRNAs (with the exception of replication-dependent histone 
mRNAs) are also enzymatically modified by addition of a poly(A) tail. Addition of this 
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poly(A) tail by poly(A) polymerase enzyme is coupled to 3′ end processing of the nascent 
transcript, which occurs through a sequence-specific endonucleolytic cleavage event by 
the Cleavage and Polyadenylation Specificity Factor (CPSF) complex via recognition of 
the cleavage and polyadenylation signal by its cofactors [10]. The poly(A) tail is bound by 
poly(A) binding proteins (PABPs) [11], which serve to facilitate closed loop formation for 
translation initiation, and modulate the mRNA’s susceptibility to poly(A) tail removal [12, 
13]. 
 
1.1.4 Nuclear export 
After being synthesized and processed in the nucleus, mRNAs are exported to the 
cytoplasm to be translated. Prior to export, mRNAs are coated with proteins accumulated 
during transcription and processing to form mature messenger ribonucleoprotein (mRNP) 
complexes [14]. The requirement for these factors adds another layer of mRNA quality 
control, ensuring that only properly processed transcripts are competent for export, 
whereas defective mRNAs are degraded. While the complement of factors involved in 
export has yet to be fully realized in metazoans, several complexes have been identified 
as key players from studies in budding yeast [14]. As with protein export, mRNPs exit the 
nucleus via the nuclear pore complex (NPC); however, the mechanism and cofactors 
involved in mRNA export differs from that of proteins [14]. Upon cleavage and 
polyadenylation, nuclear poly(A) binding proteins, such as PABPN1 and Nab2 (ZC3H14 
in mammals) associate with the poly(A) tail [15]; Nab2 association consequently restricts 
poly(A) tail length [16-18]. The TREX (TRanscription-EXport) complex couples nuclear 
mRNA processes, facilitating compositional rearrangements of the mRNP to stimulate 
association of other factors relevant to export [14, 19, 20]. Most mRNPs traverse the NPC 
in a process mediated by the NFX1/NXT1 complex, while CRM1 is involved in the export 
of some smaller mRNAs. Upon export, nuclear factors are exchanged for cytoplasmic 
factors (for example, nuclear poly(A) binding proteins for cytoplasmic PABPC1), and the 






1.2 Translation  
Upon export to the cytoplasm, mature mRNAs are utilized for protein synthesis by 
the ribosome through the process of translation. Translation is a complex multi-step 
process facilitated by many protein and RNA factors, but can be grouped into three major 
phases: initiation through assembly of the large and small ribosome subunits, elongation 
of the peptide chain, and termination upon encountering a stop codon. 
 
1.2.1 The Ribosome and Translation Factors  
The process of translation is catalyzed by the ribosome, a large multisubunit 
ribonucleoprotein complex. Translation is facilitated by an assortment of eukaryotic 
initiation factors (eIFs), elongation factors (eEFs) and termination factors [21-23]. The 
eukaryotic ribosome is comprised of two subunits: a large 60S subunit and a small 40S 
subunit containing 80 ribosome proteins (RPs) and 4 ribosomal RNAs (60S: 5S, 5.8S, 
and 25S rRNA; 40S: 18S rRNA). During the translation initiation step, the two subunits 
must join together on the mRNA to form the 80S ribosome, which is capable of catalyzing 
peptide bond formation. The mRNA is held at the interface of the two subunits, positioned 
to permit reading of the codons by incoming transfer RNA molecules (tRNAs)[21].  
Transfer RNAs that are charged with amino acids are essential ingredients for 
translation. Each amino acid is covalently appended to the appropriate cognate tRNA by 
an amino-acyl tRNA synthetase. These charged tRNAs are then delivered to the 
ribosome as RNA-protein complexes with special translation factors. The tRNA involved 
in translation initiation, tRNAi, is charged with methionine (Met-tRNAi). Met-tRNAi forms 
a ternary complex with the GTP-bound form of translation initiation factor eIF2, and 
together they associate with the 40S ribosomal subunit to function during initiation of 
protein synthesis. During initiation, the Met-tRNAi is positioned in the Peptidyl-site (P-site) 
of the ribosome. The other charged tRNAs associate with the GTP-bound form of 
translation elongation factor eEF1A, which delivers them to the Amino-acyl site (A-site) 
of the ribosome as specified by the mRNA’s codons [24, 25]. 
 
1.2.2 mRNA features in translation 
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The 5′ m7G cap and 3' poly(A) tail are crucial to translation of most mRNAs 
(exceptions will be discussed later in this chapter). In the cytoplasm, the cap facilitates 
translation by interacting with the translation initiation factor, eIF4F, which is composed 
of subunits eIF4E, eIF4G, and eIF4A. All three subunits bind to the RNA, with eIF4E 
directly contacting the 5′ cap [21]. PABPs associate with the poly(A) tail; in the cytoplasm, 
the PABPC1 protein (referred to as pAbp in Drosophila) coats the poly(A) tail and 
enhances the efficiency of translation [11].  
The protein coding capacity of the mRNA is specified by several features that 
determine where translation will begin and end, defining the open reading frame (ORF). 
The translation initiation site is typically the first AUG codon, from the 5′ end of the mRNA, 
with the proper surrounding sequence context [26]. This context, originally characterized 
by Marilyn Kozak, surrounds the initiation site AUG [27]. In vertebrates, the general 
“Kozak” consensus sequence is 5'-gccRccAUGG, where the underlined AUG initiation 
codon is flanked by uppercase nucleotides, denoting strong influence on initiation, and 
lowercase nucleotides denoting lesser importance for initiation. Note that the “R” indicates 
a purine nucleotide base. Using transcriptome-wide datasets, AUG codon contexts have 
now been defined for multiple species [28]. The 3′ end of the protein coding region is 
specified by an in-frame stop codon, either UAA, UGA, or UAG [24]. 
Messenger RNAs can contain other features that affect translation. Only a portion 
of the mRNA sequence encodes protein, while the remaining sequences are 5′ and 3′ 
Untranslated Regions (UTRs). These UTRs can range from tens of nucleotides to 
thousands of nucleotides and play important regulatory roles to control and alter 
translation [29]. 
 
1.2.3 Activated mRNAs and the Closed-Loop Conformation 
Before engaging ribosomes, mRNAs must be activated. The 5′ and 3′ ends of the 
mRNA are brought together through interactions between cap-bound eIF4F and poly(A)-
bound PABPC1. This “looping” is mediated by the eIF4G component of eIF4F, which 
bridges the cap binding protein eIF4E and PABPC1 via protein–protein interactions. 
Circular RNA-protein complexes have been observed by atomic force and electron 
microscopy [30, 31]. Moreover, evidence in several systems demonstrates synergistic 
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stimulation of translation mediated by the 5′ cap and poly(A) tail [32-34]. Thus, mRNAs 
complexed with eIF4F and PABPC1 can be considered to be in an activated state that is 
potentiated for subsequent loading of ribosomes. It is interesting to note that replication-
dependent histone mRNAs maintain a cap-to-tail closed loop, though they do not possess 
a poly(A) tail; instead, the histone mRNA closed loop is formed by specialized RNA 
binding proteins that recognize a unique 3′ end RNA structure, thereby promoting histone 
protein synthesis [35]. Thus, closed loop formation is thought to be a generalized feature 
of activated mRNAs (Figure 1.1).  
 
1.2.4 Initiation: Assembly of the Pre-initiation Complex  
Translation initiation requires at least 12 different initiation factors that act to bring 
together the ribosome subunits on the mRNA and, as the most complex stage of 
translation, this process is highly regulated. First, the small ribosomal subunit must locate 
the initiation codon, facilitated by base-pairing with the anticodon of the tRNAi. Initiation 
begins with the formation of a pre-initiation complex (Figure 1.1a). First, the 40S small 
ribosomal subunit associates with initiation factors eIF1, eIF1A, eIF5, eIF3 and the eIF2 
ternary complex (composed of GTP-bound eIF2 and Met-tRNAi) to form the 43S pre-
initiation complex (PIC). The 43S PIC is then joins an activated mRNA to form the 48S 
PIC, mediated by many protein and RNA contacts, including those formed between 
eIF4F, PABP and mRNA with the multisubunit initiation factor, eIF3. Once these 
translation factors have assembled on the mRNA, the next step is to locate the proper 
initiation codon [21, 26].  
 
1.2.5 Initiation: Scanning for the Initiation Codon   
Once the 48S PIC is assembled, the ribosome must locate the translation start site 
(typically the first AUG codon) to initiate protein synthesis. In order for the 48S PIC to 
search for the AUG start codon, it must traverse the 5′ UTR in a process known as 
ribosome scanning. 5′ UTRs frequently contain RNA structures which can impede 
scanning and thus inhibit translation. In the event that the first AUG codon has a poor 
context, downstream AUG codons can be utilized to initiate translation, a process referred 
to as leaky scanning [36, 37].  
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Scanning through RNA structure by the 48S PIC is promoted by the eIF4A protein, 
which is an ATPase/helicase that can unwind secondary structure in the 5′ UTR. Other 
helicases may also facilitate scanning. This process requires energy in the form of 
hydrolysis of adenosine triphosphate (ATP). eIF4B binds single stranded RNA (ssRNA) 
and also helps in unwinding. eIF4G is involved by facilitating the association of eIF4A [36, 
37].  
The factors eIF1, eIF1A, and eIF3 aid in scanning by stabilizing the open 
conformation of the mRNA entry channel of the small ribosome subunit, and also in start 
codon recognition. The 48S PIC slides along the mRNA, sampling the RNA until the first 
AUG codon in the proper sequence context is located. Once the AUG start codon 
successfully base pairs with its anticodon complement on the Met-tRNAi, eIF1 is released 
and the PIC adopts a more closed conformation. At this point, the Met-tRNAi is positioned 
in the P-site of the ribosome. The GTP bound to eIF2 is then hydrolyzed and eIF5 and 
GDP-bound eIF2 are released from the PIC. eIF1A is the only initiation factor from the 
PIC which remains bound throughout the entire process of initiation. The PIC is now more 
stably bound to the mRNA and Met-tRNAi, and poised for joining of the 60S subunit [36, 
37].  
 
1.2.6 Initiation: Formation of the 80S Ribosome  
The next phase of initiation is assembly of the 80S ribosome through joining of the 
60S subunit to the initiation codon associated 48S PIC. The 60S large ribosomal subunit 
first assembles with the GTPase protein eIF5B. Upon large and small ribosome subunit 
joining, eIF5B hydrolyzes its GTP. eIF5B and eIF1A are then released as the ribosome 
undergoes a conformational change. The resulting 80S ribosome is thereby primed to 
enter the elongation phase [21, 26].  
 
1.2.7 Elongation  
Once the 80S ribosome has assembled at the initiation site, protein synthesis can 
commence through ribosome-catalyzed peptide bond formation between the Met-tRNAi 
located in the P-site and the incoming amino-acylated tRNA in the A-site. The nascent 
polypeptide chain is extended through sequential rounds of peptide bond formation and 
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translocation of the ribosome along the mRNA. Subsequent amino acid additions are 
specified through complementary base-pairing between tRNA anti-codons and the triplet 
codons of the mRNA. Elongation in eukaryotes is mediated by two elongation factor 
proteins: eEF1 and eEF2 [24]. eEF1 is a multisubunit complex that delivers the amino-
acylated tRNA to the ribosome [38]. Upon proper positioning of the tRNA in the A-site, 
the eEF1A subunit hydrolyzes GTP and eEF1 dissociates from the ribosome. The eEF2 
factor facilitates the translocation of the ribosome and hydrolysis of GTP [24]. 
Figure 1.1 Translation initiation and common mechanisms of regulation.  
(A) Outline of translation initiation steps. The ternary complex is comprised of eIFs 1, 1A, 3 and 5 joined to the 40S 
small ribosomal subunit. eIF2 bound to GTP and the initiator tRNA joins the ternary complex to form the 43S pre-
initiation complex (43S PIC). The 43S PIC is then bound to an activated mRNA to form the 48S PIC. The 48S PIC 
performs scanning until the Kozak sequence is found. The 48S PIC is then joined by the 60S large ribosomal 
subunit, signaling the end of initiation and the start of elongation.  
(B) Translational efficiency is regulated negatively through phosphorylation of eIF2. eIF2 is bound to GTP, which is 
hydrolyzed during initiation. The eIF2α subunit of eIF2 can be phosphorylated at Serine 51 (S51) to negatively 
regulate its role in translation. Unphosphorylated eIF2 can initiate translation normally, whereas phosphorylated 
eIF2α prevents exchange of GDP for GTP, inhibiting initiation.  
(C) Members of the eIF4F complex are regulated by mTOR. Phosphorylation by various kinases of the mTOR 
signaling cascade enhances translational efficiency through inhibition of 4E-BP, as well as enhancing association 




Typically, multiple ribosomes are sequentially assembled on and traverse the 
mRNA simultaneously. As the first ribosome elongates away from the initiation site, new 
ribosomes can initiate and follow. The resulting mRNA with multiple associated ribosomes 
is referred to as a poly-ribosome or polysome [39, 40]. The density of ribosomes on an 
mRNA is generally proportional to the length of the open reading frame and the rates of 
initiation and elongation [41].  
 
1.2.8 Termination  
Translating ribosomes traverse the mRNA until they encounter a stop codon (UAA, 
UAG, and UGA) within the A-site, which signals the termination of polypeptide chain 
elongation. Since there is no tRNA anticodon complementary to the stop codon, no amino 
acid can be added to the end of the peptide chain. Instead, a release factor (eRF) binds 
the stop codon and triggers the release of the complete polypeptide from the ribosome. 
Eukaryotes have two release factors: eRF1, which is involved in stop codon recognition 
and hydrolysis of the nascent protein from the P-site bound tRNA, and eRF3, a GTPase 
which promotes polypeptide release. Upon termination of translation, the ribosome is 
disassembled into its large and small subunits, assisted by additional translation factors 
[24, 42].  
 
1.3 Regulation of Translation  
Translation can be regulated in multiple steps to control the amount, timing and 
location of protein synthesis. Cis-acting sequence elements and trans-acting factors can 
either activate or repress translation (Figure 1.2). Translation can be regulated globally, 
affecting protein synthesis from all mRNAs (as is the case with the mTOR pathway), or 
specifically from certain mRNAs (as with sequence-specific RNA-binding proteins and 
microRNAs). Groups of mRNAs can be translationally regulated in a coordinated fashion 
by common cis-elements and trans-factors [26, 43]. One classic example of this type of 
PTR is the 5′ terminal oligo-pyrimidine (TOP) mRNAs that encode multiple components 
of the translation apparatus and are coordinately regulated in response to stress [44]. 




1.3.1 Regulation of Translation Initiation Through the Closed Loop  
The closed loop conformation of mRNAs promotes translation initiation through the 
cap-to-poly(A) tail interactions mediated by eIF4F and PABP. Formation of the closed 
loop represents an important regulatory stage. Trans-acting factors can disrupt the closed 
loop to inhibit translation by displacing eIF4F or PABP from the mRNA or by disrupting 
their protein–protein interactions [45-47]. Enzymatic removal of the 5′ cap structure or 
poly(A) tail can disrupt closed loop formation, thereby silencing translation and leaving 
the mRNA vulnerable to degradation, as described below. In the oocyte and embryo, the 
length of the poly(A) tail can modulate translation like a rheostat, with longer poly(A) tails 
promoting protein expression, and shorter poly(A) tails reducing it. Therefore, factors that 
stabilize or shorten the tail can control translation efficiency in these contexts [48]. 
However, evidence from C. elegans and non-embryonic mammalian cells indicate that 
more highly expressed mRNAs tend to have shorter tails (median length of ~50-100 nt in 
metazoans) [49-52]; while, the mechanism is not fully understood, this could be in part 
due to PABP’s relationship to deadenylase enzymes [12, 13, 51], which will be discussed 
later in this chapter.  
Translation efficiency can be controlled by proteins that interact with PABP. PABP-
interacting proteins (PAIP1 and PAIP2) bind to PABP to either stimulate or inhibit 
translation, respectively [53, 54]. PAIP1 shares homology with eIF4G and forms a 
complex with initiation factors eIF4A and eIF3 to enhance translation by bridging PABP’s 
interaction with eIF4F and stabilizing the closed loop [55, 56]. PAIP2 competes with 
eIF4G and PAIP1 to bind PABP, reducing its affinity for the poly(A) tail and reducing 
translation efficiency [53].  
Fig. 1.2: mRNAs contain cis-acting regulatory information that controls translation efficiency and stability.  
Eukaryotic mRNAs have a 5′ 7-methylguanosine (m7G) cap that promotes translation and stability. The poly-
adenosine (poly(A)) tail is, recognized by poly(A) binding proteins (PABP), promotes translation and stability. 
Removal of the cap and poly(A) tail result in subsequent mRNA degradation. Cis regulatory elements can be 
contained in the 5′ and 3′ untranslated regions (UTRs) of an mRNA. These can include binding sides of RNA binding 
proteins and non-coding RNAs that modulate stability and translation. The open reading frame (ORF) can also 
contribute to regulation through the Kozak sequence and codon optimality (how commonly the codons it contains 
are found in the cell). 
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The 5′ cap and associated eIF4F complex are major targets for translational control 
mechanisms. Proteins that compete with eIF4F for binding to the 5′ cap can inhibit 
translation [57, 58]. A second, widely utilized control mechanism is mediated by proteins 
that directly bind to cap-binding eIF4F subunit, eIF4E. These eIF4E Binding Proteins (4E-
BPs) competitively bind to the same region of eIF4E as the eIF4G subunit. In doing so, 
4E-BPs disrupt eIF4F and the closed loop, thereby inhibiting formation of the PIC. In 
addition to repressing translation, several 4E-BPs have been shown to promote 
degradation of mRNAs [59-62].  
Multiple signaling pathways intersect on 4E-BPs, providing a nexus for controlling 
translation. Unphosphorylated 4E-BPs have a high affinity for eIF4E whereas 
phosphorylation of 4E-BPs prevents their interaction with eIF4E (Figure 1.1, panel C). 
The Target of Rapamycin (TOR) pathway is a major regulator of translation that responds 
to the availability of nutrients and amino acids. TOR is an important regulator of cell 
growth and proliferation and is inhibited in response to stress conditions and starvation. 
TOR also integrates signals from hormones such as Insulin and Brain-Derived 
Neurotrophic Factor. In turn, TOR pathway regulates translation of peptide hormones 
such as Leptin. TOR promotes translation in several ways, including phosphorylation of 
4E-BPs and activation of S6 kinase, which phosphorylates the small ribosomal subunit 6 
and eIF4B, among other targets, to promote translation [63-65]. This cascade of TOR 
signaling controls translation initiation on a broad level. 
 
1.3.2 Regulation of Initiation Through Initiation Factor eIF2  
Translation initiation depends on delivery of Met-tRNAi to the 40S subunit by GTP-
bound eIF2 and subsequent PIC formation. Thus, eIF2 represents an important regulatory 
target. eIF2 is inhibited by phosphorylation at Serine 51 (S51) on the α subunit by various 
kinases in response to diverse signals [66] (Figure 1.1b). Kinases that phosphorylate eIF2 
include: (1) PKR-like endoplasmic reticulum kinase (PERK), which is activated by the 
unfolded protein response; (2) General Control Nonderepressible 2 (GCN2), which is 
activated by diverse stressors, such glucose and amino acid starvation; (3) Protein Kinase 
R (PKR), which is activated by dsRNAs greater than 30 bp in length and plays an 
important role in anti-viral response; and (4) Heme-regulated inhibitor kinase (HRI) in 
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erythroid cells, which is activated in response to heme deficiency [66, 67]. 
Phosphorylation at S51 prevents exchange of GDP for GTP, thus the phosphorylated 
eIF2 cannot enter new rounds of translation. As a result, translation initiation is inhibited 
globally [66].  
 
1.3.3 RNA Binding Proteins Regulate Translation  
The untranslated regions (UTRs) of many mRNAs can contain important regulatory 
information that controls translation [29]. RNA binding proteins (RBPs) often recognize 
these regions to regulate the translational efficiency and stability of target mRNAs. RBPs 
serve many important biological roles where gene expression needs to be quantitatively, 
temporally and/or spatially controlled, such as in response to hormone mediated 
signaling. RBPs can bind to specific RNA structures, (e.g. stem-loop structures), or they 
can bind to specific single-stranded sequence motifs. Upon binding to a transcript, RBPs 
can use diverse mechanisms to modulate translation by either repressing or activating 
protein synthesis [43]. Here, some specific mechanisms of RBP translational repressors 
and activators will be described.  
RBP repressors can inhibit initiation by binding to the 5′ UTR of a target mRNA 
and blocking assembly of the PIC. A classic example of this mechanism is the Iron 
Response Protein (IRP), which, in response to low intracellular iron, binds to specific RNA 
stem-loop structure in the 5′UTR of ferritin mRNA, the Iron Response Element, to impede 
43S joining and thus represses translation of ferritin [68].  
RBP repressors can also bind to the 3′ UTR of transcripts to control translation. 
One mechanism is to prevent assembly of the 80S ribosome. For instance, the RBPs 
hnRNP-K and hnRNP-E1 repress lipoxygenase mRNA by preventing 60S subunit joining 
to the 48S PIC [69]. Other 3′UTR-bound RBPs can recruit 4E-BPs to a specific message 
to disrupt the closed loop and repress translation; examples of such interactions are 
numerous and include Bruno and Cup [70], Smaug and Cup,[71], and Puf5 and Eap1 
[60]. This mechanism is illustrated by the RBP called Cytoplasmic Polyadenylation 
Element Binding Protein (CPEB), which binds to U-rich sequences known as Cytoplasmic 
Polyadenylation Elements (CPEs) in the 3′UTR of certain mRNAs. One mechanism of 
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CPEB repression is recruitment of the 4E-BP Maskin to inhibit translation of specific 
mRNAs, such as Cyclin B, during oogenesis [72, 73].  
Translation initiation can be inhibited by RBP-mediated recruitment of an eIF4E 
Homologous Protein (4EHP) that competes with eIF4E for binding to the mRNAs 5′ cap 
[74]. However, unlike eIF4E, 4EHP does not interact with eIF4G, and thus prevents 
translation initiation. The 3′UTR binding protein Bicoid recruits 4EHP to repress 
translation of specific mRNAs during Drosophila embryonic development [57].  
RBPs can repress translation of specific mRNAs by causing shortening of the 
mRNA’s poly(A) tail, a process referred to as deadenylation, thereby reducing or 
eliminating the occupancy of PABP to diminish translation initiation. One of the first 
examples of deadenylation mediated silencing to be described was the finding that 
cytokine and growth factor mRNAs contained Adenine-Uridine Rich Elements (AREs) in 
their 3′UTRs, which accelerated deadenylation and mRNA degradation, limiting protein 
expression [75]. These AREs can be bound by several RBPs, including the repressive 
Tristetraprolin (TTP) protein which binds and recruits a multisubunit complex of poly(A) 
degrading enzymes that shorten the poly(A) tail of TTP bound mRNAs [76]. Likewise, 
members of the Pumilio and Fem3 Binding (PUF) family of sequence-specific RBPs bind 
to 3′UTRs and recruit specialized poly(A) degrading enzymes that remove the poly(A) tail 
to repress protein expression [77, 78], as will be described in detail in subsequent 
chapters. CPEB, as mentioned earlier, also promotes deadenylation of the mRNAs to 
which it binds by recruiting the poly(A) specific ribonuclease (PARN) [79].  
3′UTR-bound RBPs can also repress translation by promoting removal of the 
message’s 5′ cap structure. The TTP protein interacts with and recruits decapping 
enzymes to specific transcripts that contain ARE sequences in their 3′UTRs [76, 80]. One 
PUF protein can promote decapping of mRNAs by using a 4E-BP to disrupt eIF4F and to 
recruit decapping factors to the message, resulting in translational repression and mRNA 
degradation [60]. Through these mechanisms, RBP mediated translational repression 
and mRNA degradation are directly interrelated, a subject that shall be revisited in 
subsequent discussion of mRNA decay pathways in PTR later in this chapter.  
 
1.3.4 RBP Activators  
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Translation can also be activated by cis-elements and trans-acting factors, 
boosting the amount of protein produced by an mRNA. In some cases, they can also 
reanimate mRNAs that have been stored in a quiescent status, an event likely specific to 
developmental contexts [51, 81, 82]. Just as the poly(A) tail is a target for repressive 
mechanisms, it can also be employed to activate mRNAs. Polyadenylation (that is, 
lengthening of the poly(A) tail) and the resulting increased recruitment of PABP can 
promote translational activation. Thus, dormant, deadenylated mRNAs can be activated 
by polyadenylation in the cytoplasm via recruitment of poly(A) polymerase enzymes, such 
as GLD2 [82].  
Perhaps the best characterized example of polyadenylation-mediated activation is 
the sequence-specific RBP CPEB [83]. As described earlier, CPEB represses mRNAs 
via deadenylation and Maskin-mediated inhibition of eIF4F. CPEB acts as a bifunctional 
regulator during oogenesis, switching from repression to activation in response to 
signaling by the steroid hormone progesterone [72, 82, 84]. Aurora A kinase 
phosphorylates CPEB, thereby switching it to an activation mechanism wherein CPEB 
interacts with and recruits GLD2 poly(A) polymerase. CPEB-Gld2 mediated 
polyadenylation requires that the mRNA contain both a CPE and the polyadenylation 
element (AAUAAA) at the 3′ end of the mRNA. The polyadenylation element is recognized 
by a cytoplasmic version of the CPSF complex. The CPEB-GLD2 complex extends the 
poly(A) tails of the target mRNAs and increases the occupancy of poly(A) binding 
proteins. Thus, CPEB activation includes derepression and polyadenylation, resulting in 
increased efficiency of translation [82].  
 
1.3.5 Regulation of Translation Elongation  
The process of elongation is iterated with an average rate of 6 amino acid additions 
per second [85]. Global analyses suggest that protein synthesis rates vary over a wide 
range [86]. Various factors impinge on the elongating ribosome to influence its speed and 
the location and quality of protein expression. For instance, elongation rate can be 
influenced by synonymous codon usage and the availability of the necessary amino-
acylated tRNAs [87-90]. For membrane bound and secreted proteins such as hormones, 
a signal peptide in the nascent polypeptide is recognized by the Signal Recognition 
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Particle to direct the translating mRNA to the proper intracellular location. Chaperones 
(for example, heat shock proteins) associate with and fold the nascent peptide co-
translationally [91]. In several examples, signal transduction pathways have been shown 
to target elongation factors to influence the rate of protein synthesis [24, 38].  
An emerging facet of translation elongation regulation is codon optimality, or the 
observation that the differential usage of synonymous codons influences the translation 
efficiency of mRNAs [92]. This was originally based on the incommensurate 
representation of some synonymous codons within protein coding regions, and the 
observation that mRNAs containing more of these codons tend to be more stable; this 
codon bias is predicated on the differing abundance of tRNAs, thus some codons may 
correspond to rarer cognate tRNAs than others. “Rare” codons may therefore potentiate 
ribosome stalling or slowing during translation elongation, as observed in ribosome 
profiling experiments, slowing protein synthesis and rendering an mRNA more 
susceptible to decay. There is evidence that mRNA decay factors are recruited to less 
efficiently translated mRNAs in a manner dependent on rare codon content. For example, 
the DEAD box helicase, Dhh1, is recruited to poorly translated rare codon-containing 
mRNAs, making these transcripts more prone to decay. While there is much more to be 
elucidated, codon optimality implements yet another layer of translational control at the 
level of elongation [92].  
 
1.3.6 Alternative Mechanisms of Initiation: Cap-Independent Translation Initiation 
Translation generally requires the 5′ cap; however, in specialized instances, 
translation can initiate in a cap-independent manner, mediated by internal ribosome entry 
sites (IRES). IRES are highly structured elements present in the 5′ UTR of specific 
mRNAs which can allow translational initiation on that mRNA without the requirement of 
the 5′ cap and certain initiation factors through complex interactions with the ribosome, 
circumventing the process of scanning. IRESs were first discovered in viral mRNAs, but 
examples of cellular IRES-containing mRNAs have emerged. These alternative initiation 
mechanisms permit translation of specific proteins when cap-dependent translation is 
turned off by the cell in response to viral infection, or other cellular stresses [93].  
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One well known example of a viral IRES-containing mRNA is that of the Hepatitis 
C Virus, which contains both 5′ and 3′ IRES elements [94]. An extreme example of a viral 
5′ IRES is that the Cricket Paralysis Virus, which is able to bypass the requirement for all 
translation initiation factors (including eIF2-tRNAi) by mimicking the initiator tRNA in the 
P site of the ribosome [93, 95]. A well-studied example of a cellular IRES-containing 
mRNA is Vascular Endothelial Growth Factor A (VEGF-A), a mitogen and important 
stimulator of angiogenesis [96-98]. 
 
1.3.7 Alternative Mechanisms of Initiation: Specialized ribosomes 
Recent studies have revealed that ribosomes do not merely exist as non-specific 
translation machinery, but can actually vary in composition, conferring mRNA preference 
in certain cellular contexts [99, 100]. For example, it is known that translation of a few 
specific mRNAs, such as JUN, functionally utilize a subset of eIF3 complex subunits [101, 
102]; however, the mechanistic details and scope are a subject of current study. 
Moreover, eIF4F subunit isoforms exhibit tissue-specific expression patterns at the mRNA 
level [103], and these proteins can function in different capacities [104-106]. Moreover, 
eIF4F composition can change in response to cellular conditions [107]. Some ribosome 
proteins (RPs) are also heterogeneous in nature, and appear to be involved in the 
translation of specific subsets of transcripts. One example is RPS25, which is involved in 
translating most genes in the vitamin B12 pathway, among other processes, based on 
studies in mouse embryonic stem cells [108]. Intriguingly, there are multiple 
developmental phenotypes and disorders associated with several of these 
substoichiometric RPs, including Diamond-Blackfan anemia and T cell acute 
lymphoblastic leukaemia. These specific RP interactions are mediated by cis elements in 
the 5'UTR. In addition to heterogeneous RPs, there are hundreds of ribosome-associated 
proteins (RAPs) to exert further context specific influence on translation. Furthermore, the 
ribosome is also post-translationally modified, increasing the potential for specialized 






1.4 mRNA decay 
Every mRNA is eventually subject to degradation. mRNA degradation can be 
dynamic, clearing specific transcripts to establish developmental patterns or respond to 
stimuli. Decay of mRNAs also serves in quality control to clear the cell of defective 
transcripts that could have deleterious effects if translated into protein. Cytoplasmic decay 
of mRNAs generally proceeds through removal the poly(A) tail and/or 5' cap, but can also 
be initiated through endonucleolytic cleavage. Here, principles of mRNA decay will be 
discussed, followed by general mechanisms of targeted mRNA decay by RBPs and 
microRNAs. Because there is much conservation, and for consistency with later 
discussion, this section will focus on the Drosophila orthologs of the decay machinery, 
highlighting relevant differences between Drosophila, yeast and mammalian orthologs. 
 
1.4.1 Deadenylation  
The median steady state poly(A) tail length in metazoans is approximately 50-100 
nt [51, 109]. The poly(A) tail is crucial for nuclear export, translation initiation and stability 
of most mRNAs, and thus serves as an important nexus for translational control. Removal 
of the poly(A) tail, or deadenylation, typically initiates mRNA decay, and is catalyzed by 
multiple deadenylase enzymes. Much of the early work on deadenylation was done in 
yeast, but many conclusions are broadly relevant to eukaryotes. 
 Deadenylases are Magnesium-dependent enzymes that hydrolyze 
phosphodiester bonds to degrade mRNA in a manner preferential to adenosine, releasing 
AMP as a result. An mRNA with a short poly(A) tail is then substrate for exonucleolytic 
decay. Deadenylase enzymes belong to two major families: the DEDD and EEP 
(exonuclease-endonuclease-phosphatase) families [48]. The DEDD family was named 
for the Aspartate and Glutamate metal-coordinating residues that typify this deadenylase 
class. Known deadenylase members of the DEDD family include Pop2 (or 
Caf1/CNOT7/CNOT8 in mammals), and Pan2. Other orthologs in mammals (not 
conserved in flies) include Caf1z and poly(A)-specific ribonuclease (PARN). Members of 
the EEP family have conserved Asp and Histidine residues involved in catalysis and 
include Ccr4 (CNOT6 and CNOT6L in mammals); Angel is another EEP member that has 




1.4.2 Pan2-Pan3 complex 
There are two proposed general phases of poly(A) tail shortening by two different 
deadenylase complexes: initial trimming by Pan2-Pan3, followed by progressive 
deadenylation by the Ccr4-Not (CNOT) complex (Figure 1.3) (though it is likely that 
significant overlap exists between the two) [109, 111]. The poly(A) tail is shortened by the 
Pan2-Pan3 complex; it is currently unknown whether other partners associate. Pan2 is a 
DEDD deadenylase which also contains a WD40 domain and an inactive UCH doman 
(ubiquitin C-terminal hydrolase)[109, 111]. Pan3 is non-catalytic, and contains a Zinc 
finger domain, pseudokinase 
domain, conserved C-
terminal domain and a PAM2 
(PABP-interacting motif). 
Pan3 interacts with PABP, 
and therefore Pan2-Pan3 is 
thought to be recruited to 
mRNAs with longer poly(A) 
tails, corresponding to higher 
PABP occupancy. Moreover, 
PABP stimulates Pan2-Pan3 
activity in vitro, and appears 
to be required for recruitment 
to poly(A) tails in vivo. 
Consistent with these 
observations, Pan2-Pan3 can 
only shorten tails to 
approximately 20-25 nt [109, 
111], shorter than the 
approximate footprint of one 
PABP molecule (27-30 nt) 
[12, 13]. Neither Pan2 or Pan3 
Figure 1.3 Deadenylation and decapping initiates mRNA decay 
The poly(A) tail is shortened by the Pan2-Pan3 and removed by the 
Ccr4-Not deadenylase complexes. Removal of the 5' m7G  cap is 
catalyzed by the Dcp2 decapping complex. Deadenylated mRNAs are 
substrates for 3'-5' degradation by the exosome, while decapped mRNAs 
are degraded in a 5'-3' manner by XRN1. 
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is essential for life in yeast, flies, or mammalian cells; depletion results in longer poly(A) 
tails in yeast and human cells, but the biological implications of this are unclear [13, 109] 
(Flybase).  
 
1.4.3 Ccr4-Not complex: molecular and genetic characterizations of Pop2 and Ccr4 
The CNOT complex catalyzes removal of the poly(A) tail. CNOT includes the EEP 
family member Ccr4, and the DEDD deadenylase Pop2 [110]. Other members of the 
CNOT complex are non-catalytic, but are thought to enhance deadenylation activity [112]. 
Pop2 is highly conserved and contains a DEDD nuclease domain. While Pop2 prefers 
adenosines, there is evidence that other sequences can be degraded, albeit less 
efficiently. Ccr4 also contains a Leucine Rich Repeat  (LRR) domain in addition to its 
catalytic domain, which confers its interaction with Pop2 [110]. In mammals, both Ccr4 
and Caf1/Pop2 contribute to mRNA deadenylation [13]; however, based on studies in 
Drosophila Schneider-2 (S2) cells, Pop2 appears to be the more dominant deadenylase, 
with Ccr4 having a minor contribution [112]. Moreover, the Ccr4 LRR, which interacts with 
Pop2 and excludes the catalytic domain, confers all of Ccr4’s activity when tethered [113]. 
There is evidence that the CNOT deadenylases can have differential activity on mRNAs 
depending on the presence of PABP [12, 13], where Ccr4 is capable of displacing PABP 
from poly(A) tails and Pop2 is inhibited by PABP. While this appears to be conserved 
between yeast and human, it is unclear whether fly orthologs share this feature.  
Both Pop2 and Ccr4 are expressed throughout development in Drosophila (see 
Appendix A for details on tissues and developmental stages). Pop2 is essential in 
Drosophila, with mutants being embryonic lethal [110]. Intriguingly, Ccr4 mutant 
Drosophila are largely viable, but females exhibit varying levels of infertility and decreased 
viability of resulting embryos [110, 114-116]. It is unclear why the female germline is 
susceptible in Ccr4 null mutants without an apparent effect on other tissues, but this 
phenomenon is conserved in C. elegans (where Pop2 deficiency is also lethal early in 
development) [117]. It is tempting to speculate that Ccr4 might target specific mRNAs in 
the female germline, although currently no evidence exists for this. Another explanation 
could be that this context is more sensitive to subtle changes in bulk mRNA poly(A) tail 
length. It is also possible that Pop2 mRNA, while expressed in the ovary at a comparable 
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level to other contexts (see Appendix A),  is translationally regulated, making the ovary 
largely dependent on Ccr4 activity. Expression of a catalytically dead Ccr4 mutant 
partially rescues fertility, indicating that deadenylation is at least partly important for this 
function, but also implicating a deadenylation-independent function of Ccr4 required in 
the female germline [110].  
  
1.4.4 Ccr4-Not complex: molecular and genetic characterizations of core subunits 
Some of the non-catalytic CNOT subunits also play indispensable roles in biology, 
conferring other interactions with the decay machinery and specific effectors. Not1 is a 
large protein that acts as a scaffold, bridging together the other members of the complex. 
Not1 domains include the Not10/11 binding domain (Not10/11 BD), HEAT domain, MIF4G 
domain, CNOT9 (Caf40)-binding domain (CN9BD), and the Not1 SH domain [110, 118]. 
Pop2 interacts with the MIF4G domain, and bridges Ccr4 to the rest of the CNOT 
complex. Not2 and Not3 are stoichiometric components of the CNOT complex, and form 
a heterodimer; Not2 and Not3 interact with the Not1 SH domain via their homologous 
NOT boxes [110, 118]. From RNAi depletion in S2 cells, Not2 and Not3 are thought to 
enhance deadenylation activities, although the mechanism is still unclear; moreover, it is 
difficult to delineate their independent functions in cells, as depletion of one CNOT subunit 
often impacts the stability of others [112]. Caf40 (CNOT9) interacts with the Not1 CN9BD, 
and its association with Not1 does not appear to be dependent on any other subunit [110, 
118]. While the role of Caf40 in deadenylation is unclear, there are several reports of 
Caf40 as a node for targeted mRNA control by RBP repressors, such as TTP, Bag of 
Marbles (Bam) and Roquin [119-121]. Not10 and Not11 form a heterodimer that interacts 
with the N-terminal Not10/11 binding domain [110, 118], but their contributions to 
deadenylation have not been characterized in Drosophila [110]; in mammalian cells, they 
appear to be dispensable for deadenylation [122].  
Like Pop2, Not1, Not2, and Not3 are required for viability; their depletion also led 
to stabilization of longer poly(A) tail length of an Hsp70 reporter in S2 cells, indicating they 
may have some role in enhancing deadenylation [112]. All peripheral subunits of the 
CNOT complex cause repression when tethered to an mRNA, presumably through 
recruitment of the rest of the complex; however, Not10 and Not11 exhibited the least 
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amount of activity in these experiments [113]. Intriguingly, a Not1 construct with a deletion 
in the middle region/MIF4G domain that does not recruit the deadenylases can still cause 
repression at the protein and mRNA level when tethered to a reporter, demonstrating 
deadenylation-independent functions of CNOT. Additionally, this deletion construct, along 
with other CNOT subunits (all except Not10), could repress when the poly(A) tail was 
replaced with the Hammerhead ribozyme 3' end, implicating an alternative mechanism to 
deadenylation [113]. These observations could be explained by reported interactions 
between CNOT and the decapping complex, such as those between the Not1 scaffold 
and the DEAD box helicase Me31B/DDX6 [110, 123, 124]. 
 
1.4.5 3' to 5' decay: The exosome 
Once the poly(A) tail is 
deadenylated by the Ccr4-Not 
complex, the mRNA becomes a 
substrate for the cytoplasmic RNA 
exosome. The non-catalytic 
exosome core comprises 9 
subunits that form a ring structure, 
with 3 proteins that form a cap 
[125]. The core forms a channel 
that long RNAs can be fed 
through for degradation. The 
primary catalytic component in 
the cytoplasm is dDis3 (Rrp44 in 
yeast, Dis3 in mammals), which 
can catalyze both exonucleolytic 
decay in the 3'-5' direction, as well as endonucleolytic cleavage through its PIN (Pilus-
forming N-terminus) domain, leading to subsequent 3'-5' and 5'-3' decay (see Figure 1.4) 
[126-130]. Though Rrp44 is more active in vitro in the absence of the core [131], the core 
is thought to direct RNA substrates to and regulate activity of the nuclease [125, 132].  In 
addition, associated RNA helicases facilitate unwinding of structured RNA substrates 
Figure 1.4 Endonucleolytic cleavage initiates subsequent 
exonucleolytic decay 
Endoribonucleases catalyze internal cleavage of the transcript to 
yield substrates with unprotected 3' and 5' ends; in the cytoplasm, 
these cleavage products are degraded by the exosome and XRN1. 
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[133]. Once the mRNA has been degraded to 10 nts or less, the scavenger decapping 
enzyme, DcpS, hydrolyzes the cap structure yielding 7-methylguanosine phosphate and 
nucleotide diphosphate [134, 135]. There is also a nuclear exosome that functions in 
general quality control of multiple types of RNAs in the nucleus, which contains the 
catalytic Rrp6 subunit in addition to Rrp44, and associates with different nuclear cofactors 
in quality control. While the exosome is involved in general basal decay of mRNAs, it can 
also be targeted to specific mRNAs [136]. 
 
1.4.6 Decapping and 5'-3' decay 
The 5' cap also serves as an important regulatory node for mRNA stability and 
translation; its removal through hydrolysis of the 5'-5' triphosphate linkage, or decapping, 
renders the mRNA translationally incompetent and prone to rapid 5'-3' decay. Decapping 
is typically initiated on deadenylated mRNAs, as there are interactions between the 
deadenylation and decapping complexes; however, deadenylation-independent 
decapping can occur in some cases [137, 138]. 
Decapping is catalyzed by members of the Nudix hydrolase family. While there are 
several of these enzymes capable of removing the 5' cap [139-141], Dcp2 is the most 
well-characterized member to date (it is unclear if orthologs of the others exist in 
Drosophila). Dcp2 catalyzes 5'-5' triphosphate hydrolysis, releasing m7GDP [142]. Dcp2 
contains a catalytic Nudix hydrolase domain, a Box A domain, and a Box B domain. The 
Box A domain facilitates protein partner interactions, while the Box B domain binds RNA 
[140]. Besides binding the cap for catalysis, there is also evidence that Dcp2 selectively 
binds certain mRNAs based on structural elements downstream of the cap [143]. 
The decapping activity of Dcp2 is enhanced by a plethora of decapping factors 
[144]. One of these factors is Dcp1, which stably associates with the Dcp2 Box A domain 
and enhances Dcp2 activity [145, 146]. Edc3 (Enhancer of decapping 3) and Ge-1 (Edc4 
in mammals) are two other decapping factors that function as scaffolds for the complex, 
with Ge-1 helping to bridge the interaction between Dcp1 and Dcp2 [144, 147, 148].  In 
addition, the Me31B (DDX6 in human) DEAD box helicase also interacts with this complex 
and stimulates decapping. Pat1 is also a decapping enhancer through recruitment of the 
Lsm complex to the 3' end of deadenylated mRNAs [147, 149]. Moreover, Dcp2 and 
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decapping factors can be recruited to mRNAs via RBPs and microRNAs that recognize 
cis elements within mRNAs [60, 150, 151]. While decapping often seals the fate of an 
mRNA for degradation, there is evidence that certain mRNAs can be re-capped and re-
introduced to the translation machinery [152, 153]. 
Decapped mRNAs are generally subject to rapid decay. In the cytoplasm, the 
products of Dcp2 decapping bearing a 5' monophosphate are degraded by XRN1 [154]. 
XRN1 is a processive exonuclease that degrades RNA in the 5'-3' direction, releasing 
nucleotide monophosphates [154]. XRN1 is recruited to decapped mRNAs via interaction 
with decapping factors via its C-terminal domain [155, 156]. XRN2 is a nuclear 5'-3' 
exoribonuclease that is involved in RNA quality control, degrading misprocessed RNAs, 
including pre-mRNAs; XRN2 is also involved in transcription termination and maturation 
of certain non-coding RNAs [157-159].  
 
1.5 Effectors of mRNA decay: miRISC and RBPs 
Tuning of mRNA expression happens in tissue and cell-specific contexts to 
accomplish specialized cellular functions, and this often requires targeted mRNA 
regulation. mRNAs contain cis elements within their untranslated regions that are 
recognized by regulatory factors, such as RBPs and non-coding RNAs, that interface with 
decay machinery. This section will focus on these effectors of mRNA control. 
 
1.5.1 Small non-coding RNAs regulate mRNA expression: miRISC  
MicroRNAs (miRNAs) and the microRNA Induced Silencing Complex (miRISC) 
are one major source of targeted mRNA degradation. miRNAs are short (22-25 nt), 
endogenous non-coding RNAs that can target mRNAs for repression through both 
translational inhibition and decay (Figure 1.5) [160-162]. miRNA regulation is pervasive 
and broadly conserved; it is estimated that over half of all protein coding genes are 
regulated by one or more miRNAs, and that there are approximately 1500 miRNAs in the 
human genome [160, 163], many of which are conserved [164]. miRNA expression is 
often tissue-specific [165-167], or specific to developmental stages [168-170]. 




miRNA biogenesis is a multi-step process that is itself subject to regulation [173]. 
Like mRNAs, miRNA precursor transcripts are transcribed by RNAPII. These transcripts 
often are processed to contain a cap and poly(A) tail, and can encode multiple miRNAs 
[174, 175]; proteins can also be encoded in these transcripts, with the miRNA being 
present in an intronic region, in the case of “mirtrons” [173, 176, 177]. The nascent primary 
miRNA (pri-miRNA) is first processed by the endonuclease Drosha, which removes 5' 
and 3' overhangs to form the pre-miRNA consisting of a 60-70 nt stem loop [178, 179]. 
The pre-miRNA is then exported to the cytoplasm, where it is further processed by the 
Dicer endonuclease, yielding a small RNA duplex. This duplex is subsequently unwound 
to yield a mature miRNA, which is then incorporated into the RISC complex [173, 180]. 
Selection of the “guide strand” that is incorporated into RISC is based on which strand is 
more weakly base-paired at the 5' end, as well as other contributing factors [181-183]. 
The incorporation process will also produce a “passenger strand” complementary to the 
guide miRNA, which is generally degraded. The extent of strand preference varies by 
miRNA and tissue type [184]. 
In the RISC complex, the guide 
miRNA interfaces directly with 
Argonaute (Ago) proteins. There are 4 
Argonaute proteins in humans, and 2 in 
Drosophila; AGO2 is the only Argonaute 
which is capable of endonucleolytic 
“slicer” activity in humans [185], 
whereas both fly orthologs possess this 
function [186]. If the miRNA is fully 
complementary to its target sequence, 
the target will be cleaved by Argonaute, 
then subject to exonucleolytic decay 
(Figure 1.4); exogenous small interfering 
RNAs (siRNAs) also function in this way. 
However, most miRNAs will recognize 
their targets via an 7-8 nt complementary 
Figure 1.5 The miRISC complex represses mRNAs 
through multiple mechanisms 
Argonaute-bound miRNAs recognize cis elements within 
mRNA UTRs. miRISC facilitates inhibition of translation 
through antagonization of the poly(A) binding protein 
(pAbp), disrupting the mRNA closed loop (top panel). 
Decay of mRNAs can also be stimulated through 
deadenylase complex recruitment (bottom panel). 
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region within the UTR, termed the “seed site”, and this type of recognition will elicit 
translational repression and/or mRNA decay [160, 162]. Argonaute proteins form a 
complex with the large protein GW182 via highly conserved tryptophan residues (Figure 
1.5) [160]. GW182 acts as a scaffold to recruit the mRNA degradation machinery, 
recruiting both the Pan2-Pan3 and CNOT deadenylase complexes for deadenylation and 
subsequent decapping [160]; there is evidence that miRISC also recruits decapping 
factors [150, 151]. Moreover, GW182 interacts with and antagonizes the function of 
PABP, displacing it from the poly(A) tail to interfere with translation initiation [47, 160]; 
there are also reports that miRISC interferes with the eIF4A translation initiation factor 
and scanning [187-189]. Taken together, miRNA-mediated mRNA silencing is a 
widespread means of regulation that employs multiple repressive mechanisms.  
 
1.5.2 RNA binding proteins target mRNAs for degradation 
Like miRNAs, RBPs can function as destabilizing factors of mRNAs. RBPs can be 
sequence-specific in the case of PUF and ARE-binding proteins, and/or recognize 
specific structural elements, as in the case of Roquin. To date, there have been over 1500 
RBPs identified [190], with more being added to this list with the refinement of 
identification methods [191, 192]. Like miRNA regulation, regulation by RBPs is 
widespread and relevant to many different tissue and developmental contexts. While only 
a few specific examples will be discussed in this section, RBP-mediated regulation will be 
the major focus of subsequent chapters. 
 One of the quintessential classes of sequence-specific RBPs includes the AU-rich 
element (ARE)-binding proteins, such as TTP and its orthologs. TTP recognizes AREs 
within 3'UTRs of target mRNAs via tandem Zinc Fingers [193]. TTP can recruit multiple 
decay factors, including the CNOT complex, via interaction with Not1 and Caf40/CNOT9, 
and recruitment of the exosome and 5'-3 decay machinery [76, 80, 121, 194-196]. 
Moreover, TTP RNA binding, partner interaction, and stability can be modulated through 
phosphorylation [197]. TTP utilizes these mechanisms to target the mRNAs of several 
proinflammatory cytokines, such as Tumor Necrosis Factor (TNF), to regulate the immune 
response [193, 198]. In addition to ARE-binding proteins, PUF proteins are another 
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example of classic sequence-specific mRNA regulators that utilize mRNA decay factors, 
and will be discussed at length in Chapter 2 and beyond. 
Some RBPs are instead specific to RNA secondary structural elements. One 
example of this is Roquin, which recognizes stem loop structures, termed Constitutive 
Destructive Elements (CDEs) in the 3'UTRs of target mRNAs [199]. Roquin is a regulator 
of autoimmunity in T helper cells, and regulates mRNAs such as TNF [199, 200]. Despite 
varying modes of RNA recognition, Roquin has a similar regulatory mechanism as TTP 
through CNOT recruitment; TTP and Roquin interact with the CNOT complex via 
Caf40/CNOT9 [119, 121]. 
 
1.6 Quality control: co-translational mRNA decay 
This section will discuss three mechanisms of mRNA quality control that occur co-
translationally: Nonsense-mediated decay (NMD), No-go decay (NGD), and Non-stop 
decay (NSD). In these cases, the ribosome and translation termination factors are 
involved in the recruitment of decay effectors and machinery. These pathways of mRNA 
destruction have evolved to clear defective transcripts, limiting production of faulty 
proteins that could have deleterious effects. 
 
1.6.1 NMD 
Premature stop codons (PTC) can be introduced into the genome through 
mutation, or into the transcript through RNAPII errors or splicing. mRNAs containing a 
PTC are substrates for Nonsense-mediated decay [201]. The exon junction complex 
(EJC) aids in PTC recognition. Upon splicing, the EJC is deposited on spliced mRNAs 
21-24 nt upstream of an exon-exon junction, and in part, regulates quality control of 
mRNAs [201, 202]. A termination codon approximately 50-55 nt upstream of an EJC will 
be recognized as a PTC (i.e., downstream, in the case of a PTC); the EJC stimulates 
NMD through recruitment of Upf2 and Upf3, although this mechanism may be transcript-
specific, as examples of both EJC-dependent and independent NMD exists in Drosophila 
[202]. In addition to mis-spliced mRNAs, NMD can also occur on “normal” mRNAs that 
do not possess a PTC, such as those containing a 3'UTR intron or upstream open reading 
frame, potentially due to having an EJC downstream of the stop codon [3, 202]. 
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NMD can be activated through different branches and cofactors, which are likely 
specific to features of the mRNA target [3]. Cytoplasmic NMD is initiated through PTC 
recognition by the ribosome during termination of translation, where the eRF3 termination 
factors recruits the central NMD component Upf1 [201]. mRNA degradation by NMD can 
be initiated through four different mechanisms: 1) endonucleolytic cleavage by Smg6 
(Figure 1.4), 2) deadenylation via CNOT recruitment by Smg5-Smg7 complex, and 3) 
indirect or 4) direct recruitment of the decapping complex [201]. Taken together, NMD is 
a complex, potent mode of mRNA regulation. 
 
1.6.2 No-go decay and Non-stop decay 
mRNA decay can be potentiated by ribosome stalling, as in the case of Non-Stop 
Decay (NSD) and No-go decay (NGD). NSD targets mRNAs without an in-frame stop 
codon for destruction. These mRNAs can be generated through genomic mutations, 
premature transcription termination, or premature polyadenylation [203]. Without a stop 
codon, the ribosome can proceed to translate the poly(A) tail, producing a poly-lysine 
motif on the nascent peptide; this stalls the ribosome and triggers NSD. NSD can also be 
initiated when the ribosome reaches the 3' end of a transcript lacking a poly(A) tail. In 
either case, Hbs1 and Dom34, which are structurally similar to termination factors, recruit 
components of the Ski complex and exosome to degrade the mRNA [204]. There is also 
evidence that endonucleolytic cleavage can occur, but the relevant enzymes have not 
been identified [203]. NGD is accomplished by Hbs1 and Dom34-mediated recruitment 
of decay factors, but is initiated when ribosomes are stalled in elongation due to mRNA 
secondary structure, nascent peptide sequence, or rare codon content [203]. 
 
1.7 mRNA localization 
Many biological processes and cellular functions require the spatial control of 
mRNAs. mRNA localization is mediated by molecular motors and cytoskeletal 
components in the cell [205]. Control of the transcript in this manner allows for protein 
production in more functionally relevant locations. This is especially important in 
establishing developmental patterns [205]. One well-characterized example is the 
localization of bicoid mRNA to the anterior and oskar mRNA to the posterior of the 
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Drosophila oocyte to establish embryonic polarity [206]. Specialized cellular functions, 
such as cell migration, also rely on the localization of gene expression in the leading edge 
of the cell [207]. Moreover, neurons utilize localized translation in the morphogenesis and 
function of axons and dendrites [208], and there is evidence that mRNA localization is 
responsible for about half of the proteome in neuronal projections [209]. 
mRNPs can form granules in the cell through phase separation [210]. Cytoplasmic 
mRNP granules form putative sites of mRNA storage and decay [211, 212]. Proteins 
containing low complexity domains (LCDs) that are likely to be intrinsically disordered 
contribute to mRNP granule formation. Dysregulation of mRNP granules is thought to 
contribute to neurodegenerative diseases through the formation of insoluble aggregates; 
indeed, there are several granule-associated RBPs implicated in neurodegenerative 
diseases such as Alzheimer’s Disease and Amyotrophic Lateral Sclerosis [210].  
Cytoplasmic mRNP granules include Stress Granules (SGs) and Processing 
bodies (P-bodies). SGs form as a result of cellular stress, such as heat or oxidative stress, 
and are enriched in translation initiation factors [212, 213]. mRNAs do not associate with 
SGs in a sequence-specific manner, but do tend to be less efficiently translated [214]. P-
bodies are sites of translational repression [211, 212, 215]. Studies in yeast suggested 
that P-bodies are also sites of mRNA decay [216]; however, a study identifying the P-
body-associated transcriptome in mammals did not observe any correlation between P-
body inclusion and mRNA turnover [215]. Nevertheless, proteomic analysis indicates that 
decapping factors and RBP repressors are enriched in P-bodies [215], however the 
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Control of Messenger RNAs by RBPs: Pumilio, Nanos, and Brain Tumor 
 
This chapter was adapted from Arvola et al. 2017: “Combinatorial control of 
messenger RNAs by Pumilio, Nanos and Brain Tumor Proteins”. RNA Biology 
2;14(11):1445-1456. doi: 10.1080/15476286.2017.1306168, [1] and figures 2.1, 2.5 and 
2.6 originally appeared in this publication. Co-authors included Dr. Chase Weidmann, Dr. 
Traci Tanaka Hall and Dr. Aaron Goldstrohm. The putative target analysis was done by 
Dr. Chase Weidmann, and the GO term analysis by Rene Arvola using DAVID v6.8 
(https://david.ncifcrf.gov/). Figures 2.2, 2.3 and 2.4 were adapted from Weidmann, Qui et 
al (2016) [2], in which the co-authors were Dr. Chase Weidmann, Dr. Chen Qui, Dr. Traci 
Tanaka Hall, Dr. Tsu-Fang Lou, Dr. Zachary Campbell and Dr. Aaron Goldstrohm. 
 
2. Control of mRNAs by RBPs: Pumilio, Nanos and Brain Tumor 
As discussed in the previous chapter, translation of mRNAs is highly regulated to 
ensure the proper quantity, time and location of protein synthesis. The output of protein 
from each mRNA is determined in part by its abundance and the status of the translation 
apparatus. Information within the transcript also controls protein expression, including cis-
acting regulatory elements, RNA structure, and codon content. Specific regulatory 
elements that regulate a transcript’s fate are often located in 5´ or 3´ untranslated regions 
(UTRs). Many regulatory elements are recognized by trans-acting RNA-binding factors 
that determine whether the transcript is translated or instead silenced, stored, localized, 
stabilized or destroyed. 
In this chapter, mechanisms of mRNA regulation by RNA-binding proteins (RBPs) 
will be discussed, focusing on three now-classic RBPs, Pumilio (Pum), Nanos (Nos) and 
Brain Tumor (Brat). To date, >1500 RBPs have been cataloged and the functions of most 
remain to be discovered [3-6]. The sheer number of RBPs signifies the importance of 
post-transcriptional control.  
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Pum, Nos and Brat were originally identified in Drosophila decades ago and remain 
relevant because they exemplify key principles of post-transcriptional control and 
because they regulate crucial biological functions. Important new insights into their 
molecular mechanisms illuminate our understanding of regulated RNA stability and the 
spatial and temporal control of protein expression. Combinatorial control is emerging as 
a pervasive theme in post-transcriptional regulation, with mRNAs controlled by a dynamic 
constellation of RNA-binding factors. Pum, Nos and Brat represent an archetypal example 
where their combined action controls crucial biological processes including development, 
stem cell proliferation, fertility and neurological functions. Genetics revealed overlapping 
functions, and they were shown to physically interact with each other on a target mRNA, 
leading to a compelling model [7-9]. Yet the mechanism of combinatorial control was not 
well understood. Recent advances provide the detailed molecular basis of their 
collaboration. We now understand that Pum, Nos and Brat proteins each define a protein 
family with unique modes of RNA recognition. Certain transcripts can be targeted by all 
three RBPs, which bind cooperatively to synergistically repress protein expression. The 
unique features of Pum, Nos and Brat proteins will be discussed, integrating new 
biochemical, structural and functional data into an updated model of their combinatorial 
regulatory function. The implications of this model for regulation of mRNAs on a 
transcriptome-wide scale are then explored. 
 
2.1 Pumilio  
The PUF (Pumilio and fem-3 binding factor) family of eukaryotic RBPs have 
diverse regulatory roles, and RNA binding specificity conserved from yeast to humans. 
Drosophila Pum is a founding member of the PUF family [10]. Pum was originally 
identified as a maternal effect gene necessary for embryonic development [11, 12]. The 
name Pumilio is Latin for “dwarf,” referring to the small embryos from the original pum 
mutant. Pum is expressed throughout development in Drosophila, being at its highest 
level during the earliest stages of embryogenesis (0-2 h, Appendix B). Subsequently, Pum 
was shown to regulate diverse biological processes including germline stem cell 
proliferation, fertility, neuronal morphology, motor neuron electrophysiology, and memory 
formation (summarized in Table 2.1) [13-22]. Consistent with these functions, Pum is also 
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highly expressed in the Drosophila ovary and developing nervous system (see Appendix 
B). 
Pum function Pum Dysfunction Target(s) Approaches Refs Conserved? 
Embryogenesis Short, inviable 
embryos with maternal 
Pum deficiency 
hunchback Pum mutants and 
rescue, RIP from 
embryos 




Loss of germline stem 
cells/infertility; 
embryonic pole cells 













Defects in dendritic 














Long term memory 
defects 
 Dlg1, erm, 
tup, ase, zfh, 
klu, en,  
Target predictions, 
validated in vitro 
























cause ataxia  
Pum is a 1533 amino acid residue protein with a conserved Pum RNA binding 
domain (Pum RBD) located in the C-terminal third (Figure 2.1, panel A). The Pum RBD, 
which defines the PUF family, is a sequence-specific RNA-binding domain of ~40 kDa 
composed of repeated triple alpha helical units [8, 29, 30]. Pum has eight repeats that 
form a crescent shaped molecule, and each repeat presents three amino acid residues, 
termed the tripartite motif (TRM), that recognize a single RNA nucleotide [2, 30]. Pum 
thereby binds an eight nucleotide, single-stranded RNA sequence with the consensus 5´-
UGUANAUA (where N=A, G, C or U), herein referred to as the Pum Response Element 
(PRE) [2, 24, 31-33]. X-ray crystal structures of the RNA-binding domains of PUF proteins 
bound to RNA ligands, including the high resolution structure of Pum bound to a PRE, 
clearly illustrate the modular RNA recognition, and recent reviews provide a 
comprehensive discussion of the determinants of PUF RNA-binding specificity [2, 34-36]. 
Table 2.1 Summary of Pum biological roles in Drosophila melanogaster 
Pum has documented conserved roles in development, fertility, and the nervous system. Known examples of mRNA 




Pum binds and represses specific mRNAs that contain one or more PREs, 
resulting in reduced protein expression and accelerated mRNA degradation [37-40]. We 
now understand that Pum repression occurs through multiple mechanisms. The Pum 
RBD represses by targeting the poly(A) tail of target mRNAs. Normally, the poly(A) tail 
acts to promote translation and stability of an mRNA, mediated by poly(A) binding protein, 
PABP. It was previously shown that the Pum RBD associates with and antagonizes the 
translational activity of PABP, thereby contributing to repression [38] .The Pum RBD also 
directs repression by promoting removal of poly(A) from target mRNAs by recruiting the 
Pop2 deadenyase enzyme [38, 41, 42], which is part of the Ccr4-Not complex (CNOT) 
that catalyzes deadenylation and causes translational repression [43, 44]. Notably, 
poly(A)-dependent repression mechanisms are conserved functions of PUF proteins [38, 
40-42, 45, 46]. 
Pum also elicits poly(A)-independent repression. In both cultured cells and 
embryos, Pum represses reporter mRNAs lacking a poly(A) tail, albeit with reduced 
efficiency [38, 40, 47]. Structure-function analysis revealed that the N-terminus of Pum, 
wholly outside of the Pum RBD, conferred poly(A)-independent repression activity [37]. 
The N terminus was largely a mystery as it is not homologous to other proteins or 
domains. However, genetic evidence indeed supports the importance of the Pum N 
terminus, as its inclusion in transgenes was necessary to fully rescue developmental 
defects of a pum mutant [31]. Dissection of the Pum N terminus revealed three 
autonomous repression domains capable of poly(A)-independent repression, potently 
inhibiting protein expression and stimulating mRNA decay when targeted to a reporter 
mRNA [37]. The function of the Pum N terminus and Repression Domains will be 
discussed in Chapters 3 and 4. 
 
2.2 Nanos  
Nos is a founding member of the eukaryotic Nos protein family, with orthologs 
found throughout multicellular eukaryotes. Nos was originally identified as a maternally 
provided determinant of posterior development [12, 48]. The name nanos is Greek for 
“dwarf” and describes the morphology of original mutant embryos, which is identical to 
the pum phenotype. In fact, Nos shares several biological roles with Pum including 
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embryonic development, control of germline stem cell proliferation, neuronal morphology, 
and long-term memory formation [13, 15, 17, 18, 26]. These commonalities are indicative 
of collaborative control by Nos and Pum. 
Nos protein is 401 amino acid residues in length with two unique C-terminal CCHC-
type Zinc Finger (ZF) domains that define the Nanos family (Figure 2.1, panel A). The ZF 
domains were reported to mediate non-specific binding to RNA [49, 50]. We found that 
Nos ZFs bind specifically to a Nanos Binding Site (NBS) in RNA, but only when that RNA 
includes a downstream PRE sequence that is bound by Pum [2]. Crystal structures of the 
ZFs of Nos bound to RNA in conjunction with Pum provide evidence of specific nucleotide 
binding pockets formed by the tandem ZF domains [2]. 
Like Pum, Nos is a repressor that reduces protein expression and stimulates decay 
of target mRNAs [51, 52]. Recent research has revealed that Nos binds and recruits the 
CNOT complex to repress translation and elicit decay by promoting deadenylation and 
decapping of the 5´ 7-methyl guanosine cap structure [53-55].  
 
2.3 Brain Tumor 
Brat is an RBP with important roles in oogenesis, embryogenesis and the nervous 
system [7, 56-58]. Brat was originally identified as a growth suppressor in the larval brain, 
its name derived from the mutant phenotype wherein neural cells aberrantly proliferate 
[57, 58]. Brat has many documented functions including regulation of neuromuscular 
junction formation, neuronal differentiation, axon maintenance in mushroom bodies and 
control of motor neuron electrophysiology [26, 59-61]. Brat has overlapping functions with 
Pum and Nos in the germline and embryo, as discussed below, and also has functions 




Figure 2.1 Pum, Nos, and Brat are RNA-binding proteins that bind the hunchback mRNA (from Ref. [1])  
(A) Schematic diagrams of Pum, Nos, and Brat proteins with relevant domains labeled: Pum N-terminal Repression 
Domains (RD1, RD2, and RD3), and Pum Homology Domain (Pum-HD); Nos Effector Domain (NED), Zinc Fingers 
(Z), and C-terminal extension (C); Brat B-box Zinc Fingers 1 and 2 (B1 and B2), coiled coil (CC), and NCL-1, HT2A, 
and Lin-41 (NHL) domain. (B) Pum, Nos and Brat bind to the Nanos Response Element 2 (NRE2) RNA from 
the hunchback 3´UTR with color-coded binding sites for Brat, Nos, and Pum. Box A and B elements of the NRE 
are outlined by a black box. Direct interactions are indicated by solid lines whereas dashed lines indicate putative 
interactions. The loop between repeats 7 and 8 of Pum, which mediates protein-protein interaction with Nos, is 
shown in black. (C) Structural model of Brat (NHL domain), Nos (ZC regions), and Pum (Pum-HD) proteins with 
NRE RNA. The crystal structures of Brat in complex with a BBS (red, PDB ID 4ZLR) and Nos (blue)/Pum (yellow) 
in complex with NBS-PRE RNA (PDB ID 5KL1) are shown with the 4 nucleotide spacer RNA (gray) present in the 
native hunchback NRE2 RNA. Brat and Pum proteins are shown as ribbon diagrams. Nos is shown with a molecular 




Brat is a 1037 amino acid residue protein that belongs to the TRIM-NHL class of 
proteins, which are defined by an N-terminal TRIM (Tripartite Motif) and C-terminal NHL 
(NCL-1, HT2A, and Lin-41) domain (Figure 2.1, panel A) [63]. The C-terminal NHL domain 
forms a six-bladed beta propeller structure that is crucial for function [9, 57, 64]. Initially, 
Brat was thought to function as an adapter protein that mediated protein-protein 
interactions [7, 9]; however, the NHL domain of Brat was recently shown to be an RNA-
binding domain, specifically recognizing the Brat binding site (BBS) with consensus 5´-
WYGUUD (where W = A or U; Y = U or C; D = G, A, or U) [39, 64, 65]. The TRIM region 
of Brat contains two B-box type ZFs, which are broadly found in DNA- and RNA-binding 
proteins, but it is unknown whether these domains contact RNA. 
Like Pum and Nos, Brat represses translation from target mRNAs and accelerates 
their decay [7, 39, 62]; however, less is known about its mechanism. Evidence from 
embryos demonstrates that Brat causes turnover of numerous transcripts during the 
maternal-to-zygotic transition (MZT) a developmental stage in which maternally provided 
transcripts are degraded and zygotic genome transcription is initiated [25, 66], and this 
effect can be recapitulated in cultured cells with reporter mRNAs [39, 64, 65]. Brat 
appears to work in conjunction with the translational repressor protein, 4EHP (eIF4E 
homologous protein); the NHL domain was reported to interact with 4EHP, and 4EHP 
mutations reduced Brat-mediated repression [62]. Brat is also reported to associate with 
the CNOT deadenylase complex [67], suggesting that it may promote deadenylation of 
mRNAs, although this supposition remains unproven. 
 
2.4 Combinatorial control by Pumilio, Nanos and Brain Tumor: the hunchback 
mRNA paradigm 
No case better exemplifies combinatorial control by Pum, Nos and Brat than 
collaborative regulation of hunchback mRNA, their first identified target in the early 
embryo [68-71]. Justified by its biological significance, intense focus on the mechanisms 
of hunchback regulation helped to establish key parameters of the Pum-Nos-Brat 
partnership. During early embryogenesis in Drosophila, the zygotic genome is 
transcriptionally silent and development is directed by maternally supplied gene products. 
Maternal mRNAs, including hunchback, must be precisely regulated for development to 
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proceed. Hunchback is a transcription factor that controls body pattern formation, and its 
expression must be limited to the anterior portion of the syncytial embryo prior to the MZT 
[72]. Because hunchback mRNA is distributed throughout the embryo, its mRNA is 
translated only in the anterior whilst being repressed in the posterior to achieve proper 
spatial distribution of Hunchback protein [69, 71, 73]. Repression of hunchback is 
achieved by Pum, Nos and Brat, and mutations that inactivate them result in improper 
expression of the Hunchback protein in the posterior, subsequent loss of abdominal 
segments, and developmental failure [7, 11, 23, 70, 74, 75]. 
The spatial distribution of Hunchback protein is determined by an opposing 
concentration gradient of Nos protein [48, 69, 70, 75].  nos mRNA is localized to the 
embryo’s posterior where its localized translation, coupled to simultaneous repression of 
unlocalized nos mRNA in the bulk cytoplasm [76-79], establishes a Nos protein gradient 
that is highest in the posterior, quickly diminishing towards the anterior. Pum and Brat 
proteins are distributed throughout the embryo, and although crucial for hunchback 
mRNA regulation, they do not provide the spatial cue [7, 23, 80]. In addition to controlling 
hunchback translation during early embryogenesis, the combinatorial action of Pum and 
Brat (and likely Nos) mediates degradation of maternally provided hunchback mRNA 
during the MZT [39, 73]. 
Early work mapped the features of hunchback mRNA necessary for Nos-mediated 
repression. Two separate Nanos Response Elements (NREs) were identified within the 
hunchback mRNA 3´UTR that are necessary and sufficient to confer Nos-mediated 
repression in embryos [49, 51, 81]. Each NRE contains two distinct, conserved elements 
termed Box A and Box B, which are required for complete regulation. These NREs are 
the nexus for combinatorial regulation of hunchback mRNA by Nos, Pum and Brat. 
 
2.5 Cis elements in combinatorial control: the Nanos Response Element is directly 
bound by Pumilio, Nanos and Brain Tumor. 
A synthesis of early and recent discoveries firmly establishes direct binding and 
combinatorial regulation of hunchback mRNA by Nos, Pum and Brat. Pum was first shown 
to bind each NRE element of hunchback [33, 81]. The Pum-NRE interaction was 
interrogated through mutational analysis and binding assays, defining a high affinity PRE 
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within each NRE bound by a single Pum [32, 33]. Structural, high throughput selection 
and sequencing, and transcriptome-wide analyses corroborated and defined the 
specificity of the Pum-PRE interaction [2, 24, 30]. We now understand that each 
hunchback NRE contains a single high affinity eight nucleotide PRE, the 5´ half of which 
overlaps with each conserved Box B element.  
 
2.5.1 Insights into Nos function 
Insight into the role of Nos in hunchback regulation emerged from structure-
function analysis using Nos transgenes, which identified the ZFs and C terminus as being 
critical for hunchback regulation [49]. Purified, recombinant Nos was also reported to bind 
the NRE without apparent specificity, though we now understand that the NRE mutations 
tested were in fact outside the Nos binding site [2, 49]. Key insights into the Nos-NRE 
interaction came from yeast 3-hybrid assays, which showed that Nos binds to the NRE in 
a Pum-dependent manner, and the resulting ternary complex could also be detected by 
in vitro pulldown assays. Mutations that disrupt Nos, Pum or NRE function prevented 
formation of the ternary complex. Nos did not bind the NRE in the absence of Pum; 
however, when Pum was included, Nos could be crosslinked to the RNA. Nos did not 
stably bind Pum in the absence of NRE RNA. These results indicated that Pum provides 
sequence-specific RNA-binding, whereas Nos recognizes a combination of Pum and 
RNA. Importantly, nucleotides upstream of the PRE were shown to be important for 
incorporation of Nos into this ternary complex [82]. 
We reported biochemical, structural and cell-based studies that show how Nos and 
Pum cooperatively bind NRE RNA [2]. Using RNA electrophoretic mobility shift assays 
(EMSA), we found that Nos tightly binds the Pum-NRE complex and increases the affinity 
of Pum for the NRE, correlating with its ability to enhance translational repression in cells 
in a dosage dependent manner. A critical revelation is that Pum does not merely recruit 
Nos for repression activity; Nos enhances the binding of Pum to hunchback RNA, bringing 
the combined repressive activities of Nos and Pum to bear on hunchback mRNA 




structure of the Nos-Pum-
NRE ternary complex 
illuminated the mechanism 
of Nos-Pum 
cooperativity.[2] Pum 
recognizes the PRE 
sequence in the 
recognizably modular 
fashion, while Nos 
embraces both Pum and 
RNA, effectively clamping 
them together (Figure 2.2). 
The Nos C terminus 
interacts with a loop region 
between the 7th and 8th 
repeats of the Pum RBD. 
Conformational changes in the loop of Pum are induced by the Nos interaction, which 
enables an alpha helix at the C terminus of the Pum RBD to unfold and contact the NRE. 
Mutational analysis affirmed the importance of observed interactions for complex 
formation in vitro; moreover, point mutants of these residues impaired Nos-stimulated 
repression activity of a Renilla luciferase reporter bearing the hb 3'UTR in cells (Figure 
2.3) [2]. The observed contacts also illustrate how mutants of Pum (mutations in the loop 
between repeat 7 and 8), Nos (mutations in the ZFs or C terminus) and Box B of the NRE 
result in loss of hunchback mRNA regulation in embryos [31, 48, 51, 75]. 
The Nos-Pum-NRE structure revealed that the tandem ZFs of Nos bind three 
nucleotides immediately upstream of the PRE, defining the NBS [2]. By performing Nos-
Pum selection of a randomized RNA library and high throughput sequencing (SEQRS), 
we showed that Nos confers specificity for A/U rich NBS sequences in the presence of 
Pum [2, 83]. Nos-NBS specificity is verified in cells and embryos, where mutations of the 
NBS prevent Nos-mediated repression [2, 31, 51, 81]. Moreover, Nos can stimulate Pum 
Figure 2.2 Crystal Structure of Nos-Pum-PRE and Pum-PRE complexes 
(from Ref. [2]) 
Crystal structures by Chen Qui and Traci Hall and published in Weidmann, 
Qui et al. Ref [2]. (A) Nos-Pum-PRE ternary complex. Pum RBD shown as 
yellow ribbon diagram, Nos Zinc Fingers and C terminus as blue surface 
representation, and PRE2 RNA from hunchback (hb) shown as a stick 
model. (B) Pum RBD shown as ribbon diagram bound to hb PRE2 RNA 
shown as stick model.  
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mediated repression of 
mRNAs bearing an NBS, 
but a canonically weak PRE 
sequence (Figure 2.4), as 
in the case of one of the 
cycB NREs; this activity is 
dependent on the dosage 
of Nos. Together, these 
data support a model 
wherein Nos acts as a 
clamp that promotes the 
binding of Pum to the NRE, 
and together they recognize 
an extended NBS+PRE sequence encompassing the Box B region of the NRE. In turn, 
the ternary complex elicits robust repression of hunchback mRNA. 
 
2.5.2 Insights into Brat function 
Brat was identified as a third protein recruited by the Nos-Pum-NRE ternary 
complex [7]. Using a yeast 4-hybrid strategy, the Brat NHL domain was found to bind the 
Pum-Nos-hb NRE complex. Yeast hybrid-based protein interaction assays and in vitro 
pulldown assays indicated that Nos and Pum were both needed to recruit Brat to the NRE. 
Yet no direct interaction of Brat with NRE, Nos or Pum individually could be detected by 
these means. A model was put forth wherein Pum and Nos bind the NRE and then recruit 
Brat through simultaneous protein-protein interactions with Nos and Pum to form a 
quaternary complex [7-9]. Genetic analysis showed that brat mutants disrupted 
hunchback mRNA regulation and abdominal segmentation in embryos, mirroring the 
effects of Nos, Pum or NRE mutants [7, 62]. 
New data on Brat’s RNA-binding properties and its interaction with the NRE 
warrant a re-evaluation of the quaternary complex model. Three studies have now shown 
that Brat is an RNA-binding protein that directly contacts the Box A sequence in each 
hunchback NRE [39, 64, 65]. A crystal structure of the Brat NHL domain bound to RNA 
Figure 2.3 Validation of Nos C terminus and Pum RBD contacts (from 
Ref. [2]) 
(A) Contacts between Pum RBD (yellow ribbon diagram) and Nos C-
terminal helix (shown in dark red). Nos Zinc fingers shown as blue ribbon 
diagram. (B) Repression of Renilla luciferase (RnLuc) reporter bearing 
hunchback (hb) 3'UTR by Nos C-terminal helix (ITMEDAI) deletion and 
point mutants in d.mel-2 cells. Mean percent repression values and 
standard error for four technical replicates are graphed for each effector. 
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revealed an electropositive 
surface of the NHL domain that 
recognizes the six nucleotide, 
single-stranded RNA element, 
and mutation of observed Brat-
RNA contacts (including 
R875A, F916A, and N933A) 
disrupted its RNA-binding and 
cellular repression activities 
[64, 65]. Based on these data, 
it is now apparent that Brat 
does not require Pum and Nos 
to bind the NRE. Although Brat 
and Pum are able to bind to 
the NRE cooperatively [64], it 
is unclear whether protein-
protein interactions underlie 
this cooperative binding, since 
a Brat-Pum interaction could 
not be detected in the absence of NRE RNA [64]. One proposal is that cooperative Brat-
NRE-Pum binding is mediated by changes in RNA secondary structure induced by 
protein-RNA contact [65]. More importantly, it remains uncertain whether the observed 
cooperative binding even impacts repression activity, since synergism between Brat and 
Pum has not yet been demonstrated [64]. 
New insights from structure-function analyses also prompt reassessment of the 
effects of specific mutations on the quaternary complex, as summarized in Table 2.2. For 
example, Pum mutants C1365R, T1366D, or N1368S were reported to disrupt Brat 
recruitment, but the Nos-Pum-NRE structure shows that these residues are at the Nos-
Pum interface, and thus are unlikely to interact with Brat in a quaternary complex [2]. Pum 
mutant G1330D, which is located in a loop between repeats 6 and 7 of the Pum RBD,  
Figure 2.4 Nos expands the target repertoire of Pum (from Ref. [2]) 
(A) Schematic of Renilla luciferase (Rnluc) reporter assay with varying  
NBS-PRE sequences in the 3'UTR. NBS-PRE sequences arranged in 
order of highest affinity (top), including the two hunchback (hb) PREs, to 
lowest affinity (bottom), including a mutant PRE (ACA) and no PRE 
(MCS) 3'UTR. (B) Western blots showing expression of Nos (right) and 
Halotag negative control (left) in titration experiments. (C) Repression 
data from dual luciferase assay expressing gradient of transfected Nos 
and Halotag negative control. Mean percent repression values and 
standard error for four technical replicates are graphed for each effector. 
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does not affect RNA binding or cellular repression activities [7, 37]. Moreover, G1330D 
does not contact Nos in the ternary complex structure, nor does it compromise Nos-Pum 
synergy [2, 37]. Instead, G1330D was proposed to mediate Brat-Pum interaction [7-9], 
but no assay has detected this putative protein-protein interaction and its effect on 
cooperative RNA binding by Pum and Brat has not been evaluated. 
Nos was previously thought to be necessary for Brat recruitment to the NRE [7], 
but direct binding of Brat to Box A obviates that conclusion. Moreover, the Nos mutant 
M378K (referred to as M379K in the original study) prevented Brat recruitment, but the 
Nos-Pum-NRE ternary complex revealed that this residue is at the interface of the Nos-
Pum interaction and is necessary for Nos-Pum synergism [2, 37]. The potential influence 
of Nos on Brat-NRE interaction remains to be re-evaluated considering this new 
information. What effect might Nos have on the Brat-NRE-Pum interaction? Since Nos 
enhances Pum affinity for the NRE, and Pum and Brat cooperatively bind the NRE, we 
speculate that Nos may enhance the Brat-NRE interaction acting through Pum. If true, 
this potential mutual cooperativity would be expected to contribute to spatiotemporal 
control of hunchback mRNA. 
Protein Mutation Original Model New Model Reference 
Pum G1130D Binding to Nos-Pum-NRE Unknown [7] 
Pum C1365R Blocked binding to Nos-
Pum-NRE 
Located at the interface of Nos-Pum, 
predicted to disrupt binding to Nos 
[2, 8] 
Pum T1366D Blocked binding to Nos-
Pum-NRE 
Located at the interface of Nos-Pum, 
predicted to disrupt binding to Nos 
[2, 8] 
Pum N1368S Blocked binding to Nos-
Pum-NRE 
Located at the interface of Nos-Pum, 
predicted to disrupt binding to Nos 
[2, 8] 
Nos M378A or K Blocked binding of Brat to 
Nos-Pum-NRE 
Necessary for Nos-Pum binding to NRE [2, 7, 37] 
Bratfs1 G774D Blocked binding to Nos-
Pum-NRE 
Effect on NRE binding unknown.  Reported 
to disrupt Brat binding to Mira. 
[7, 59, 65] 
Bratfs3 H802L Blocked binding to Nos-
Pum-NRE 
Reduced affinity for NRE, but does not 
directly contact RNA 
[7, 64, 65] 
Brat Y829A Blocked binding to Nos-
Pum-NRE 
Reduced binding to NRE [9, 64, 65] 
Brat R847A Blocked binding to Nos-
Pum-NRE 
Reduced binding to NRE [9, 64, 65] 
Brat R875A Blocked binding to Nos-
Pum-NRE 
Blocked binding to NRE [9, 64, 65] 
Brat G860D  Disrupt 4EHP interaction [62] 
Brat K809A/E810A  Disrupt 4EHP interaction [62] 
Brat K882E  Disrupt 4EHP interaction [62] 
Table 2.2 Pum, Nos and Brat functional residues 
List of documented Pum, Nos, and Brat mutants which disrupt protein-protein and protein-RNA interactions, 
comparing the interpretations from the “Original Model” relative to the “New Model” based on recent studies, as 




Several Brat mutations were originally attributed to disrupt protein-protein 
interactions with the ternary complex [7]. Instead, new information shows that these Brat 
mutations negatively affect its ability to bind RNA, including H802L (bratFS3 allele)[7] and 
three residues located on the “top” electropositive interface (Y829A, R847A, 
R875A)(Table 2.2) [9, 64, 65]. With the exception of H802, the crystal structure of a Brat-
RNA complex shows that these mutated residues line the RNA-binding interface [64, 65]. 
Using current information, we illustrate a model of the quaternary complex on the 
hunchback NRE RNA (Figure 2.1, panel C). The model depicts interaction of the Brat 
NHL domain with its binding site overlapping Box A, the contacts of the Pum RBD bound 
to the PRE and the Nos-NBS interactions [2, 65]. From a structural standpoint, it is not 
possible to dock the proteins consistent with the proposed Brat-Pum contacts. First, the 
Nos-Pum interface occludes the previously proposed interaction site for Brat on Pum [9]. 
As mentioned above, the previously modeled Brat-Pum interface is now known to be the 
RNA-binding interface. Moreover, the intervening four nucleotides between Box A and 
the NBS-PRE do not provide enough distance to permit interaction between the Brat NHL 
domain and Pum G1330. Multiple features are missing from this model including the N 
termini of Brat, Nos and Pum, for which structural information is currently not available. 
Future biochemical and structural analyses are necessary to provide a more complete 
understanding of the quaternary complex architecture. 
 
2.6 Multiple mechanisms of synergistic repression by Pumilio, Nanos and Brain 
Tumor 
Why are three repressors necessary to regulate hunchback mRNA? Redundancy 
is a possibility, but the fact that Pum, Nos and Brat are all required in vivo argues against 
that explanation. Instead, four principles have emerged. First, cooperative RNA binding 
contributes to the observed synergistic regulation through increased RNA affinity and 
specificity, as documented for Nos and Pum [2, 37]. Whether cooperative RNA binding 
by Brat and Pum also contributes to synergism remains unknown. Second, each regulator 
is independently capable of repression, and therefore their collaborative regulation 
provides multiple repression mechanisms that inhibit translation and accelerate mRNA 
decay. Pum can repress PRE-containing mRNAs independent of Nos or Brat. Brat can 
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repress mRNAs bearing BBS motifs independent of Nos and Pum [64, 65]. Nos also 
possesses its own repression activity, as demonstrated by artificial tethering Nos directly 
to mRNA [41, 53]; however, in the natural context, it requires Pum [2, 37]. Acting together, 
the combined activities of Brat, Nos and Pum offers increased magnitude of repression, 
as shown by synergistic repression by Nos and Pum [2, 37], though synergism between 
Brat and Pum has not been demonstrated [64]. The third principle is that the repressors 
each contact specific subunits of the same effector complex, as described for the CNOT 
complex below, resulting in enhanced recruitment to the target mRNA. A fourth principle 
is that collaboration imparts versatility in the means of controlling protein expression. For 
instance, repression of Hunchback protein synthesis is caused by translational inhibition 
and deadenylation early in embryogenesis followed by hunchback mRNA degradation 
during the MZT [39, 47, 52, 73].  
Collaborative repression by 
Pum, Nos and Brat is mediated 
through multiple mechanisms, as 
shown in Figure 2.5. Repression of 
translation by Pum, Nos and Brat is 
caused by inhibition of both 5´ cap 
and poly(A)-mediated translation 
(Figure 2.5, panel A). First, Pum 
antagonizes the translational activity 
of PABP; PABP interference has 
been demonstrated in cellular 
repression assays [38], but the use 
of this poly(A)-mediated mechanism 
in the embryo must be verified. 
Second, Brat recruits 4EHP, which 
inhibits translation by displacing 
eIF4E from the 5´ cap structure [62]. 
Supporting this mechanism, the cap 
binding activity of 4EHP is required 
Figure 2.5 Multiple mechanisms of repression by Pum, Nos, 
and Brat (from Ref. [1]) 
(A) Translational repression of target mRNAs can be mediated 
through recruitment of alternative cap-binding protein 4EHP by 
Brat, which is proposed to prevent binding of eIF4F translation 
initiation complex with the m7G. In addition, Pum antagonizes 
the translation activity of Poly(A) binding protein (PABP).  (B) 
mRNA decay can be initiated through recruitment of the (CNOT) 
complex, which catalyzes deadenylation and promotes 
decapping of the target mRNA. Pum recruits the Pop2 
deadenylase to stimulate deadenylation, and Nos directly 
recruits Not1 and Not3 of the CNOT complex to stimulate 
deadenylation and decapping. Solid lines indicated documented 




in vivo. Brat mutants (G860D, K809A/E810A, R837D, K882E) that prevent 4EHP 
recruitment were identified, and Brat R837D or K882E did not repress hunchback mRNA 
in embryos [62]. In cellular repression assays, however, the Brat R837D mutation had no 
effect, providing conflicting information about the importance of 4EHP recruitment for 
Brat-mediated repression in all contexts [64]. Third, Nos causes translational repression 
in cell-based assays via a Nos Effector Domain (NED) in the protein’s N terminus. The 
mechanism of this Nos-mediated translational repression is currently unknown, but might 
involve the action of CNOT complex and associated translational repressors 4E-T and 
Me31B (homolog of mammalian DDX6) [84-86]. 
Pum, Nos and Brat also accelerate mRNA decay through multiple mechanisms, 
with collaborative recruitment of the CNOT complex emerging as a central theme.[37-40, 
51, 52] Both Nos and Pum promote deadenylation by recruiting the CNOT complex[38, 
41, 53-55]. The Pum RBD binds the Pop2 deadenylase subunit [38, 40-42], whereas the 
Nos NED contacts the CNOT1 and CNOT3 subunits [53]. Brat also associates with the 
CNOT complex [67], but the contacts and its effect on deadenylation remain to be 
determined. When combined on NRE-containing mRNA, Brat, Nos and Pum may 
synergistically enhance deadenylase recruitment, resulting in accelerated deadenylation 
and subsequent mRNA decay [43]. To test this prediction, the contributions of the 
individual RBP-CNOT contacts on decay of hunchback mRNA should be evaluated in 
embryos. Nos also accelerates 5' decapping (Figure 2.5), and inactivation of the 
decapping enzyme Dcp2 blocked Nos-mediated mRNA decay, as did depletion of CNOT3 
[53]. It remains unclear whether Nos directly contacts the decapping enzyme. 
Alternatively, Dcp2 may be linked to Nos through the CNOT complex, which associates 
with decapping factors [85, 86]. 
Additional repression mechanisms appear to contribute to the repression of 
hunchback mRNA. For instance, we identified three repression domains (RDs) in the N 
terminus of Pum, each of which potently represses translation and promotes mRNA 
decay in cell-based assays. As will be described in subsequent chapters, we found that 
the Pum RDs utilize the CNOT complex, in addition to decapping and 5'-3' decay [38]. 
Future research will focus on how the Pum RDs contribute to synergistic regulation to 
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ensure proper spatial and temporal control of Hunchback protein expression (for progress 
on this aim, see Appendix C). 
 
2.7 Global impact of Pumilio, Nanos, and Brain Tumor on gene expression 
With our new understanding of combinatorial control by Brat, Nos and Pum, it is 
now possible to survey their potential impact on the transcriptome (and thus proteome), 
both individually and collaboratively. Here we integrate experimental and transcriptome-
wide predictions, revealing broad potential impact on gene expression. Target mRNAs 
fall into several categories (Figure 2.6) including those individually targeted by Brat or 
Pum, jointly targeted by Brat and Pum, jointly targeted by Nos and Pum, and 
combinatorially controlled by all three RBPs. 
 
2.7.1 Analysis of bound mRNAs from existing datasets 
To begin, we integrated experimental evidence from several transcriptome-wide 
studies that used RNA-protein coimmunoprecipitation with microarray (i.e. RIP-Chip) to 
identify mRNAs bound by Pum and Brat. Unfortunately, no such dataset exists for Nos. 
Gerber et al. identified mRNAs enriched by epitope-tagged Pum RBD purified from 
embryos or adult ovaries [24], and Laver et al. performed RIP-Chip of endogenous Pum 
from early embryos [39]. Together, 1163 Pum-associated mRNAs were reported; of 
these, 679 have a consensus PRE. Laver et al. also identified mRNAs that copurified with 
endogenous Brat from early embryos, and Loedige et al. identified mRNAs enriched by 
epitope-tagged Brat purified from late-stage embryos [39, 65]. When combined, 3601 
mRNAs were associated with Brat, with 605 shared between datasets, and 3117 mRNAs 
contain a BBS. Together, this evidence indicates widespread targeting of mRNAs by Pum 
or Brat, a conclusion that is bolstered by the fact that Pum and Brat repress translation 
and promote decay of many mRNAs during embryogenesis [39]. 
Comparison of the Pum- and Brat-bound mRNAs reveals an overlap of 484 
mRNAs, indicating the potential coregulation of many mRNAs. Functional assays lend 
support for dual regulation of several mRNAs by Brat and Pum [39, 64, 65]. For example, 
the dMyc mRNA, which contains 6 PREs and 46 BBS motifs, is repressed by Pum and 
Brat in the differentiating cystoblast and in cellular repression assays, where Nos is 
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absent [65, 87]. However, since the majority of targets identified for each regulator did not 
overlap, Loedige et al and Laver et al (2015) concluded that Brat and Pum individually 
regulate most of their respective target mRNAs. It is noteworthy that these analyses 
focused on the early embryo and adult female germline and likely miss targets in different 
tissues and life stages, such as the nervous system, where Pum and Brat have 
documented roles [15, 17, 21, 22, 26, 28, 57, 59-61, 88-90]. 
 
2.7.2 Analysis of putative targets: PRE-containing mRNAs 
To survey the genome-wide regulatory potential of each RBP, we searched the 
3´UTRs of all Drosophila mRNAs for potential binding sites. The number of each predicted 
binding site was calculated for annotated 3´UTR isoforms. When tallying total numbers of 
binding sites throughout the 
transcriptome, we considered for each 
unique gene only the mRNA isoform 
with the longest 3’UTR. The PRE 
consensus that we chose to search for, 
5´-UGUANAUA, was derived from 
multiple approaches, including SEQRS, 
RNAcompete, and RIP-Chip, and 
validated by EMSA and structural 
analyses [2, 5, 24, 35, 39, 91]. In total, 
2477 mRNAs possess one or more 
PREs in their 3´UTR, including many 
potential targets with interesting 
biological implications. The mRNA 
encoding the antiproliferative protein, 
Tob, contains the highest number of 
PREs, with 12 found in its 3´UTR. The 
second and third highest number of 
PREs were in the cpx mRNA (11 
PREs), encoding a protein involved in 
Figure 2.6  Classification of Pum, Nos, and Brat targets 
(from Ref. [1]) 
Classification of target mRNAs regulated by Pum, Nos, 
and/or Brat, based on experimental evidence and 
bioinformatics analysis of Drosophila 3´UTRs using RNA-
binding affinity, specificity, and cooperativity. Brat Binding 
Site (BBS), Pum Response Element (PRE), relaxed PRE 
(rPRE), and Nos Binding Site (NBS), described in the text, 
are indicated for each of six categories. 
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synaptic transmission, and eag mRNA (9 PREs), encoding a voltage gated potassium ion 
channel that controls neuronal excitability. Some of the top Gene Ontology (GO) terms 
enriched for PRE-containing mRNAs include nervous system processes such as long 
term memory, axon guidance, dendrite morphogenesis, and synaptic organization (see 
Appendix D for list of top ten GO terms). Several of the top GO terms for PRE-containing 
transcripts (as well as mRNAs containing NBS and BBS motifs) are also related to the 
regulation of transcription, suggesting broader implications of these RBPs for gene 
regulatory networks.  
 
2.7.3 Analysis of putative targets: BBS-containing mRNAs 
We used the consensus BBS, 5´-WYGUUD, derived from RIP-Chip and 
RNAcompete analyses and supported by EMSA and structural analyses [39, 64, 65], and 
found that 9018 mRNAs contain at least one BBS. Note that we opted to include a C at 
nucleotide position 2 of the BBS search motif to be inclusive of the functional BBS of 
hunchback NRE1, which contributes to regulation in vivo, though it is reported to be lower 
affinity relative to the BBS in NRE2 [64]. Of all mRNAs containing BBS motifs, the mei-
P26 mRNA, which encodes another TRIM-NHL tumor suppressor involved in germline 
differentiation, contains the most at 76 potential sites. Brat mRNA contains the second 
highest number with 70 BBS motifs, supporting the potential for autoregulation, as 
suggested by Laver et al, 2015. Interestingly, the smooth mRNA, encoding a regulator of 
axon guidance, has 66 BBS sites. The top enriched GO terms for BBS-containing mRNAs 
include long term memory, axon guidance (consistent with its previously established 
function in mushroom body neurons), dendrite morphogenesis, and neurotransmitter 
secretion (Appendix D). Other top terms relate to developmental processes, including 
wing morphogenesis in which Brat plays a documented role [92]. 
 
2.7.4 Putative combinatorial targets 
A consensus binding site has not been found for Nos alone, despite our attempts 
[2]. Instead, Nos requires Pum for specific binding to RNA, and we identified a consensus 
NBS, encompassing four nucleotides upstream of the PRE, using SEQRS and 
corroborated by EMSA, Nos-Pum-RNA structures, and functional assays [2]. Nos binding 
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to the NBS enhances binding of Pum to “perfect” consensus PREs, 5’-
DDWWUGUANAUA (NBS+PRE) (where D=A/G/T and W=A/T), including those in the 
hunchback NREs. Some 1077 mRNAs have a 3´UTR with a NBS+PRE, with the cpx (8 
motifs), tob (7 motifs), and kruppel (5 motifs) mRNAs containing the highest number of 
these motifs. Similar to PRE-containing mRNAs, the top enriched GO terms for the NBS-
PRE category include nervous system-related terms such as long term memory and axon 
guidance; in addition, terms for motor neuron axon guidance and ventral cord 
development were enriched (the latter being a unique term to this binding site category) 
(Appendix D). 
Additionally, Nos enables Pum binding to “relaxed” PRE sites (rPRE), wherein 
nucleotides in position 5-8 of the PRE do not match the consensus (NBS+rPRE: 5’-
DDWWUGUA) [2]. This category includes Nos-Pum targets bicoid and Cyclin B and was 
validated by SEQRS, EMSA, a Nos-Pum-Cyclin B RNA crystal structure and cellular 
repression assays [2, 18, 41, 51, 93]. NBS+rPREs are present in 6225 mRNAs. The mei-
P26 mRNA contains 47 such motifs in its 3´UTR, consistent with its CNOT-dependent 
repression by Nos and Pum in germline stem cells [55]. The smooth mRNA has the 
second most NBS+rPREs (41 motifs), suggesting a possible relationship of Pum and Nos 
to axon guidance. The longest brat mRNA isoform has 36 NBS+rPRE motifs (and no 
perfect PREs), which likely underlie the ability of Nos and Pum to repress its translation 
in germline stem cells.[87] We also analyzed the Pum-bound target mRNAs for the 
presence of these motifs and found significant enrichment: 56% have a PRE, 79% have 
NBS+rPRE and 28% have NBS+PRE (p values < 0.002) relative to 19%, 52% and 8%, 
respectively, for all 3´UTRs. Based on these data, we predict that Nos expands the 
regulatory potential of Pum. In summary, our global target predictions suggest that 
regulation by Pum, Nos and Brat is pervasive. The top enriched GO term biological 
processes for NBS-rPRE mRNAs include long term memory, axon guidance, motor 
neuron axon guidance, and wing morphogenesis (Appendix D). 
We next asked how many transcripts may be combinatorially regulated by Brat and 
Pum and found that 2124 mRNAs possess both BBS and PRE motifs (BBS+PRE)(Figure 
2.6). In only 182 of these mRNAs, a BBS is located 1-13 nucleotides upstream of a PRE, 
the range of separation found in verified targets that are jointly regulated by Brat and 
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Pum. Enriched GO terms for BBS-PRE mRNAs included developmental processes, such 
as wing and branch structure morphogenesis; however, the common terms for the 
previous categories (PRE, BBS, NBS-PRE, NBS-rPRE) of long term memory and axon 
guidance were absent from the top ten terms of BBS-PRE mRNAs (Appendix D).  
We also assessed how many mRNAs possess binding sites for Brat, Nos and Pum 
and found that 1858 mRNAs possess at least one binding site for each protein within the 
3´UTR (Figure 2.6). The paralytic (para) mRNA, a known target of Brat, Nos and Pum 
belongs to this category [26, 94]. Para encodes a sodium ion channel that functions in the 
larval motor neurons and its longest 3´UTR has one PRE, 26 NBS+rPRE sites and 19 
BBS motifs. In fact, many of the predicted targets have the potential to be combinatorially 
regulated: nearly 81% of 3´UTRs with PRE or NBS+rPRE/PRE sites also possess BBS 
motifs, and reciprocally, 66% of 3´UTRs with BBS motifs also contain a PRE or 
NBS+rPRE/PRE. GO term analysis for these binding sites yielded the most unique top 
terms among binding site categories, including locomotor rhythm, olfactory learning, 
synaptic growth at neuromuscular junction, dorsal closure, regulation of glucose 
metabolic process, and protein phosphorylation (Appendix D). 
If the distance between the BBS and PRE motifs is restricted to <13 nucleotides, 
as is the case in hunchback NREs, only 24% of 3´UTRs with PRE or NBS+rPRE/PRE 
sites also possess an upstream BBS motif and only 19% of 3´UTRs with BBS motifs also 
contain a downstream PRE or NBS+rPRE/PRE. Together, these results indicate that 
collaborative regulation of many mRNAs is possible, but the extent depends on the 
importance of proximity of the RBP binding sites. Interestingly, only 63 mRNAs have a 
BBS located upstream (<13 nucleotides between BBS and PRE) of a NBS+PRE (a 
perfect NRE), and, most surprisingly, the only target with more than one such perfect 
NRE motif is hunchback, perhaps making it the most sensitive to Nos-Pum-Brat 
cooperative regulation. Other genes in the perfect NRE category function in signal 
transduction (such as tolloid, rhomboid and Ric) and transcription (such as knirps, sex 
combs reduced, clock, and drop). Indeed, knirps mRNA is bound and repressed by Pum 
and Brat [39, 65]. The tolloid mRNA uniquely has three tandem BBS motifs in the context 
of one perfect NRE and encodes a metalloprotease that promotes Decapentaplegic (Dpp) 
signaling, which controls dorsal embryonic development and germline stem cell 
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maintenance [95-97]. In addition, the pum mRNA contains a perfect NRE, supported by 
binding data, suggesting a means of feedback to regulate the regulator [24, 39]. 
Interestingly, many of the top enriched GO terms for the NRE category are related to 
development. Overall, these results suggest that combinatorial regulation by Pum, Nos 
and Brat could impact many transcripts and biological processes, but functional analysis 
is essential to determine if cooperative RNA binding and synergistic repression are 
widespread.  
 
2.7.5 Considerations for transcript binding site analysis 
These binding site predictions are informative and can stimulate future 
investigations, but have limitations that are important to acknowledge. Regulation will be 
affected by parameters that we cannot yet integrate, including the level, timing, and cell 
type expression of each RBP in vivo. Nos is a prime example. Nos is predominantly 
expressed in the adult ovary and early embryo [98], although it also has documented 
roles in neurons [15, 21, 26, 27]. Regulation of Cyclin B mRNA provides an example of 
cell type specific regulation. Nos and Pum repress Cyclin B in primordial germ cells, which 
have a high concentration of Nos. The Cyclin B 3´UTR has no perfect PRE, but instead it 
possesses five NBS+rPRE motifs that confer regulation. Cyclin B also has 7 BBS motifs, 
but since Brat is absent in primordial germ cells, they are irrelevant for regulation in this 
cell type. Mei-P26 mRNA is another example of cell-type specific regulation [55].  As 
noted above, its 3´UTR contains both perfect PREs and many NBS+rPREs, and it is 
repressed by Pum and Nos in germline stem cells. Despite its many BBS elements, mei-
P26 mRNA is not likely affected by Brat in germline stem cells, as brat mRNA itself is 
repressed in this cell type by Nos and Pum via multiple NBS+rPREs. The expression 
pattern of the predicted targets will also determine whether they are regulated by Brat, 
Pum, and/or Nos, dictated by coincidence of target and regulator expression. In the 
example of hunchback, its mRNA is most highly expressed in early embryo and adult 
female ovary, coincident with high expression of Pum, Nos and Brat [23, 73, 75, 80, 98]. 
The effect of the number, location, and spacing of each binding site is also not fully 
known. For our survey, we required that at least one binding site is present in the putative 
target. Indeed, for Nos and Pum, reporter assays indicate that one PRE or NBS+rPRE is 
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sufficient to confer repression, and increased number and affinity of binding sites 
correlates with stronger repression [2]. For Brat, one binding motif can by recognized by 
the protein, but two BSS motifs in the same RNA were bound more tightly [64]. Moreover, 
in cellular repression assays, multiple BBS motifs conferred regulation by Brat, with two 
motifs being the minimum tested [39, 64]. The relative orientation of the binding sites is 
also likely relevant. For Nos-Pum targets, the NBS must be directly upstream of the PRE 
[2]. For Brat-Pum targets, we allowed up to 13 nucleotides of separation between BBS 
and PRE, a parameter that is consistent with validated targets. The impact of the proximity 
of the BBS to an NBS or PRE is not known, although it is likely to affect collaboration. 
Based on cellular repression assays with reporter mRNAs, other spacing and 
arrangements of BBS and PRE motifs may be permissible for Brat or Pum-mediated 
repression [65], but no data are available regarding cooperative RNA binding or 
synergistic repression. 
RNA structure is likely to influence accessibility of the predicted binding sites, but 
how this parameter affects binding and regulation by Pum, Nos and Brat remains 
uncertain. Since each RBP binds a single-stranded RNA motif, structure may occlude or 
reduce binding affinity; however, evidence indicates that mammalian Pum proteins can 
disrupt double-stranded RNA to gain access to a PRE [99, 100]. RNA binding by the Brat 
NHL domain was reduced when the BBS motif was within a stem loop of an RNA; when 
an RNA with a structure-occluded BBS also contained a PRE, addition of Pum 
strengthened binding by Brat, perhaps promoted by Pum’s ability to disrupt RNA structure 
[65]. The ability of Nos and Pum to bind structured RNA cooperatively remains untested. 
Because of these remaining questions and lack of information on the effect of RNA 
structure on regulation in vivo, and the difficulties of accurately predicting RNA structure, 
we did not incorporate RNA structure predictions into our analysis at this time. 
Alternative 3´ end processing of mRNAs could impact regulation by Brat, Nos and 
Pum in cases where their binding sites are altered. The hid mRNA, which is regulated by 
Nos and Pum in neurons [27], is an example where two mRNA isoforms are produced by 
alternative 3' end processing: the hid-RA mRNA has a long 3´UTR with multiple 
NBS+PREs that is regulated by Nos-Pum, whereas these sites are eliminated in the 
shorter hid-RB version. Alternative processing of para mRNA produces three 3´UTR 
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isoforms: the longest has one perfect PRE, 26 NBS+rPRE motifs and 19 BBS motifs; the 
medium length isoform has multiple NBS+rPREs but no PRE; and the short isoform lacks 
these sites altogether. Intriguingly, regulation of para depends on Brat in certain neuronal 
subtypes but not others, perhaps the result of alternative processing of the 3´UTR or on 
differential expression of Brat [26]. In the case of hunchback mRNA, alternative 3´ end 
processing is developmentally regulated to produce two mRNA isoforms: a long 3´UTR 
present on the zygotically-expressed hunchback-RA mRNA and a short 3´UTR on the 
maternally-provided hunchback-RB isoform in early embryos. Importantly, each isoform 
contains both NRE elements. 
 
2.8 Conclusion  
With the revelation of many uncharacterized RBPs [3-6], future studies are 
necessary to analyze their individual regulatory activities, RNA-binding specificities and 
target mRNAs. However, as exemplified by Pum, Nos and Brat, to succeed in 
understanding post-transcriptional regulatory networks, it is imperative to address 
combinatorial control. Control by the many more uncharacterized RBPs will likely involve 
cooperative RNA binding, altered specificity, and the interplay of multiple regulatory 
mechanisms that contribute to synergistic regulation or even bifunctional switches [45, 
101]. We have learned a great deal about the functions of Pum, Nos and Brat mediated 
regulation, but important challenges remain, including identification of combinatorially 
regulated mRNAs on a global scale, comprehensive dissection of the protein interaction 
network between the trio of RBPs and their corepressors, and interrogation of the multiple 
repression mechanisms in vivo. Future work should also extend the paradigms of 
Drosophila Pum, Nos and Brat to investigate the targets, RNA and protein interactions, 
and regulatory mechanisms of their mammalian homologs. Ultimately these efforts should 
uncover more of the underlying code of combinatorial regulation by RBPs. 
 
2.9 References 
1. Arvola, R.M., C.A. Weidmann, T.M. Tanaka Hall, and A.C. Goldstrohm, 
Combinatorial control of messenger RNAs by Pumilio, Nanos and Brain Tumor 
Proteins. RNA Biol, 2017. 14(11): p. 1445-1456. 
75 
 
2. Weidmann, C.A., C. Qiu, R.M. Arvola, T.F. Lou, J. Killingsworth, Z.T. Campbell, 
T.M. Tanaka Hall, and A.C. Goldstrohm, Drosophila Nanos acts as a molecular 
clamp that modulates the RNA-binding and repression activities of Pumilio. Elife, 
2016. 5. 
3. Baltz, A.G., M. Munschauer, B. Schwanhausser, A. Vasile, Y. Murakawa, M. 
Schueler, N. Youngs, D. Penfold-Brown, K. Drew, M. Milek, E. Wyler, R. 
Bonneau, M. Selbach, C. Dieterich, and M. Landthaler, The mRNA-bound 
proteome and its global occupancy profile on protein-coding transcripts. Mol Cell, 
2012. 46(5): p. 674-90. 
4. Castello, A., B. Fischer, K. Eichelbaum, R. Horos, B.M. Beckmann, C. Strein, 
N.E. Davey, D.T. Humphreys, T. Preiss, L.M. Steinmetz, J. Krijgsveld, and M.W. 
Hentze, Insights into RNA biology from an atlas of mammalian mRNA-binding 
proteins. Cell, 2012. 149(6): p. 1393-406. 
5. Gerstberger, S., M. Hafner, and T. Tuschl, A census of human RNA-binding 
proteins. Nat Rev Genet, 2014. 15(12): p. 829-45. 
6. Kwon, S.C., H. Yi, K. Eichelbaum, S. Fohr, B. Fischer, K.T. You, A. Castello, J. 
Krijgsveld, M.W. Hentze, and V.N. Kim, The RNA-binding protein repertoire of 
embryonic stem cells. Nat Struct Mol Biol, 2013. 20(9): p. 1122-30. 
7. Sonoda, J. and R.P. Wharton, Drosophila Brain Tumor is a translational 
repressor. Genes Dev, 2001. 15(6): p. 762-73. 
8. Edwards, T.A., S.E. Pyle, R.P. Wharton, and A.K. Aggarwal, Structure of Pumilio 
reveals similarity between RNA and peptide binding motifs. Cell, 2001. 105(2): p. 
281-9. 
9. Edwards, T.A., B.D. Wilkinson, R.P. Wharton, and A.K. Aggarwal, Model of the 
brain tumor-Pumilio translation repressor complex. Genes Dev, 2003. 17(20): p. 
2508-13. 
10. Wickens, M., D.S. Bernstein, J. Kimble, and R. Parker, A PUF family portrait: 
3'UTR regulation as a way of life. Trends Genet, 2002. 18(3): p. 150-7. 
11. Lehmann, R. and C. Nusslein-Volhard, Involvement of the pumilio gene in the 




12. Nusslein-Volhard, C., H.G. Frohnhofer, and R. Lehmann, Determination of 
anteroposterior polarity in Drosophila. Science, 1987. 238(4834): p. 1675-81. 
13. Forbes, A. and R. Lehmann, Nanos and Pumilio have critical roles in the 
development and function of Drosophila germline stem cells. Development, 1998. 
125(4): p. 679-90. 
14. Lin, H. and A.C. Spradling, A novel group of pumilio mutations affects the 
asymmetric division of germline stem cells in the Drosophila ovary. Development, 
1997. 124(12): p. 2463-76. 
15. Ye, B., C. Petritsch, I.E. Clark, E.R. Gavis, L.Y. Jan, and Y.N. Jan, Nanos and 
Pumilio are essential for dendrite morphogenesis in Drosophila peripheral 
neurons. Curr Biol, 2004. 14(4): p. 314-21. 
16. Schweers, B.A., K.J. Walters, and M. Stern, The Drosophila melanogaster 
translational repressor pumilio regulates neuronal excitability. Genetics, 2002. 
161(3): p. 1177-85. 
17. Dubnau, J., A.S. Chiang, L. Grady, J. Barditch, S. Gossweiler, J. McNeil, P. 
Smith, F. Buldoc, R. Scott, U. Certa, C. Broger, and T. Tully, The staufen/pumilio 
pathway is involved in Drosophila long-term memory. Curr Biol, 2003. 13(4): p. 
286-96. 
18. Asaoka-Taguchi, M., M. Yamada, A. Nakamura, K. Hanyu, and S. Kobayashi, 
Maternal Pumilio acts together with Nanos in germline development in 
Drosophila embryos. Nat Cell Biol, 1999. 1(7): p. 431-7. 
19. Olesnicky, E.C., B. Bhogal, and E.R. Gavis, Combinatorial use of translational 
co-factors for cell type-specific regulation during neuronal morphogenesis in 
Drosophila. Dev Biol, 2012. 365(1): p. 208-18. 
20. Burow, D.A., M.C. Umeh-Garcia, M.B. True, C.D. Bakhaj, D.H. Ardell, and M.D. 
Cleary, Dynamic regulation of mRNA decay during neural development. Neural 
Dev, 2015. 10: p. 11. 
21. Menon, K.P., S. Andrews, M. Murthy, E.R. Gavis, and K. Zinn, The translational 
repressors Nanos and Pumilio have divergent effects on presynaptic terminal 
growth and postsynaptic glutamate receptor subunit composition. J Neurosci, 
2009. 29(17): p. 5558-72. 
77 
 
22. Menon, K.P., S. Sanyal, Y. Habara, R. Sanchez, R.P. Wharton, M. Ramaswami, 
and K. Zinn, The translational repressor Pumilio regulates presynaptic 
morphology and controls postsynaptic accumulation of translation factor eIF-4E. 
Neuron, 2004. 44(4): p. 663-76. 
23. Barker, D.D., C. Wang, J. Moore, L.K. Dickinson, and R. Lehmann, Pumilio is 
essential for function but not for distribution of the Drosophila abdominal 
determinant Nanos. Genes Dev, 1992. 6(12A): p. 2312-26. 
24. Gerber, A.P., S. Luschnig, M.A. Krasnow, P.O. Brown, and D. Herschlag, 
Genome-wide identification of mRNAs associated with the translational regulator 
PUMILIO in Drosophila melanogaster. Proc Natl Acad Sci U S A, 2006. 103(12): 
p. 4487-92. 
25. Laver, J.D., A.J. Marsolais, C.A. Smibert, and H.D. Lipshitz, Regulation and 
Function of Maternal Gene Products During the Maternal-to-Zygotic Transition in 
Drosophila. Curr Top Dev Biol, 2015. 113: p. 43-84. 
26. Muraro, N.I., A.J. Weston, A.P. Gerber, S. Luschnig, K.G. Moffat, and R.A. 
Baines, Pumilio binds para mRNA and requires Nanos and Brat to regulate 
sodium current in Drosophila motoneurons. J Neurosci, 2008. 28(9): p. 2099-109. 
27. Bhogal, B., A. Plaza-Jennings, and E.R. Gavis, Nanos-mediated repression of 
hid protects larval sensory neurons after a global switch in sensitivity to apoptotic 
signals. Development, 2016. 143(12): p. 2147-59. 
28. Chen, G., W. Li, Q.S. Zhang, M. Regulski, N. Sinha, J. Barditch, T. Tully, A.R. 
Krainer, M.Q. Zhang, and J. Dubnau, Identification of synaptic targets of 
Drosophila pumilio. PLoS Comput Biol, 2008. 4(2): p. e1000026. 
29. Edwards, T.A., J. Trincao, C.R. Escalante, R.P. Wharton, and A.K. Aggarwal, 
Crystallization and characterization of Pumilo: a novel RNA binding protein. J 
Struct Biol, 2000. 132(3): p. 251-4. 
30. Wang, X., J. McLachlan, P.D. Zamore, and T.M. Hall, Modular recognition of 
RNA by a human pumilio-homology domain. Cell, 2002. 110(4): p. 501-12. 
31. Wharton, R.P., J. Sonoda, T. Lee, M. Patterson, and Y. Murata, The Pumilio 




32. Zamore, P.D., D.P. Bartel, R. Lehmann, and J.R. Williamson, The PUMILIO-RNA 
interaction: a single RNA-binding domain monomer recognizes a bipartite target 
sequence. Biochemistry, 1999. 38(2): p. 596-604. 
33. Zamore, P.D., J.R. Williamson, and R. Lehmann, The Pumilio protein binds RNA 
through a conserved domain that defines a new class of RNA-binding proteins. 
Rna, 1997. 3(12): p. 1421-33. 
34. Hall, T.M., De-coding and re-coding RNA recognition by PUF and PPR repeat 
proteins. Curr Opin Struct Biol, 2016. 36: p. 116-21. 
35. Wang, X., P.D. Zamore, and T.M. Hall, Crystal structure of a Pumilio homology 
domain. Mol Cell, 2001. 7(4): p. 855-65. 
36. Hall, T.M., Expanding the RNA-recognition code of PUF proteins. Nat Struct Mol 
Biol, 2014. 21(8): p. 653-5. 
37. Weidmann, C.A. and A.C. Goldstrohm, Drosophila Pumilio protein contains 
multiple autonomous repression domains that regulate mRNAs independently of 
Nanos and brain tumor. Mol Cell Biol, 2012. 32(2): p. 527-40. 
38. Weidmann, C.A., N.A. Raynard, N.H. Blewett, J. Van Etten, and A.C. 
Goldstrohm, The RNA binding domain of Pumilio antagonizes poly-adenosine 
binding protein and accelerates deadenylation. RNA, 2014. 20(8): p. 1298-319. 
39. Laver, J.D., X. Li, D. Ray, K.B. Cook, N.A. Hahn, S. Nabeel-Shah, M. Kekis, H. 
Luo, A.J. Marsolais, K.Y. Fung, T.R. Hughes, J.T. Westwood, S.S. Sidhu, Q. 
Morris, H.D. Lipshitz, and C.A. Smibert, Brain tumor is a sequence-specific RNA-
binding protein that directs maternal mRNA clearance during the Drosophila 
maternal-to-zygotic transition. Genome Biol, 2015. 16: p. 94. 
40. Van Etten, J., T.L. Schagat, J. Hrit, C.A. Weidmann, J. Brumbaugh, J.J. Coon, 
and A.C. Goldstrohm, Human Pumilio proteins recruit multiple deadenylases to 
efficiently repress messenger RNAs. J Biol Chem, 2012. 287(43): p. 36370-83. 
41. Kadyrova, L.Y., Y. Habara, T.H. Lee, and R.P. Wharton, Translational control of 
maternal Cyclin B mRNA by Nanos in the Drosophila germline. Development, 
2007. 134(8): p. 1519-27. 
79 
 
42. Goldstrohm, A.C., B.A. Hook, D.J. Seay, and M. Wickens, PUF proteins bind 
Pop2p to regulate messenger RNAs. Nat Struct Mol Biol, 2006. 13(6): p. 533-9. 
43. Goldstrohm, A.C. and M. Wickens, Multifunctional deadenylase complexes 
diversify mRNA control. Nat Rev Mol Cell Biol, 2008. 9(4): p. 337-44. 
44. Temme, C., M. Simonelig, and E. Wahle, Deadenylation of mRNA by the CCR4-
NOT complex in Drosophila: molecular and developmental aspects. Front Genet, 
2014. 5: p. 143. 
45. Suh, N., S.L. Crittenden, A. Goldstrohm, B. Hook, B. Thompson, M. Wickens, 
and J. Kimble, FBF and its dual control of gld-1 expression in the Caenorhabditis 
elegans germline. Genetics, 2009. 181(4): p. 1249-60. 
46. Chritton, J.J. and M. Wickens, A role for the poly(A)-binding protein Pab1p in 
PUF protein-mediated repression. J Biol Chem, 2011. 286(38): p. 33268-78. 
47. Chagnovich, D. and R. Lehmann, Poly(A)-independent regulation of maternal 
hunchback translation in the Drosophila embryo. Proc Natl Acad Sci U S A, 2001. 
98(20): p. 11359-64. 
48. Lehmann, R. and C. Nusslein-Volhard, The maternal gene nanos has a central 
role in posterior pattern formation of the Drosophila embryo. Development, 1991. 
112(3): p. 679-91. 
49. Curtis, D., D.K. Treiber, F. Tao, P.D. Zamore, J.R. Williamson, and R. Lehmann, 
A CCHC metal-binding domain in Nanos is essential for translational regulation. 
Embo J, 1997. 16(4): p. 834-43. 
50. Hashimoto, H., K. Hara, A. Hishiki, S. Kawaguchi, N. Shichijo, K. Nakamura, S. 
Unzai, Y. Tamaru, T. Shimizu, and M. Sato, Crystal structure of zinc-finger 
domain of Nanos and its functional implications. EMBO Rep, 2010. 11(11): p. 
848-53. 
51. Wharton, R.P. and G. Struhl, RNA regulatory elements mediate control of 




52. Wreden, C., A.C. Verrotti, J.A. Schisa, M.E. Lieberfarb, and S. Strickland, Nanos 
and pumilio establish embryonic polarity in Drosophila by promoting posterior 
deadenylation of hunchback mRNA. Development, 1997. 124(15): p. 3015-23. 
53. Raisch, T., D. Bhandari, K. Sabath, S. Helms, E. Valkov, O. Weichenrieder, and 
E. Izaurralde, Distinct modes of recruitment of the CCR4-NOT complex by 
Drosophila and vertebrate Nanos. EMBO J, 2016. 35(9): p. 974-90. 
54. Bhandari, D., T. Raisch, O. Weichenrieder, S. Jonas, and E. Izaurralde, 
Structural basis for the Nanos-mediated recruitment of the CCR4-NOT complex 
and translational repression. Genes Dev, 2014. 28(8): p. 888-901. 
55. Joly, W., A. Chartier, P. Rojas-Rios, I. Busseau, and M. Simonelig, The CCR4 
deadenylase acts with Nanos and Pumilio in the fine-tuning of Mei-P26 
expression to promote germline stem cell self-renewal. Stem Cell Reports, 2013. 
1(5): p. 411-24. 
56. Schupbach, T. and E. Wieschaus, Female sterile mutations on the second 
chromosome of Drosophila melanogaster. II. Mutations blocking oogenesis or 
altering egg morphology. Genetics, 1991. 129(4): p. 1119-36. 
57. Arama, E., D. Dickman, Z. Kimchie, A. Shearn, and Z. Lev, Mutations in the beta-
propeller domain of the Drosophila brain tumor (brat) protein induce neoplasm in 
the larval brain. Oncogene, 2000. 19(33): p. 3706-16. 
58. Woodhouse, E., E. Hersperger, and A. Shearn, Growth, metastasis, and 
invasiveness of Drosophila tumors caused by mutations in specific tumor 
suppressor genes. Dev Genes Evol, 1998. 207(8): p. 542-50. 
59. Lee, C.Y., B.D. Wilkinson, S.E. Siegrist, R.P. Wharton, and C.Q. Doe, Brat is a 
Miranda cargo protein that promotes neuronal differentiation and inhibits 
neuroblast self-renewal. Dev Cell, 2006. 10(4): p. 441-9. 
60. Shi, W., Y. Chen, G. Gan, D. Wang, J. Ren, Q. Wang, Z. Xu, W. Xie, and Y.Q. 
Zhang, Brain tumor regulates neuromuscular synapse growth and endocytosis in 




61. Marchetti, G., I. Reichardt, J.A. Knoblich, and F. Besse, The TRIM-NHL protein 
Brat promotes axon maintenance by repressing src64B expression. J Neurosci, 
2014. 34(41): p. 13855-64. 
62. Cho, P.F., C. Gamberi, Y.A. Cho-Park, I.B. Cho-Park, P. Lasko, and N. 
Sonenberg, Cap-dependent translational inhibition establishes two opposing 
morphogen gradients in Drosophila embryos. Curr Biol, 2006. 16(20): p. 2035-41. 
63. Tocchini, C. and R. Ciosk, TRIM-NHL proteins in development and disease. 
Semin Cell Dev Biol, 2015. 47-48: p. 52-9. 
64. Loedige, I., M. Stotz, S. Qamar, K. Kramer, J. Hennig, T. Schubert, P. Loffler, G. 
Langst, R. Merkl, H. Urlaub, and G. Meister, The NHL domain of BRAT is an 
RNA-binding domain that directly contacts the hunchback mRNA for regulation. 
Genes Dev, 2014. 28(7): p. 749-64. 
65. Loedige, I., L. Jakob, T. Treiber, D. Ray, M. Stotz, N. Treiber, J. Hennig, K.B. 
Cook, Q. Morris, T.R. Hughes, J.C. Engelmann, M.P. Krahn, and G. Meister, The 
Crystal Structure of the NHL Domain in Complex with RNA Reveals the 
Molecular Basis of Drosophila Brain-Tumor-Mediated Gene Regulation. Cell Rep, 
2015. 13(6): p. 1206-20. 
66. Tadros, W. and H.D. Lipshitz, The maternal-to-zygotic transition: a play in two 
acts. Development, 2009. 136(18): p. 3033-42. 
67. Temme, C., L. Zhang, E. Kremmer, C. Ihling, A. Chartier, A. Sinz, M. Simonelig, 
and E. Wahle, Subunits of the Drosophila CCR4-NOT complex and their roles in 
mRNA deadenylation. RNA, 2010. 16(7): p. 1356-70. 
68. Tautz, D., Regulation of the Drosophila segmentation gene hunchback by two 
maternal morphogenetic centres. Nature, 1988. 332(6161): p. 281-4. 
69. Hulskamp, M., C. Pfeifle, and D. Tautz, A morphogenetic gradient of hunchback 
protein organizes the expression of the gap genes Kruppel and knirps in the early 
Drosophila embryo. Nature, 1990. 346(6284): p. 577-80. 
70. Irish, V., R. Lehmann, and M. Akam, The Drosophila posterior-group gene nanos 
functions by repressing hunchback activity. Nature, 1989. 338(6217): p. 646-8. 
82 
 
71. Struhl, G., P. Johnston, and P.A. Lawrence, Control of Drosophila body pattern 
by the hunchback morphogen gradient. Cell, 1992. 69(2): p. 237-249. 
72. Lehmann, R. and C. Nusslein-Volhard, hunchback, a gene required for 
segmentation of an anterior and posterior region of the Drosophila embryo. Dev 
Biol, 1987. 119(2): p. 402-17. 
73. Tautz, D. and C. Pfeifle, A non-radioactive in situ hybridization method for the 
localization of specific RNAs in Drosophila embryos reveals translational control 
of the segmentation gene hunchback. Chromosoma, 1989. 98(2): p. 81-5. 
74. Hulskamp, M., C. Schroder, C. Pfeifle, H. Jackle, and D. Tautz, Posterior 
segmentation of the Drosophila embryo in the absence of a maternal posterior 
organizer gene. Nature, 1989. 338(6217): p. 629-32. 
75. Wang, C. and R. Lehmann, Nanos is the localized posterior determinant in 
Drosophila. Cell, 1991. 66(4): p. 637-47. 
76. Zaessinger, S., I. Busseau, and M. Simonelig, Oskar allows nanos mRNA 
translation in Drosophila embryos by preventing its deadenylation by 
Smaug/CCR4. Development, 2006. 133(22): p. 4573-83. 
77. Gavis, E.R. and R. Lehmann, Translational regulation of nanos by RNA 
localization. Nature, 1994. 369(6478): p. 315-8. 
78. Smibert, C.A., J.E. Wilson, K. Kerr, and P.M. Macdonald, smaug protein 
represses translation of unlocalized nanos mRNA in the Drosophila embryo. 
Genes Dev, 1996. 10(20): p. 2600-9. 
79. Semotok, J.L., R.L. Cooperstock, B.D. Pinder, H.K. Vari, H.D. Lipshitz, and C.A. 
Smibert, Smaug recruits the CCR4/POP2/NOT deadenylase complex to trigger 
maternal transcript localization in the early Drosophila embryo. Curr Biol, 2005. 
15(4): p. 284-94. 
80. Macdonald, P.M., The Drosophila pumilio gene: an unusually long transcription 
unit and an unusual protein. Development, 1992. 114(1): p. 221-32. 
83 
 
81. Murata, Y. and R.P. Wharton, Binding of pumilio to maternal hunchback mRNA is 
required for posterior patterning in Drosophila embryos. Cell, 1995. 80(5): p. 747-
56. 
82. Sonoda, J. and R.P. Wharton, Recruitment of Nanos to hunchback mRNA by 
Pumilio. Genes Dev, 1999. 13(20): p. 2704-12. 
83. Lou, T.F., C.A. Weidmann, J. Killingsworth, T.M. Tanaka Hall, A.C. Goldstrohm, 
and Z.T. Campbell, Integrated analysis of RNA-binding protein complexes using 
in vitro selection and high-throughput sequencing and sequence specificity 
landscapes (SEQRS). Methods, 2016. 
84. Waghray, S., C. Williams, J.J. Coon, and M. Wickens, Xenopus CAF1 requires 
NOT1-mediated interaction with 4E-T to repress translation in vivo. RNA, 2015. 
21(7): p. 1335-45. 
85. Nishimura, T., Z. Padamsi, H. Fakim, S. Milette, W.H. Dunham, A.C. Gingras, 
and M.R. Fabian, The eIF4E-Binding Protein 4E-T Is a Component of the mRNA 
Decay Machinery that Bridges the 5' and 3' Termini of Target mRNAs. Cell Rep, 
2015. 11(9): p. 1425-36. 
86. Ozgur, S., J. Basquin, A. Kamenska, W. Filipowicz, N. Standart, and E. Conti, 
Structure of a Human 4E-T/DDX6/CNOT1 Complex Reveals the Different 
Interplay of DDX6-Binding Proteins with the CCR4-NOT Complex. Cell Rep, 
2015. 13(4): p. 703-11. 
87. Harris, R.E., M. Pargett, C. Sutcliffe, D. Umulis, and H.L. Ashe, Brat promotes 
stem cell differentiation via control of a bistable switch that restricts BMP 
signaling. Dev Cell, 2011. 20(1): p. 72-83. 
88. Bello, B., H. Reichert, and F. Hirth, The brain tumor gene negatively regulates 
neural progenitor cell proliferation in the larval central brain of Drosophila. 
Development, 2006. 133(14): p. 2639-48. 
89. Betschinger, J., K. Mechtler, and J.A. Knoblich, Asymmetric segregation of the 
tumor suppressor brat regulates self-renewal in Drosophila neural stem cells. 
Cell, 2006. 124(6): p. 1241-53. 
84 
 
90. Bowman, S.K., V. Rolland, J. Betschinger, K.A. Kinsey, G. Emery, and J.A. 
Knoblich, The tumor suppressors Brat and Numb regulate transit-amplifying 
neuroblast lineages in Drosophila. Dev Cell, 2008. 14(4): p. 535-46. 
91. Ray, D., H. Kazan, K.B. Cook, M.T. Weirauch, H.S. Najafabadi, X. Li, S. 
Gueroussov, M. Albu, H. Zheng, A. Yang, H. Na, M. Irimia, L.H. Matzat, R.K. 
Dale, S.A. Smith, C.A. Yarosh, S.M. Kelly, B. Nabet, D. Mecenas, W. Li, R.S. 
Laishram, M. Qiao, H.D. Lipshitz, F. Piano, A.H. Corbett, R.P. Carstens, B.J. 
Frey, R.A. Anderson, K.W. Lynch, L.O. Penalva, E.P. Lei, A.G. Fraser, B.J. 
Blencowe, Q.D. Morris, and T.R. Hughes, A compendium of RNA-binding motifs 
for decoding gene regulation. Nature, 2013. 499(7457): p. 172-7. 
92. Ferreira, A., L. Boulan, L. Perez, and M. Milan, Mei-P26 mediates tissue-specific 
responses to the Brat tumor suppressor and the dMyc proto-oncogene in 
Drosophila. Genetics, 2014. 198(1): p. 249-58. 
93. Gamberi, C., D.S. Peterson, L. He, and E. Gottlieb, An anterior function for the 
Drosophila posterior determinant Pumilio. Development, 2002. 129(11): p. 2699-
710. 
94. Mee, C.J., E.C. Pym, K.G. Moffat, and R.A. Baines, Regulation of neuronal 
excitability through pumilio-dependent control of a sodium channel gene. J 
Neurosci, 2004. 24(40): p. 8695-703. 
95. Harris, R.E. and H.L. Ashe, Cease and desist: modulating short-range Dpp 
signalling in the stem-cell niche. EMBO Rep, 2011. 12(6): p. 519-26. 
96. Ferguson, E.L. and K.V. Anderson, Localized enhancement and repression of 
the activity of the TGF-beta family member, decapentaplegic, is necessary for 
dorsal-ventral pattern formation in the Drosophila embryo. Development, 1992. 
114(3): p. 583-97. 
97. Ferguson, E.L. and K.V. Anderson, Decapentaplegic acts as a morphogen to 
organize dorsal-ventral pattern in the Drosophila embryo. Cell, 1992. 71(3): p. 
451-61. 
98. Thomsen, S., S. Anders, S.C. Janga, W. Huber, and C.R. Alonso, Genome-wide 
analysis of mRNA decay patterns during early Drosophila development. Genome 
Biol, 2010. 11(9): p. R93. 
85 
 
99. Filipovska, A., M.F. Razif, K.K. Nygard, and O. Rackham, A universal code for 
RNA recognition by PUF proteins. Nat Chem Biol, 2011. 7(7): p. 425-7. 
100. Kedde, M., M. van Kouwenhove, W. Zwart, J.A. Oude Vrielink, R. Elkon, and R. 
Agami, A Pumilio-induced RNA structure switch in p27-3' UTR controls miR-221 
and miR-222 accessibility. Nat Cell Biol, 2010. 12(10): p. 1014-20. 








Pum Utilizes the CNOT Complex to Stimulate Messenger RNA Decay through the 
N-terminal Repression Domains (RDs) 
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Freddolino and Dr. Aaron Goldstrohm. Experiments and diagram in Figure 3.4 panels B-
D were done by Chung-Te Chang and Eugene Valkov (Max Planck Institute for 
Developmental Biology).  
 
3.1 Introduction 
As introduced in Chapters 1 and 2, proper control of gene expression is 
accomplished in part by RBPs that affect processing, transport, translation, and 
degradation of mRNAs. Drosophila Pumilio (Pum) is a quintessential sequence-specific 
RBP that regulates the fate of mRNAs in the cytoplasm. Pum is a founding member of 
the eukaryotic PUF family (named after Pum and C. elegans fem 3-binding factor), which 
share a conserved Pum homology domain (Pum-HD) [1]. In Drosophila, Pum is essential 
for development and impacts a wide range of biological processes [2]. Pum is broadly 
expressed and is abundant in embryos, the nervous system, and the female germline. Its 
first identified function was early embryogenesis, wherein Pum represses expression of 
the morphogen, Hunchback, a crucial factor in the establishment of embryonic polarity 
and body plan [3-9]. Important functions of Pum have also been documented in the 
germline, where it regulates stem cell proliferation and differentiation [10-14]. Moreover, 
Pum plays multiple roles in the nervous system, where it controls neuronal morphology, 
electrophysiology, motor function, and learning and memory formation [15-21]. 
Pum regulates specific mRNAs by binding to a short RNA sequence, termed the 





encompasses the Pum-HD and flanking residues [5, 22-26]. The RBD is comprised of 
eight repeats of a triple alpha-helical motif and recognizes the consensus PRE sequence 
5' UGUANAUA [2]. Crystal structures of the RBD of Pum and other PUF proteins revealed 
an arched molecule that recognizes RNA along the concave surface [25, 27]. Each repeat 
presents three amino acids, termed the tripartite motif (TRM), that specifically interact 
with a ribonucleotide base in a modular fashion. Pum binds to an extensive network of 
mRNAs that have been characterized in embryos and ovaries [2, 5, 28-30]. The majority 
of these Pum target mRNAs contain one or more PREs located in the 3' untranslated 
region (3'UTR). 
Despite substantial insights into Pum's biological roles, structure, and RNA-binding 
activity [2], our understanding of the mechanisms by which it represses gene expression 
remains incomplete. An early model proposed that Pum recruits Nanos (Nos) and Brain 
tumor (Brat) to block translation of hunchback mRNA [31-33]; however, recent 
developments have substantially revised that model. As discussed in the previous 
chapter, we now know that Pum, Nos, and Brat are each sequence specific RBPs that 
can combinatorially regulate a select subset of mRNAs [25, 29, 34, 35], with hunchback 
mRNA representing the best characterized target [2]. Importantly, Pum can repress PRE-
containing mRNAs independent of Nos or Brat [36]. For example, Pum potently represses 
PRE-bearing reporter mRNAs in d.mel-2 cells, which do not express detectable Nos. 
Moreover, depletion of Nos and/or Brat did not alter Pum's ability to repress. Further, Pum 
can potently repress mRNAs that are not bound by Nos or Brat. Nos can bind in a 
cooperative manner with Pum to certain mRNAs that contain a Nos Binding Site (NBS) 
immediately upstream of a PRE, thereby strengthening Pum-mediated repression [25]. 
Additionally, Brat binds to specific mRNAs on its own and confers repressive function 
independent of Nos or Pum [29, 34, 35]. In the case of the hunchback mRNA in 
developing embryos, Brat, Pum, and Nos collectively repress it by binding to two Nos 
Response Elements (NREs), each of which contain a Brat binding site, an NBS, and a 
PRE [2, 25, 29, 34, 35, 37]. This chapter will focus on determining the mechanism by 
which Pum represses mRNAs. The resulting knowledge is essential in understanding how 
Pum regulates its multitude of targets and how it collaborates with other regulatory RBPs, 





Multiple studies have provided insights into the mechanism of Pum-mediated 
repression. Early evidence correlated repression of hunchback mRNA by Pum - along 
with Nos and Brat – in embryogenesis with shortening of that transcript's 3' poly-
adenosine (poly(A)) tail (i.e., deadenylation) [8, 37]. The poly(A) tail promotes translation 
and stability of mRNAs, and thus deadenylation reduces protein expression and initiates 
mRNA decay [38, 39]. Like all eukaryotes, Drosophila possesses multiple deadenylase 
enzymes [40-42]. Pum was reported to interact with the Ccr4-Not (CNOT) complex [43-
45], which contains both Pop2/Caf1 and Ccr4/twin deadenylases.  
Pum also cooperates with Nos or Brat in certain contexts, and again deadenylation 
is implicated. In the germline, Pum and Nos regulate cyclin B (cycB) in pole cells and mei-
P26 mRNA in germline stem cells (GSCs) [43, 44]. In both cases, Pum and Nos are 
thought to utilize the CNOT deadenylase complex. Pum and Brat regulate targets in the 
cystoblast to attenuate the local effects of Dpp signaling, and this effect is thought to 
require CNOT, as the Pop2 deadenylase was necessary for Pum and Brat to repress a 
reporter bearing the mad 3'UTR [11]. In terms of the Pum repression mechanism, a 
complication in interpreting these experiments is that Nos and Brat are also linked to 
CNOT and deadenylation [41, 46, 47]. Thus, it was necessary to develop approaches that 
specifically dissect repression of mRNAs by Pum alone. 
We previously used PRE-containing reporter genes to measure Pum repression 
activity in Drosophila cells and showed that it reduces both protein and mRNA levels [36]. 
Four regions of Pum contribute to its repressive activity. The highly conserved RBD made 
a minor contribution to repression activity whereas the N terminus of Pum contains the 
major repressive activity. Repression by the Pum RBD was shown to require poly-
adenosine and the cytoplasmic poly(A) binding protein (pAbp) [45]. The Pum RBD 
associates with pAbp and antagonizes its ability to promote translation. Interestingly, the 
RBD of Pum also interacts with Pop2 and promotes deadenylation dependent on Pop2 
and Ccr4 [43, 45]. While depletion of those deadenylases blocked mRNA decay induced 
by the Pum RBD, it did not prevent RBD-mediated translational repression, whereas pAbp 






The robust repressive activity of the Pum N terminus is conferred by three 
repression domains (Figure 3.1A: RD1, RD2, and RD3) [36]. These RDs are unique to 
Pum orthologs spanning from insects to vertebrates. They do not share homology with 
each other or previously characterized protein domains. Each is capable of potently 
repressing protein expression when directed to a reporter mRNA. Moreover, they do not 
require Nos or Brat [36]. The crucial remaining challenge is to determine how the Pum N-
terminal RDs regulate target mRNAs. In this chapter, we characterize their regulatory 
activities and investigate the mRNA features and co-repressors necessary for their 
activities. 
We show that the Pum N-terminal repression domains accelerate degradation of 
PRE-bearing mRNAs by utilizing deadenylase machinery. The Pum RDs each contribute 
to mRNA destruction by employing the CNOT deadenylase complex. Pum RD2 and RD3 
are completely dependent on CNOT, whereas Pum RD1 is partly dependent on CNOT. 
Dissection of the involvement of the eight CNOT subunits reveals specific involvement of 
the Pop2 deadenylase subunit and the core structural component Not1 for repression 
activities of the RDs. Strikingly, depletion of either Not1 or Pop2 eliminates Pum-mediated 
mRNA decay, whereas depletion of other CNOT subunits had little or no effect on Pum 
repression. Taken together, this dissection of Pum effector domains provides mechanistic 
insights into Pum mediated regulation of mRNAs. 
 
3.2 Pumilio accelerates mRNA degradation 
To investigate the mechanism of Pum-mediated repression, we utilized a d.mel-2 
cell-based reporter assay, as previously characterized [25, 36, 45], wherein over-
expression of full-length Pum (Figure 3.1A) potently and specifically represses expression 
of a reporter protein from an mRNA bearing three PRE sequences in a minimal 3'UTR 
(Figure S3.1A). In this case, the reporter gene encodes Nano-luciferase (Nluc 3xPRE) 
(Figure 3.1B). This repression activity requires a wild type PRE consensus and the RNA-
binding activity of Pum, as mutation of the RNA recognition amino acids of the 7th Pum 
repeat alleviates the observed repression (mut R7, Figures 3.1C and S3.1A) [25, 36, 45]. 












transcription shut-off approach with Actinomycin D, and found that wild type Pum 
accelerated decay of the Nluc 3x PRE reporter, resulting in a 4-fold reduction in half-life 
relative to the mut R7 Pum (Figure 3.1C). Moreover, the presence of PRE sequences in 
the 3'UTR is sufficient to confer instability of this mRNA (Figure S3.1B). These results 
indicate that Pum-stimulated mRNA degradation plays an important role in the repression 
mechanism.  
We previously showed that the N terminus of Pum confers its major repressive 
activity, mediated by three Repression Domains (RD1, RD2, and RD3) [36] (Figure 3.1A). 
Each of these domains can autonomously repress in a tethered function assay, wherein 
they are directed to the 3’UTR of a reporter mRNA (Figure 3.1D) [36, 48-50]. In this 
experimental design, the Pum N terminus or individual RDs are expressed as fusions to 
MS2 coat protein (Figure S3.1C), which specifically binds tandem MS2 stem loop 
sequences with high affinity. The Pum N terminus and each RD reduced reporter protein 
expression (Figure 3.1E), in agreement with our previous observations [36, 45], whereas 
the negative control MS2-EGFP fusion did not. As a positive control, the decapping 
enzyme subunit Dcp1, fused to MS2, was tethered to the reporter and thereby elicited 
strong repression (Figure 3.1E). Next we performed Northern blot analysis to detect the 
impact of each effector on Nluc 2xMS2 mRNA. The Pum N terminus and RDs reduced 
reporter mRNA levels with magnitudes corresponding to their effects on protein 
Figure 3.1. Pumilio accelerates mRNA degradation and the Pumilio N-terminal Repression Domains (RDs) 
repress RNA and protein expression 
(A)  Scale diagram of Pum domains. Specific residues for putative cap-binding motif and R7 mutations indicated 
above Pum domains. Diagram also incorporates hydrophobic versus hydrophilic residues  and secondary structure 
prediction based on amino acid content. Adapted from Goldstrohm et al. (2018) [26]. (B)  Diagram of Nano-
luciferase (Nluc) reporter mRNA containing three Pum Response Elements (3x PRE) sequences in 3'UTR, along 
with 7-methyl guanosine cap (m7G) and poly(A) tail (pA). (C)  Transcription shut-off with Actinomycin D to measure 
half-life of the Nluc 3x PRE reporter in response to over-expressed wild type Pum or RNA-binding defective mutant 
mut R7. Northern blots of Nluc 3x PRE reporter and 18S rRNA from representative experiment are shown on the 
left. The graph of fraction mRNA remaining versus time (minutes) after transcription shut-off is shown on the right. 
The measured half-life of the reporter mRNA in each condition is shown below the respective blots. Mean values 
from three biological replicates with standard error are plotted for each time point. First order exponential decay 
trend line, calculated using non-linear regression analysis is also plotted. (D)  Diagram of tethered function dual 
luciferase reporter and internal control. An Nluc reporter, Nluc 2xMS2, bearing two MS2 stem loops in its 3'UTR 
was used to measure repression by tethered effectors that are expressed in cells as fusions to the MS2 RNA-
binding protein. (E)  Repression activity of Pum N terminus and individual repression domains was measured using 
the tethered function dual luciferase assay. Mean values and standard error for three biological replicates of Pum 
repression of reporter protein level (black bars) and RNA level (grey bars) are plotted for each sample. Repression 
was calculated relative to the negative control, MS2-EGFP. Tethered decapping enzyme subunit, Dcp1, serves as 
a positive control that strongly represses the reporter’s protein and mRNA levels. (F)  Northern blot detection of 
tethered function reporter Nluc 2xMS2, internal control FFluc, and loading control 18S rRNA for three biological 





expression (Figure 3.1E and 3.1F). The internal control, Firefly luciferase mRNA (FFluc), 
was not affected by the tethered effectors (Figure 3.1F). The 18S ribosomal RNA served 
as an internal control to demonstrate equivalent loading and blotting (18S was not 
included in percent repression calculation). Together, these results demonstrate that the 
Pum N-terminal RDs stimulate RNA decay.  
 
3.3 CNOT complex components are essential for Pum Repression Domain activity 
We next sought to identify the co-repressors necessary for the Pum RDs to 
facilitate repression. The CNOT deadenylase plays a crucial role in the initiation of mRNA 
decay, thus we evaluated its role in repression by the Pum N terminus and the individual 
RDs. The Drosophila CNOT complex contains 8 subunits (Figure 3.2A), including the 
Ccr4 and Pop2 deadenylases [41]. In Drosophila, the Pop2 subunit is thought to be the 
major deadenylase [41]; thus, we first performed RNAi, using two different double 
stranded RNAs (dsRNAs) to deplete Pop2. One dsRNA targets the Pop2 open reading 
frame (#1) whereas the second targets the 5'UTR (#2). Both dsRNAs depleted Pop2 from 
the d.mel-2 cells relative to non-targeting control dsRNA (NTC), as confirmed by western 
blotting (Figure 3.2B) and RT-qPCR (Figure S3.2A). Using these conditions, we then 
measured the effect of Pop2 depletion on repression by tethered Pum N terminus and 
RDs (Figure 3.2C). We observed that Pop2 is required for repressive activity of RD2 and 
RD3, whereas depletion of Pop2 reduced RD1 activity by roughly half (Figure 3.2C, 
compare ~77% repression by RD1 in NTC condition to 35-41% in Pop2 RNAi conditions. 
Likewise, Pop2 depletion reduced but did not eliminate repression by the Pum N terminus. 
As expected, Pop2 depletion did not alleviate repression by tethered decapping enzyme 
subunit Dcp1 (Figure 3.2C). Effector expression was verified in each condition (Figure 





To investigate whether the 
deadenylase activity of Pop2 is 
involved in Pum RD mediated 
repression, we tested the ability of 
RNAi-resistant Pop2 cDNA clones 
to rescue repression. To do so, 
cells were treated with Pop2 
dsRNA #2, which targets the 
5'UTR of the endogenous Pop2 
mRNA. Cells were then transfected 
with plasmid expressing RNAi 
resistant wild type or catalytically 
inactive Pop2 mutant (D53A and 
E55A) [41]. Repression of tethered 
effectors was then measured, 
revealing that wild type Pop2, but 
not mutant, rescued repression 
activity of Pum RD1, RD2, and 
RD3 (Figure 3.2D). Protein 
expression of all effectors and the 
wild type and mutant Pop2 
proteins was confirmed in Figure 
S3.2C. These observations 
indicate that the deadenylation 
activity of Pop2 is important for 
RD activity. Ccr4 is the second 
deadenylase present in the CNOT 
complex [42, 51]. We next 
evaluated the involvement of Ccr4 
and observed that substantial 
depletion of its mRNA and protein 
Figure 3.2. The Pop2 subunit of the CNOT complex is 
necessary for repression by Pum RDs. 
(A)  Diagram of the Ccr4-Not complex, containing 8 subunits. 
Adapted from Wahle et al (2014) [69]. (B)  Western blot confirming 
RNAi-mediated depletion of Pop2 deadenylase subunit induced by 
treating d.mel-2 cells with two different double-stranded RNAs 
corresponding to Pop2 (dsRNA#1, which targets the Pop2 coding 
sequence, or dsRNA#2, which targets the Pop2 5'UTR) in 
comparison to non-targeting control dsRNA (NTC). Western blot 
detection of tubulin serves as a control for equal loading of lanes. 
(C)  Tethered function assay measuring the effect of Pop2 depletion 
on repression by Pum N terminus and individual RDs relative to 
negative control effector MS2-EGFP. Tethered decapping enzyme 
subunit, Dcp1, serves as a positive control. Non-targeting control 
(NTC) RNAi serves as a negative control for RNAi. Mean values 
and standard error for four technical replicates are plotted for each 
effector. Differences between NTC and knockdown conditions have 
p-value <0.05 (two-tailed t-test). (D)  Tethered function assay 
measuring the ability of wild type or active site mutant Pop2 to 
rescue repression by Pum N terminus and RDs. RNAi conditions 
included negative control NTC and Pop2 dsRNA #2. The effect of 
wild type Pop2 expression was compared to EGFP negative control 
and mutant Pop2, wherein the active site residues were mutated. 
Mean percent repression values and standard error for four 





(Figure S3.2D) did not affect repression by the Pum N terminus or RDs (Figure S3.2E). 
This observation suggests that Ccr4 is not crucial, whereas Pop2 has a specialized role 
in Pum repression. That said, it is important to acknowledge the inherent limitations of 
RNAi, wherein the potential exists for residual low levels of Ccr4 to support Pum activity. 
We also examined the role of non-catalytic CNOT subunits in Pum RD-mediated 
repression, starting with Not1, which is the central scaffold of the complex [51]. RNAi 
depletion of Not1 eliminated repression by RD2 and RD3, and substantially reduced 
repression by RD1, from 72% in the control to 39% in the Not1 depleted sample (Figure 
3.3A). Not1 depletion also reduced repression by the Pum N terminus from 70% to 48% 
(Figure 3.3A). Depletion of Not1 protein and mRNA was confirmed by western blot and 
RT-qPCR, respectively (Figure 3.3B and S3.3A), and Pum effector expression was 
confirmed in Figure S3.3B. Based on these observations, we conclude that Not1 is 
important for Pum RD activity, and its depletion mimics the effect of Pop2 depletion. 
The other CNOT subunits form modules that interact with Not1, as depicted in 
Figure 3.2A [51]. We observed that depletion of Not2 and Not3 (Figure 3.3B and S3.3A) 
had a modest effect on Pum RD repression (Figure 3.3A; Pum N terminus Not2 RNAi 
versus NTC had p-value of >0.05). Expression of each effector in each condition was also 
confirmed (Figure S3.3B). We also tested the effects of depletion of the remaining CNOT 
subunits, Caf40, Not10, and Not11 (see Figure S3.4A-D), none of which alleviated the 
repressive activity of the Pum N terminus or individual RDs. Overall, these results indicate 
that certain CNOT subunits, specifically Not1 and Pop2, play key roles in Pum RD 
repression.  
We observed that depletion of Not1 also reduced the level of Pop2, which interacts 
directly with Not1, consistent with a previous report (Figure S3.5A) [41]. Therefore, we 
considered that the effect of RNAi of Not1 on Pum RD activity could be the result of 
diminished Pop2. To test this idea, we attempted to rescue the effect of Not1 depletion 
with exogenous Pop2. First, we titrated Pop2 expression vector to approximately match 
endogenous Pop2 levels (Figure S3.5A). We then performed tethered function assays 
with the Pum RDs and found that exogenous Pop2 did not rescue the loss of RD mediated 
repression caused by Not1 depletion (Figure S3.5B). This result supports the conclusion 






3.4 CNOT associates with the Pum N terminus 
The observation that CNOT components are important for activity of Pum N-
terminal RDs suggested a model wherein they act to recruit the CNOT complex. We used 
a co-immunoprecipitation assay to assess physical interaction between flag-tagged Pum 
N-terminus or RBD with endogenous CNOT. Flag-tagged GST served as a negative 
control. Several positive controls were also utilized including the RNA-binding protein 
Nanos, which was previously shown to directly contact Not1 [46], and the stoichiometric 
CNOT complex subunits Not2 and Not3. We observed that the Pum N terminus 
associates with Not1 (Figure 3.4A), similar to Nanos, and that this interaction is resistant 
to treatment with RNase (Figure 3.4A and S3.6), suggesting that the association is not 
bridged by RNA. As expected, Not1 robustly co-purified with Not2 and Not3 subunits. 
Interestingly, while the Pum RBD was previously shown to interact with Pop2 [43, 45], we 
did not detect co-immunoprecipitation with Not1 under these conditions, perhaps 
reflecting differences in protein-protein contacts and their affinities. Together, these 
Figure 3.3 The Not1 scaffold is required for repression activity of Pum RDs. 
(A)  Tethered function assays measured the effect of Not1, Not2, and Not3 depletion on the repression activity of 
Pum N terminus and RDs. Non-targeting control (NTC) serves as negative control for comparison. Activity of each 
effector was determined relative to tethered EGFP negative control in each condition. Mean percent repression 
values and standard error for four technical replicates are plotted for each effector. Differences between NTC and 
knockdown conditions for each effector have p-value <0.05 (two-tailed t-test), with the exception of the Pum N 
terminus in the Not2 knockdown condition. (B)  Western blot using antibodies to the endogenous proteins confirms 
depletion of Not1, Not2 or Not3 proteins in three representative biological replicate samples. The * designates a 





observations indicate that the Pum N-terminus, containing the three RDs, associates with 
CNOT. 
Figure 3.4 Pum N terminus and RDs interact with the CNOT complex 
(A) Pum N terminus co-immunoprecipitates with Not1. Western blot detection of endogenous Not1 protein and Flag-
tagged Pum N terminus (N) or RBD in cell lysates (Input) and anti-Flag immunoprecipitates (Flag IP) from samples 
treated with or without RNase One. Flag-tagged GST serves as negative control. Positive controls for Not1 
interaction include Flag-tagged Nanos (Nos) and core CNOT subunits Not2 and Not3. The relative percent of total 
for each sample is indicated above lanes. (B) Coomassie stained SDS-PAGE gel of in vitro pulldown with MBP-
Pum-strep fragments and MBP-strep negative control, with purified human CNOT complex components. (C) 
Diagram of CNOT modules: each module consists of specific subunits and bound fragment of the Not1 scaffold 
(color-coded; made by Eugene Valkov and Chung-Te Chang). (D) Coomassie stained SDS-PAGE gel of in vitro 





 To interrogate the direct interactions between the RDs and members of the CNOT 
complex, an in vitro pulldown was performed (Chung-Te Chang and Eugene Valkov), with 
purified recombinant Maltose Binding protein (MBP) and Strep-tagged Pum domain (RDs 
and RBD) bait and human CNOT complex  prey (Figure 3.4, panel B). In this experiment, 
each RD pulls down multiple members of the CNOT complex, including CNOT1, CNOT2, 
CNOT3 and both deadenylases. In vitro pulldowns performed with specific CNOT 
modules (Figure 3.4, panel C) further dissect the direct interactions between the RDs and 
CNOT.  RD1, RD2, RD3 and the RBD each interact with the Not10/11, catalytic, and NOT 
modules. Moreover, RD1 and RD3 exhibited interaction with the Caf40 module. (Figure 
3.4, panel D). Taken together, these data demonstrate that the RDs interact directly with 
CNOT, forming multiple contacts with different modules. 
Figure 3.5 Pum-mediated mRNA decay 
requires Not1 and Pop2 
(A) Measurement of the effect of RNAi-mediated 
depletion of Not1 on the mRNA decay rate of 
Nluc 3xPRE reporter mRNA in response to wild 
type Pum (WT) or negative control mut R7 Pum 
following inhibition of transcription. The top 
panel shows the Northern blot detection of Nluc 
3xPRE reporter and 18S rRNA loading control. 
The measured half-life of the reporter mRNA in 
each condition is shown below the respective 
blots. The graph of fraction mRNA remaining 
versus time (minutes) after transcription shut-off 
is shown. Mean values from three experimental 
replicates with standard error are plotted for 
each time point. First order exponential decay 
trend lines, calculated using non-linear 
regression analysis are shown for the mut R7 
and WT Pum, NTC dsRNA treated samples. 
Linear trend lines are shown for the mut R7 and 
WT Pum, Not1 dsRNA treated samples. 
(B) Measurement of the effect of RNAi-mediated 
depletion of Pop2 on the mRNA decay rate of 
Nluc 3xPRE reporter mRNA in response to wild 
type Pum (WT) or negative control mut R7 Pum 
following inhibition of transcription. As above, 
the top panel shows the Northern blot detection 
and the half-life of the reporter mRNA in each 
condition is shown below the respective blots. 
The graph of fraction mRNA remaining versus 
time (minutes) after transcription shut-off is 
shown. Mean values from three experimental 
replicates with standard error are plotted for 
each time point. First order exponential decay 
trend lines are shown for the mut R7 and WT 
Pum, NTC dsRNA treated samples. Linear trend 
lines are shown for the mut R7 and WT Pum, 







3.5 CNOT is required for Pum-mediated mRNA decay 
Given the importance of CNOT for mRNA decay and Pum RD activity, we next 
asked whether CNOT was required for Pum-mediated mRNA degradation. To do so, we 
depleted Not1 by RNAi and measured decay of the Nluc 3xPRE reporter in response to 
over-expressed Pum. As expected, in the control RNAi condition (NTC), wild type Pum 
accelerated reporter mRNA decay relative to the negative control, RNA-binding defective 
mut R7 (Figure 3.5A). Depletion of Not1 blocked decay of the reporter RNA in the 
presence of WT or mutant (Figure 3.5A), demonstrating that Not1 is required for Pum-
mediated mRNA decay. Using the same strategy, we next analyzed the involvement of 
the Pop2 deadenylase, and observed that depletion of Pop2 also led to severe 
impairment of Pum-mediated mRNA decay (Figure 3.5B).  
 
3.6 Discussion 
Our work demonstrates that Pum utilizes the CNOT complex to potently stimulate 
mRNA destruction, and that this activity is primarily facilitated by the N-terminal RDs. 
Moreover, RNAi experiments indicate that this function appears to specifically require the 
Not1 scaffold and the catalytic activity of the Pop2 deadenylase. Our biochemical work 
shows that the Pum N terminus interacts with Not1 in a manner resistant to RNAse, and 
that the Pum RDs make multiple direct contacts with different modules of the human 
CNOT complex, including the functionally important catalytic and NOT modules. 
This works supports a model in which Pum makes multiple contacts with CNOT 
through its N-terminal RDs. As discussed in Chapter 1, recruitment of deadenylation 
machinery is a common theme in post-transcriptional regulation, as several examples 
exist of RBP repressors interacting with specific subunits of the CNOT complex. For 
example, Pum’s partner, Nanos makes direct, RNA-independent contacts with Not1 and 
Not3 through its N terminus [46]. Our work showing that Pum uses the CNOT 
deadenylase complex  is also consistent with the previous observation that Drosophila 
Pum was linked to deadenylation of hunchback mRNA in vivo [8] (although this study did 
not delineate Pum and Nanos function). This mechanism is evolutionarily conserved, as 





deadenylation [52, 53]. Importantly, human Pumilio proteins also utilize deadenylases 
[54].  
Our data supports the conclusion that Pum specifically requires the Pop2 
deadenylase for repression. While we cannot rule out that Ccr4 could contribute to 
repression activities, we do not see an effect on Pum with partial depletion of Ccr4. 
Moreover, the catalytic function of Pop2 appears to specifically be important (Figure 4.2). 
In S2 cells, Pop2 is the primary deadenylase, as the catalytic domain of Ccr4 is 
dispensable for activity when tethered, and the Pop2-interacting LRR domain confers 
Ccr4 activity [55]. Furthermore, Ccr4 depletion did not have a large impact on bulk poly(A) 
tail length [42], and catalytic mutant expression did not affect deadenylation of the hsp70 
mRNA [41]. However, Ccr4 appears to play a role in the female germline [42, 56, 57]. The 
possibility remains that Ccr4 has context-specific activities that can be utilized by Pum in 
these contexts. 
Future work will include dissecting the specific motifs in Pum and CNOT involved 
in this interaction. Further experiments will also address how this mechanism is relevant 
in vivo, and whether CNOT utilization is most relevant to specific developmental stages 
(for example, after MZT, when maternal mRNAs are degraded). Ongoing work includes 
investigating this mechanism and the specific CNOT subunits involved in the function of 
human Pumilio proteins. Together, this work provides crucial mechanistic insights into 






3.7 Supplemental Figures 
Figure S3.1 Repression by overexpressed Pum, decay of Nluc 3xPRE versus ΔPRE mRNA and tethered 
effector expression from Figure 3.1E-F 
(A) Dual luciferase assay measured repression activity of over-expressed full-length Pum with the Nluc 3x NRE 
reporter activity relative to negative control mut R7 under conditions used to measure mRNA decay rate in Figure 
1C. (B) Transcription shut-off with Actinomycin D to measure half-life of Nluc 3x PRE reporter versus Nluc ∆PRE 
reporter. Northern blots of Nluc reporter and 18S rRNA from representative experiment are shown in the top 
panel. The graph of fraction mRNA remaining versus time (minutes) after transcription shut-off is shown in the 
bottom panel. Mean values from three experimental replicates with standard error are plotted for each time point. 
First order exponential decay trend line, calculated using non-linear regression analysis is also plotted. (C) 
Western blot of tethered effectors from Figure 1, panel E. For each effector replicate, 10 µg of total protein was 






Figure S3.2 Pop2 knockdown efficiency, expression of tethered effectors from Figures 3.2C-D, and Ccr4 
RNAi does not impair repression by tethered Pum  
(A) Efficiency of Pop2 mRNA depletion was measured using RT-qPCR. Fold changes were calculated relative to 
non-targeting control (NTC). Mean fold change values and standard error for three biological replicates are graphed 
for each dsRNA. (B) Western blot confirmed expression of each tethered effector in Figure 2C. For each sample, 10 
µg of total protein was used to normalize loading between samples. (C) Western blot of V5-tagged tethered effectors 
and myc-tagged Pop2, mutant Pop2, or negative control V5-tagged EGFP from Figure 2D. For each sample, 10 µg 
of total protein was used to normalize loading between samples. (D) Confirmation of RNAi-mediated depletion of 
Ccr4 by RT-qPCR in the top panel and western blot of three biological replicate samples using anti-Ccr4 antibody 
in the lower panel. Fold change in Ccr4 mRNA was calculated relative to NTC dsRNA. Western blot detection of 
actin served as a loading control. Mean fold change values and standard error for three biological replicates samples 
are graphed for each dsRNA. (E) Tethered function assays measured the effect of Ccr4 depletion, relative to NTC, 
on repression activity of Pum N terminus and RDs relative to MS2-EGFP negative control. Mean percent repression 






Figure S3.3 Knockdown efficiency of Not1-3 and tethered effector expression from Figure 3.3A 
(A) RNAi mediated depletion of Not1, Not2, and Not3 mRNAs was confirmed by RT-qPCR. Fold change in each 
mRNA was calculated relative to non-targeting control (NTC) dsRNA). Mean fold change values and standard error 
for three biological replicates are graphed for each dsRNA (B) Western blot confirmation of expression of each 







Figure S3.4 Depletion of Caf40, Not10, and Not11 does not impair tethered function of Pum N terminus and 
RDs 
(A) The effect of RNAi-mediated depletion of Caf40 on repression by Pum N terminus and RDs relative to tethered 
EGFP was measured using the tethered function assay. Mean percent repression and standard error for four 
technical replicates are graphed for each effector. (B) RNAi depletion of Caf40 mRNA was confirmed by RT-qPCR. 
Mean fold change values and standard error are graphed for three biological replicates. (C) The effect of RNAi-
mediated depletion of Not10 and Not11 on repression by Pum N terminus and RDs relative to tethered EGFP was 
measured using the tethered function assay. Mean percent repression and standard error are graphed for four 
technical replicates for each effector. (D) RNAi depletion of Not10 and Not11 mRNAs was confirmed by RT-qPCR. 






Figure S3.5 Pop2 expression does not rescue impaired Pum N terminus and RD activity from Not1 
depletion 
(A) Western blot confirming loss of endogenous Pop2 protein resulting from Not1 depletion. Rescue of Pop2 was 
done with exogenous expression of myc-Pop2 plasmid transfected at 100ng and 150ng to restore Pop2 
approximately to or above endogenous levels. (B) Analysis of the ability of Pop2 to rescue Pum RD mediated 
repression in Not1 depleted cells. The effect of RNAi-mediated depletion of Not1 on repression by Pum N terminus 
and RDs relative to tethered EGFP was measured using the tethered function assay. Myc-Pop2 was expressed 
using 100ng and 150ng of transfected plasmid. Mean percent repression and standard error for four technical 
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Multiple Mechanisms of Pum Mediated Repression: the Pum N-Terminus Utilizes 
Decapping Factors 
 
Material in this chapter is currently being considered for publication, in which the 
co-authors are Joseph Buytendorp, Dr. Chung-Te Chang, Yevgen Levdansky, Dr. 
Eugene Valkov, Dr. Peter Freddolino and Dr. Aaron Goldstrohm. Experiments in Figures 
4.2, panels B and C, were performed by Joseph Buytendorp (University of Minnesota).  
 
4.1 Introduction 
Multiple mechanisms are often employed by mRNA repressors to efficiently seal 
the fate of target mRNAs (see discussion of TTP and miRISC in Chapter 1, and Pum, 
Nos and Brat in Chapter 2). In addition to CNOT recruitment and inhibition of pAbp-
stimulated translation, a previous model proposed that the m7G cap of target mRNAs is 
also important for Pum repression [1]. The 5' cap plays a key role in translation and mRNA 
stability, and its removal via decapping initiates 5'-3' mRNA decay [2, 3]. Analysis of the 
Xenopus Pum ortholog identified a 5' cap-binding motif that contributes to cap-dependent 
translation inhibition in oocytes [1]. Because this motif is conserved in Drosophila Pum [1, 
4], it was postulated to contribute to Pum mediated translational inhibition; however, 
conflicting data have been reported. First, deletion of the putative cap-binding region 
(PCMb) did not alleviate Pum repression, and the cap-binding region did not display 
repression activity when directly tethered to an mRNA [5]. In contrast, another study 
reported that mutation of a conserved tryptophan in the cap-binding motif reduced Pum 
activity [4]. In this chapter, we further scrutinize the potential contribution of this motif. It 
has also been reported that Pum and Nos can repress reporter genes expressed through 
either 5' cap-dependent or cap-independent IRES-driven translation using a Drosophila 
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rough eye phenotypic assay, [6] suggesting a cap-independent mechanism. However, 
there are a few important caveats to this experimental setup and analysis. First, the 
internal ribosome entry site that was used has not been fully characterized [7, 8]. Second, 
the contribution of mRNA decay was not assessed. Third, the experimental system did 
not delineate the separate contributions by Pum and Nos. Therefore, the potential 
relevance to Pum activity remains unknown. 
In addition to the utilization of the CNOT complex described in Chapter 3, we found 
that the Pum N terminus has an additional repressive activity that is resistant to CNOT 
depletion and circumvents requirement for the poly(A) tail. We interrogated the potential 
contribution of the putative 5' cap binding motif and found that mutation of that motif did 
not impair repression in our assays. We then investigated the role of the 5' mRNA decay 
pathway and found that decapping factors participate in repression by the Pum N 
terminus. We measured the contribution of these multiple mechanisms to endogenous 
Pum activity, further emphasizing that CNOT, decapping, and pAbp are utilized by Pum. 
Taken together, our data reveals that Pum stimulates mRNA decay through multiple 
pathways, and that the Pum N terminus contributes to regulation through stimulation of 
decapping and 5'-3' decay. 
 
4.2 Pum N terminus possesses poly(A)-independent repression activity 
We observed that the Pum N terminus retains some repression activity upon 
depletion of components Not1 and Pop2 (Figure 3.2 and Figure 4.1A). CNOT depletion 
results in stabilization of both FFluc and Nluc mRNAs (Figure 1.4B), reflecting the role of 
CNOT in global mRNA deadenylation; however, normalization to both FFluc and EGFP 
negative control specifically measures repression of the Nano luciferase 2xMS2 reporter 
by the Pum N terminus; the Pum N terminus still represses this mRNA, indicating that an 
additional mechanism is involved. Thus, we next sought to determine the source of this 
activity. First, we examined the role of the poly(A) tail by comparing repression of the 
polyadenylated Nluc 2xMS2 reporter to that of a non-adenylated reporter bearing a 3' 
Histone Stem Loop (HSL) processing signal (Figure 4.1C) [9]. The Pum N terminus 
retains about one-third of its repressive activity towards the HSL reporter in comparison 
to the polyadenylated reporter (Figure 4.1D). Thus, the N terminus wields an additional 
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inhibitory mechanism that can circumvent the poly(A) tail. For each experiment in Figure 
4.1, expression of the effectors was verified (Figure S4.1A and S4.1B). Furthermore, we 
confirmed that each reporter generated the correct 3' end product by cleaving them with 
RNase H and an antisense deoxyoligonucleotide that is complementary to the Nluc 
coding region (Figure S4.1C). In addition, deadenylated 3' end RNA fragments were 
generated for each reporter by adding oligo deoxythymidine (oligo dT) to the indicated 
samples (Figure S4.1D). The resulting 3' end fragments were detected by high resolution 
Northern blotting (Figure S4.1D). As expected, the Nluc 2xMS2 pA reporter produced a 
distribution of poly(A) lengths spanning 0-200 adenosines appended to the 228 nucleotide 
3' end product, whereas the Nluc 2xMS2 HSL reporter mRNA produced the expected 
non-adenylated 210 nucleotide product. Based on these observations, we conclude that 
the Pum N terminus can repress by an additional poly(A) independent mechanism that is 
not abrogated by depletion of CNOT components.  
 
4.3 The putative Pum cap-binding motif is not required for repression 
To address the source of poly(A)-independent activity, we interrogated a model 
wherein Pum was hypothesized to repress translation via a 5' cap-binding motif located 
in its N terminus [1, 4]. This motif does not correspond to the three RDs, but instead 
resides within a non-repressive conserved region (previously designated PCMb) [5]. First, 
we introduced a mutation in the Pum N terminus, W783G, that was reported to disrupt 
cap binding [1] and compared its activity (Figure 4.2A) and expression (Figure 4.2B) to 
wild type in the tethered function assay. Both wild type and mutant Pum N terminus 
repressed the reporter in a dose-dependent manner, with equivalent effectiveness at 
each amount (Figure 4.2A). We also examined the effect of the W783G mutant on 
repression of a PRE-containing reporter by full length Pum (Figure 4.2C, D) and observed 
no significant reduction in the ability of the mutant Pum to repress. We then considered 
that the putative repressive activity of the cap-binding motif could be masked by the 
dominant CNOT and poly(A)-dependent repression activity of the RDs. We therefore also 
measured the repression activity of Pum in assays with the HSL reporter. Again, 
repression by the wild type and mutant Pum was indistinguishable (Figure 4.2E, F). Based 
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on this data, and our previous observation that PCMb was neither necessary nor sufficient  
for repression [5], we conclude that - in these experimental conditions - we do not detect 
a role of the proposed 5' cap binding motif in Pum-mediated repression. 
 
Figure 4.1 The Pum N terminus exhibits poly(A)-independent activity 
(A) Tethered function assay measuring the effect of Not1 or Pop2 depletion on repression of reporter protein and 
mRNA levels by tethered Pum N terminus, relative to negative control MS2-EGFP repression of MS2 reporter. 
Tethered Dcp1 served as a positive control. (B)  Northern blot detection of Nluc 2xMS2 reporter and internal control 
FFluc mRNAs in three biological replicate samples for each effector and RNAi condition. Mean values and standard 
error are graphed for repression of protein and mRNA levels. (C) Diagram comparing Nluc 2xMS2 reporters with 
poly(A) tail or the Histone Stem Loop (HSL) used for tethered function assays. The reporters are identical except 
that the cleavage/poly-adenylation element was replaced with a Histone Stem Loop and Histone Downstream 
Element (HDE) in the Nluc 2xMS2 HSL reporter, which produces a non-adenylated 3’ end. (D) Tethered function 
assay comparing the ability of Pum N terminus to repress the poly-adenylated reporter to the non-adenylated HSL 
reporter. Mean values and standard error are graphed for repression of protein and mRNA levels from three 
experimental replicates. Difference between Pum N terminus repression of poly(A) and HSL reporters has p-value 
<0.05 (two-tailed t-test). (E)  Representative Northern blot of the Nluc 2xMS2 pA and HSL reporter mRNAs, internal 
control FFluc mRNA, and 18S rRNA loading control for each effector analyzed in panel D 
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4.4 Decapping factors participate in repression by the Pum N terminus 
Removal of the 5' cap of mRNAs plays a key role in the destruction of mRNAs 
through the 5' decay pathway [2], and decapping is catalyzed by the enzyme Dcp2, which 
forms a heterodimer with Dcp1 [10]. We examined the potential role of decapping in the 
Figure 4.2. Putative cap-binding motif is not required for repression activity of Pum 
(A)  Tethered function assay measuring repression activity of three amounts of transfected wild type or cap-binding 
mutant (W873G) Pum N terminus relative to corresponding amount of transfected MS2-EGFP negative control 
using the Nluc 2xMS2 pA reporter. Mean values and standard error for four technical replicates are plotted for each 
condition. (B)  Western blot confirmation of expression of tethered effectors from analysis in panel A. Tubulin served 
as a loading control. (C)  Tethered function assay measuring repression activity of three amounts of transfected wild 
type or cap-binding mutant (W873G) full length Pum using the Nluc 3xPRE pA reporter relative to corresponding 
amount of negative control, RNA-binding defective mutant Pum (mut R7). Transfected V5-tagged EGFP plasmid 
served to balance total mass of transfected plasmids in samples with 50 and 500 ng of Pum effector plasmid. Mean 
values and standard error for four technical replicates are plotted for each condition. (D)  Western blot confirmation 
of expression of Pum effectors and EGFP-V5 balancer from analysis in panel C. (E)  Same experimental design as 
panel C, except using the non-adenylated 3xPRE HSL reporter to measure Pum repression. (F)  Western blot 
confirmation of expression of Pum effectors from analysis in panel E. 
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poly(A)-independent repression activity of the 
Pum N terminus. To inhibit decapping, we 
depleted Dcp2 via RNAi while simultaneously 
over-expressing an RNAi-resistant, 
catalytically inactive, dominant negative Dcp2 
mutant (E361Q) (Figure S4.2A and B). As 
previously established [11-13], this combined 
approach was necessary to effectively 
abrogate decapping-mediated mRNA decay, 
resulting in stabilization of the Nluc reporter 
mRNA and Firefly luciferase internal control 
mRNA (Figure 4.3A and B). Further 
corroborating the effectiveness of blocking 
decapping, we observed that mRNA 
degradation by tethered Dcp1 was prevented 
by inhibition of Dcp2 (Figure 4.3A and B). 
Interestingly, tethered Dcp1 retained the 
ability to repress reporter translation, which 
likely reflects its association with 
translational inhibitory factors (Figure 4.3A) 
[10].  
Inhibition of decapping diminished 
repression of reporter protein expression by 
the Pum N terminus (Figure 4.3A) and also 
alleviated the ability of the N terminus to 
reduce reporter Nluc 2xMS2 pA mRNA 
level from 64% to 21% (Figure 4.3A), 
indicating that decapping participates in the 
repression mechanism. To separately 
Figure 4.3. Decapping factors contribute to 
repression by the Pum N terminus 
(A) Tethered function assay using the Nluc 2xMS2 pA 
reporter to measure the effect of inhibition of 
decapping on the repression of reporter protein and 
mRNA levels by the Pum N terminus. Decapping was 
inhibited by simultaneous RNAi depletion of Dcp2 and 
over-expression of the dominant negative mutant Dcp2 
E361Q. Tethered EGFP served as a negative control 
and tethered Dcp1 served as a positive control. Mean 
values and standard error for three biological replicates 
are plotted for each condition. Differences between 
control (NTC + empty vector) and Dcp2 knockdown 
conditions for Pum N terminus have p-value <0.05 
(two-tailed t-test). (B) Northern blot detection of Nluc 
2xMS2 reporter and FFluc internal control in three 
replicate samples for tethered effectors analyzed in 
panel A. (C) The same experimental strategy as in 
panel A was used to measure the effect of decapping 
inhibition on the activity of tethered Pum N terminus 
with the poly-adenylated Nluc 2xMS2 pA reporter in 
comparison to the non-adenylated Nluc 2xMS2 HSL 
reporter. Mean values and standard error for four 
technical replicates are plotted for each condition. 
117 
 
analyze the poly(A)-independent activity of 
the Pum N terminus, we again employed 
the non-adenylated Nluc 2xMS2 HSL 
reporter. Strikingly, the ability of the Pum N 
terminus to repress the HSL reporter was 
eliminated by inhibition of decapping, 
indicating that decapping accounts for the 
poly(A)-independent repression activity 
(Figure 4.3C). Expression of each effector 
was confirmed, as shown in Figure S4.2C). 
Further supporting this conclusion, we also 
depleted decapping factors Ge-1/Edc4 and 
Dcp1 (Figure S4.2D and S4.2E) [14, 15], 
as these factors bridge the interaction of 
Dcp2 to the decapping complex, and this 
approach was previously reported to 
reduce decapping [16]. We observed a loss 
of poly(A)-independent repression by the 
Pum N terminus, similar to that of Dcp2 
knockdown (Figure S4.2D). From these 
data, we conclude that decapping 
contributes to the repression activity of 
the Pum N terminus. 
 
4.5 Multiple mechanisms contribute to 
Pum-mediated repression. 
Having identified multiple co-
repressors (Not1, Pop2, Dcp2, and 
pAbp; this study and [17]) that are 
important for the individual activities of 
multiple repression domains (N-terminal 
Figure 4.4. Multiple mechanisms and cofactors 
contribute to repression by Pum 
(A)  Western blot detection for RNAi-mediated depletion 
of Pum, Not1, and Pop2 in three biological replicate 
samples using antibodies to endogenous proteins. Pum 
and Not1 antibodies each recognize two isoforms of their 
respective proteins. Tubulin serves as a loading control for 
the blots. (B)  The effect of RNAi depletion of co-
repressors Not1, Pop2, Dcp2, and pAbp on repression of 
Nluc 3xPRE reporter protein and mRNA expression levels 
by endogenous Pum was measured in d.mel-2 cells.  Fold 
change induced by RNAi was compared to negative 
control NTC dsRNA. RNAi of Pum served as a positive 
control. The effect of RNAi of each factor on the Pum 
repressed, PRE containing reporter was normalized to the 
effect on the unregulated Nluc ∆PRE reporter, which 
contains a minimal 3’UTR that lacks Pum binding sites. 
Three biological replicates were measured. Differences in 
NTC and knockdown conditions have p-value <0.05 (two-
tailed t-test), with the exception of pABP RNAi Nluc 
mRNA. (C)  Northern blot detection of Pum-regulated Nluc 
3xPRE, unregulated Nluc ∆PRE reporter mRNA and 
FFluc internal control mRNAs in three biological replicate 
samples for each RNAi condition measured in panel A. 
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RDs and the C-terminal RBD), we investigated their contributions to regulation by full-
length, endogenous Pum. To do so, Pum repression was measured using the Nluc 
3xPRE reporter and compared to the unregulated control reporter Nluc ΔPRE, which 
lacks PRE sequences. As before, FFluc mRNA served as an internal control. Not1, Pop2, 
Dcp2, or pAbp were each depleted by RNAi, as confirmed in Figures 4.4A and S4.3, and 
reporter protein and mRNA levels were measured. As before, the RNAi depletion of Dcp2 
was accompanied by over-expression of mutant Dcp2 E361Q. RNAi depletion of Pum 
served as a positive control (Figure 4.4A) and alleviated PRE-mediated repression 
resulting in increased reporter protein (2.4 fold) and mRNA levels (2.9 fold) (Figure 4.4B 
and 4.4C). To specifically measure PRE-dependent regulation, the response of the Nluc 
3xPRE reporter was normalized to the unregulated Nluc ΔPRE reporter, and the fold 
change values for each RNAi condition were then calculated relative to the negative 
control (NTC) RNAi condition. Depletion of Not1 or Pop2 alleviated PRE-dependent 
repression (2.1 and 2.0 fold, respectively) and stabilized the reporter mRNA (1.6 and 1.9 
fold, respectively) (Figure 4.4B and 4.4C). Inhibition of Dcp2 more modestly stabilized the 
PRE-containing reporter (1.5 fold; Figure 4.5B), as did depletion of pAbp (1.3 fold), 
reflecting their respective contributions to repression by the Pum N terminus and RBD. 
These results demonstrate the multiple co-repressors and mechanisms contribute to 
Pum-mediated repression in Drosophila cells. 
 
4.6 Discussion 
Our work demonstrates that the Pum N terminus can modestly stimulate 
repression and degradation of an mRNA lacking a poly(A) tail, and that the putative cap-
binding function of Pum is not the source of this activity. Furthermore, we show that 
decapping factors, including Dcp2, Dcp1 and Ge-1, and 5'-3' mRNA degradation 
participate in Pum mediated repression. Taken together, Pum employs multiple 
mechanisms of mRNA repression, including antagonization of pAbp, deadenylation, and 
decapping, and these mechanisms are evolutionarily conserved. Yeast PUF proteins, for 
example, have been shown to promote mRNA decapping [18-20]; while poly(A) 
independent mechanisms were previously implicated for Drosophila Pum, this is the first 
evidence to our knowledge linking Pum repression to the decapping pathway. Future 
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direction will include determining whether Pum makes specific contacts with decapping 
factors, and/or whether this is still in part mediated by the CNOT complex. Another 
question is whether these mechanisms are most relevant to specific developmental 










Figure S4.1 Tethered effector expression from Figure 4.1A-B and D-E, and validation of Histone Stem Loop 
reporter mRNA by RNAse H cleavage assay from Figure 4.1D-E 
(A) Western blot confirmation of effector expression in each replicate and each RNAi condition for experiment 
shown in Figure 5A. For each sample, 10 µg of total protein was used to normalize loading between samples. (B) 
Western blot confirmation of effector expression from experiment shown in Figure 5D. For each sample, 10 µg of 
total protein was used to normalize loading between samples. (C) Diagram of tethered function reporters used in 
Figure 5 including location of Northern blot probe and RNAse H cleavage oligonucleotide used to cleave the 
mRNAs for high resolution Northern blotting shown in panel D. (D) High resolution Northern blot of Nluc 2xMS2 pA 
and HSL reporter mRNAs, confirming poly-adenylation of the pA reporter and lack of poly-adenylation of the HSL 
reporter. Control samples included oligo dT15 to enable RNase H mediated cleavage of the poly(A) tail. RNA size 




Figure S4.2 Tethered effector expression from decapping assays in Figure 4.3 and Dcp1/Ge-1 knockdown 
impairs poly(A) independent repression by the Pum N terminus 
(A) Western blot detection of three replicate samples for tethered effectors analyzed in Figure 7A. For each sample, 
10 µg of total protein was used to normalize loading between samples. (B) RT-qPCR based measurement of Dcp2 
RNAi-mediated knockdown efficiency. Fold changes were calculated relative to negative control NTC dsRNA. (C) 
Western blot detection of tethered effectors analyzed in Figure 7C. For each sample, 10 µg of total protein was 
used to normalize loading between samples. (D) Tethered function assay measuring the effect of RNAi depletion 
of decapping factors Dcp1 and Ge-1 on repression of the Nluc 2xMS2 HSL reporter by tethered Pum N terminus. 
Tethered EGFP served as a negative control. The effect of knockdown of Dcp1 and Ge-1 was compared to non-
targeting control dsRNA (NTC). Mean values and standard error are plotted for four technical replicates each 
condition. On the right, western blot detection confirming expression of tethered effectors. For each sample, 10 µg 
of total protein was used to normalize loading between samples. (E) Knockdown efficiency of Dcp1 and Ge-1 for 
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Discussion and Future Directions 
 
Material in this chapter is currently being considered for publication, in which the 
co-authors are Joseph Buytendorp, Dr. Chung-Te Chang, Yevgen Levdansky, Dr. 
Eugene Valkov, Dr. Peter Freddolino and Dr. Aaron Goldstrohm. 
 
5.1 Mechanistic insights into Pumilio mediated repression 
Investigation of the Pum-mediated repression mechanism has relevance beyond 
Drosophila biology. Orthologs of Pum exist in mammals, wherein they regulate many 
hundreds of mRNAs [1]. Mammalian Pum orthologs have crucial, diverse roles in growth, 
development, hematopoiesis, neurogenesis, and gametogenesis [2-10]. Mammalian Pum 
proteins also function in the nervous system to control neuronal morphology and function 
[11], influencing behavior, learning and memory formation [5, 8]. Moreover, their 
dysfunction contributes to neurodegeneration, ataxia, epilepsy, and cancer through their 
control of critical mRNA targets [1, 2, 12-18]. Given the pervasive and conserved roles of 
Pum, we are compelled to gain a further understanding of its function. These results 
provide new insights into the molecular mechanism by which Pum represses gene 
expression. Previous work correlated Pum repression with reduction in mRNA levels, and 
we now show that Pum uses multiple repression domains to directly accelerate mRNA 
decay via the CNOT and decapping complexes. This information enhances our 
understanding of Pum’s biological roles and impact on the transcriptome. 
 
5.1.1 The Pum RDs utilize the CNOT complex to stimulate mRNA decay 
The emerging model is that four repressive domains of Pum contribute to mRNA 
decay by utilizing CNOT, including RD1-3, and the RBD (Figure 5.1). The major 
repressive activity of Pum emanates from the three RDs within its N terminus, each of 
which contributes to mRNA decay. Their activities depend on the co-repressor Not1 and 
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the catalytic function of the Pop2 deadenylase. In addition, the C-terminal RBD of Pum 
was previously shown to interact with Pop2 and promote deadenylation [19, 20]. Based 
on these observations, we propose that multiple regions of Pum contribute to CNOT 
recruitment to target mRNAs. Why does Pum use multiple regions to recruit CNOT? 
Perhaps their activities combine to increase the avidity of Pum for CNOT, likely mediated 
by multiple contacts between Pum domains and CNOT components (Figure 5.1). 
Mapping of the precise protein-protein interactions necessary for CNOT recruitment by 
Pum will require detailed biochemical and structural mapping to be pursued in future 
studies. 
Recruitment of CNOT by RNA-binding factors has emerged as an important 
mechanism of post-transcriptional regulation [21-26]. Indeed, utilization of CNOT by Pum 
orthologs has been reported in Saccharomyces cerevisiae, C. elegans, Drosophila and 
mammals [20, 27-31], and thus represents an evolutionarily conserved mechanism. Like 
Drosophila Pum, the highly conserved RBD of Pum orthologs spanning from yeast to 
human universally interact with Pop2 orthologs. In contrast, the N-terminal RDs are a 
more recent evolutionary addition, being found in Pum orthologs spanning insects through 
mammals [32]. Based on the results of this study, we speculate that analogous regions 
of those Pum orthologs repress by recruiting the CNOT complex. Consistent with this 
idea, experimental evidence showed that the N termini of human Pum orthologs, PUM1 
and PUM2, exhibit repressive activity when directed to an mRNA in Drosophila cells [32]. 
Future research should dissect the repressive mechanism of mammalian Pum N termini. 
It is tempting to speculate that Pum might recruit a subcomplex of CNOT, based 
on the observation that only Pop2 and Not1 were important for Pum RD activity whereas 
depletion of others had little (i.e. Not2 and Not3) or no effect (i.e. Ccr4, Not10, Not11, 
Caf40) (Figure 5.1). Indeed, evidence in yeast and human cells revealed heterogeneity 
in size and composition of CNOT complexes [33-36]. The requirement of specific CNOT 
subunits for repression by Pum orthologs was also observed in Saccharomyces 
cerevisiae [27, 37]. However, we observe that in addition to the Not and catalytic modules, 
the Pum RDs make contacts with modules of CNOT that are not required for their function 
in our assays, including Not10/11 and Caf40. It is possible that while these interactions 
strengthen Pum’s recruitment of CNOT, only specific subunits are necessary for mRNA 
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decay activity. However, it is important to acknowledge that this biochemical dissection 
does not resolve RD contacts with individual subunits (i.e. the RDs could be recruiting the 
Not1 component of the modules in these cases, and not the other subunits). We also 
acknowledge that interpretation of the negative results in our experiments is limited by 
the effectiveness of RNAi-mediated depletion, and that residual levels of a CNOT 
component may be sufficient to support activity. A future approach could include CRISPR 
mediated deletions of CNOT components. 
 
5.1.2 The Pum N terminus utilizes decapping factors 
We also found that decapping contributes to repression by Pum. The N terminus 
retains partial repressive activity when the target mRNA lacks a poly(A) tail and therefore 
is not subject to deadenylation. In addition, the N terminus retains repression activity 
when Not1 or Pop2 are depleted. We found that this poly(A) independent activity requires 
the decapping enzyme complex including Dcp2, Dcp1 and Ge-1, indicating that one or 
more regions of the Pum 
N terminus promote 
decapping of target 
mRNAs (Figure 5.1). 
Future analyses will be 
necessary to delineate the 
specific regions of Pum 
that modulate decapping 
and whether they directly 
associate with decapping 
enzyme or do so via 
bridging proteins that 
interface with the 
decapping machinery 
[38]. Decapping may also 
be a conserved 
mechanism of Pum 
Figure 5.1 Model of Pum-mediated repression  
The RNA-binding domain (RBD) of Pum binds to mRNAs that contain a PRE. 
Multiple domains of Pum contribute to repression activity including N-terminal 
repression domains (RD1, RD2, and RD3) and C-terminal RBD. Pum 
represses the target mRNA by multiple mechanisms including acceleration of 
mRNA decay via Ccr4-Pop2-Not (CNOT) deadenylase complex mediated 
deadenylation of the 3’ poly-adenosine tail and decapping enzyme (Dcp2) 
mediated removal of the 5’ 7-methyl guanosine cap (7mGppp). Dcp2 interacts 
with protein partners Dcp1 and Ge-1. Pum RBD also antagonizes the 
translational activity of poly-adenosine binding protein (pAbp). Red arrows 
indicate enzyme-catalyzed hydrolysis of the RNA. Solid lines with arrowheads 




repression, supported by the observations that yeast PUF proteins associate with 
decapping factors and promote decapping of target mRNAs [27, 39, 40]. 
How does Pum affect protein synthesis? Because the 5' cap is crucial for 
translation of most mRNAs, and the poly(A) tail and pAbp promote translation, Pum-
mediated deadenylation and decapping can contribute to both repression of protein 
synthesis and mRNA destruction. Indeed, Pum-mediated repression of protein level 
corresponds in magnitude to the reduction in mRNA level. Based on conservation of a 
cap-binding motif that contains a key tryptophan residue (W783) [41], Pum was proposed 
to directly inhibit translation by binding the 5' cap of target mRNAs, and mutation of W783 
moderately reduced Pum's ability to repress a GFP reporter bearing the mad 3'UTR in S2 
cells [30]. However, we did not observe an effect of this mutation on repression by the 
Pum N terminus in the tethered function assay or by full length Pum using the PRE 
reporter. Likewise, previous analysis showed that the PCMb (Pum Conserved Motif b) 
domain encompassing the putative cap binding motif was neither necessary nor sufficient 
for repression [20]. Thus, the proposed mechanism of cap-dependent inhibition does not 
appear to make an essential contribution to the Pum activity measured here. We cannot 
rule out that it might have a potential role in repression in other cellular or developmental 
contexts, or within the context of certain mRNAs such as the mad 3’UTR, which is affected 
by other RNA-binding regulatory factors, including Brat [30, 42]. The importance of the 
cap binding motif could be further assessed by generating transgenic Drosophila bearing 
the W783G mutation and measuring the protein output of Pum targets. 
 
5.1.3 Deadenylases and PABP 
The Pum RBD contributes to translational repression by associating with and 
antagonizing the activity of pAbp (Figure 5.1) [20]. Consistent with this role, we observed 
that depletion of pAbp diminished Pum-mediated repression of protein and mRNA levels. 
These observations lead us to speculate about the potential functional interplay between 
Pum, pAbp, and deadenylation. Binding of pAbp to poly(A) was originally thought to 
interfere with deadenylation [43]; however, recent studies indicate that the relationship is 
more complex [44, 45], wherein Ccr4 and Pop2 deadenylase activities were shown to be 
differentially affected by pAbp orthologs. Analysis of human PABPC1 and S. pombe Pab1 
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indicate that they are required for Ccr4 deadenylase activity, whereas they inhibit activity 
of Pop2 orthologs. Further evidence in vitro suggests that S. pombe Ccr4 can displace 
Pab1 from the poly(A) tail, whereas Pop2 cannot. Whether these properties carry over to 
Drosophila remains to be determined. In principle, Pum could cause displacement of 
pAbp from the mRNA, thereby bypassing the role of Ccr4, resulting in accelerated Pop2-
catalyzed deadenylation. Contradicting this hypothesis, however, is the observation 
based on RNA immunoprecipitation of pAbp, that the Pum RBD did not dislodge pAbp 
from mRNA [20]. Alternatively, the Pum RBD may interfere with the ability of pAbp to 
promote translation initiation. This idea is supported by functional assays, wherein we 
showed the Pum RBD inhibits the ability of pAbp to promote translation when bound to 
an internal poly(A) tract within an mRNA engineered without a 3’ poly(A) tail [20]. Future 
work will include determining the specific interactions between Pum and pAbp, and how 
this might influence translation efficiency and/or deadenylation. 
 
5.2 Relevance of Pumilio’s repressive mechanism in vivo 
Our results have important implications for understanding Pum-mediated 
repression in embryos, the germline, and neurons. Pum repression of hunchback mRNA 
in early embryogenesis was linked to poly(A) tail shortening [46]. Pum repression was 
also correlated with mRNA decay during the maternal-to-zygotic transition (MZT), wherein 
many PRE-containing, maternally provided mRNAs are coordinately degraded [47-49]. 
Additionally, Pum-mediated repression is linked to deadenylation by CNOT in primordial 
germ cells, where Pum contributes to repression of cyclin B mRNA [19], and in GSCs, 
where Pum participates in repression of mRNAs such as mei-P26 [29]. The mechanisms 
of Pum-mediated deadenylation and decapping likely contribute to mRNA degradation 
observed in these contexts. Pum also represses specific mRNAs in neurons, such as 
paralytic, which encodes a voltage-gated sodium channel [50-52]; however, the impact 
on mRNA decay remains to be examined in this context. Future analysis should 
investigate the contributions of Pum RDs to these and other processes. Ongoing work 
includes investigating whether there are distinct roles for the RDs during embryogenesis 
through generation of transgenic Drosophila bearing deletions in one, two, or all three 
130 
 
RDs (see Appendix C). These transgenes will also be used to investigate Pum regulation 
of mRNA targets throughout development, and how each RD contributes to regulation. 
Several isoforms of Pum exist  in Drosophila, but the implications of their functional 
domain content in vivo are unclear. There are 8 mRNA isoforms that produce a total of 5 
unique proteins (Flybase) (Figure 5.2). Isoforms A, C and D encode the full-length Pum 
containing all functional domains, while Isoform B is lacking RD1. Isoforms E, F and H 
produce shorter Pum proteins lacking RD1, PCMa and a section of RD2. Two isoforms 
of Pum were initially detected in ovaries and embryos, at approximately 130 kD and 156 
kD, consistent with isoform B and full-length Pum (isoforms A, C and D), respectively [53]; 
these are the same approximate sizes that we detect in d.mel-2 cells using an antibody 
to the C-terminal extension (Figure 4.4), which is common in all isoforms (Figure 5.2). 
The 130 kD isoform B omits RD1, which we observe to be more resistant to CNOT 
depletion than RD2 and RD3 (Figures 3.2, 3.3 and 4.1). This study reported that either 
isoform of maternal Pum could compensate for the other in the early embryo [53], but 
there could be interesting implications for Pum function in other contexts, where different 
isoforms yield Pum proteins with varying efficacy, potentially tuning Pum activity in 
different tissues and developmental stages. Moreover, the more severely truncated 
isoforms PCMa may have interesting implications for both Pum repression and 
autoregulation, as will be discussed in section 5.4. 
 
5.3 Pum localization 
Another facet of regulation by Pum is subcellular localization. Human Pumilio  
proteins are localized within Stress Granules (SGs) in multiple cellular contexts [54, 55], 
including neuronal projections [56]. In dendrites, human PUM2 is thought to facilitate 
localized repression of translation of specific targets to regulate morphology and synaptic 
function [11]. Human PUM1 was also found to be enriched in P-bodies [57], which were 
previously thought to be sites of mRNA decay (see Chapter 1) [58]. However, recent work 
suggests that this relationship may be more complicated, as mRNAs associated with P-
bodies are not more prone to turnover [57]; nevertheless, P-bodies are sites of 
translational repression [57, 59, 60]. What is the consequence of Pum’s enrichment P-
bodies? One possibility is that localization sequesters Pum proteins to attenuate their 
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decay function, although there is currently no evidence for this. It is also possible that 
localization facilitates Pum’s association with decapping factors, which are also enriched 
in P-bodies [57]. If this were the case, perhaps these P-body associated target mRNAs 
are decapped, but not rapidly degraded; this would be consistent with our observation 
that Pum mediated decay is largely CNOT-dependent. Interestingly, CNOT components 
were not found to be enriched in P-bodies [57]. Future work will include dissecting the 
functional implications of localization on Pum activity. 
What facilitates Pum’s association with P-bodies and SGs? The Pum N terminus 
is rich is low complexity sequence, a common feature of the mRNP granule-associated 
proteome [61]. Indeed, PUM2 association with dendritic stress granules is dependent on 
a glutamine-rich region in the N-terminus [56] (amino acids 225-651, corresponding to 
domains RD2, B and RD3), although it is important to consider that interpretation of this 
work is complicated by potential artifacts from overexpression. Future work will include 
further dissection of the domains involved in localization, and whether Pumilio proteins 
help mediate the localization of target mRNAs. 
  
5.4 Pum Autoregulation 
Another avenue of investigation will be how the Pum RD mechanism relates to the 
function of the putative autoregulatory domains, PCMa and PCMb [32]. These domains 
are more conserved with human orthologs than the RDs, with 37% and 38% segment 
identity for PCMa and 62% and 67% for PCMb. In d.mel-2 cell reporter assays, PCMb 
inhibits the function of RD2 and RD3 when fused to either domain, however the 
mechanism for this is not clear. Could PCMb function to inhibit interactions between the 
RDs and CNOT? One possible model is that B induces a conformational change in Pum 
to occlude the Pum-CNOT interaction under certain conditions, or recruits an inhibitor of 
CNOT activity. Future work will include investigating the impact of PCMb on RD CNOT 
recruitment in vitro and in cells. 
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PCMa antagonizes the inhibitory function of PCMb [32], although the mechanism 
is not yet characterized. [32]. PCMa is highly phosphorylated in the embryo, containing 
11 putative phosphorylation sites [62], but the relevance of phosphorylation to Pum 
function is unclear. One study reports genetic evidence that Pan Gu Kinase (PNG) 
reduces Pum function during egg activation [63]; while Pum can be a substrate of PNG 
in vitro [64], evidence of a direct interaction and phosphorylation in vivo has yet to be 
demonstrated. One possible model is that phosphorylation negatively regulates PCMa’s 
inhibition of PCMb activity, but further work is needed to test this. It is unclear how 
phosphorylation impacts Pum in other contexts.  
 
5.5 Combinatorial control 
Regulation of a growing number of Pum target mRNAs involves collaboration with 
other RBPs, with Nanos and Brat being the best documented examples. How can the 
mechanisms of Pum repression integrate with the activities of these RBPs? In the case 
of Nanos, it binds cooperatively with Pum to certain target mRNAs that possess a Nanos 
binding site preceding a PRE motif [65, 66]. Nanos also confers its own repressive activity 
that accelerates deadenylation [24]. Nanos may synergize with Pum in the recruitment of 
Figure 5.2 Pum protein isoforms in Drosophila melanogaster 
Scale diagram of each unique Pum protein produced by different mRNA isoforms. White box indicate amino acid 
sequence unique to that isoform. 
133 
 
CNOT by contributing additional contacts with the Not1 and Not3 subunits. Nos was also 
reported to interact with Not4 [19], though the potential role of Not4 in deadenylation and 
its involvement in Nos activity are unclear. In fact, Drosophila Not4 does not appear to be 
a stable, stoichiometric CNOT component [67]. Nanos also promotes decapping, but like 
Pum, how it does so is presently not well understood [24]. Thus, combinatorial control by 
Pum and Nos together accelerate the same key steps contributing to silencing of 
translation and mRNA destruction [68].  
Pum can also collaborate with Brat to repress certain mRNAs that contain both a 
PRE and Brat binding site [30, 42, 48, 69, 70]. The mechanism of Brat-mediated 
repression in embryos was reported to involve recruitment of the translational repressor 
eIF4E homologous protein (4EHP) [71]. Brat may also affect mRNA decay, supported by 
the observation that it co-purifies with the CNOT complex [67]. Depletion of Pop2 reduced 
the combined repressive activity of Pum and Brat [30]. Future analyses will be necessary 
to interrogate the role of CNOT in Brat-mediated repression and whether Pum and Brat 
can synergistically recruit CNOT to mutual target mRNAs. Pum, Nanos, and Brat all 
collaborate to bind and repress the maternal hunchback mRNA during embryogenesis 
through a combination of cooperative RNA-binding, translational repression, 
deadenylation, and mRNA decay (reviewed in [68]). It is noteworthy that the assembly of 
this triumvirate of repressors on one mRNA is likely a rare scenario, as few mRNAs are 
predicted to contain the requisite cluster of binding sites for these three RBPs [68]. 
 
5.6 Conservation of Pum mechanism and relevance to human health 
The mechanistic insights into Pum-mediated repression have important 
implications for Pum orthologs in other species. Drosophila Pum serves as an archetype, 
and the conservation of repressive Pum domains, including those in its N terminus and 
RBD, in animals ranging from insects to vertebrates suggests that the mechanisms and 
co-repressors described here will be relevant. Indeed, as noted above, accumulating 
evidence supports the role of deadenylation, decapping, and translational inhibition in 
Pum repression in multiple model organisms. Mammalian Pum orthologs have 
multifaceted roles in growth and development, gametogenesis, hematopoiesis, 
neurogenesis, behavior, motor function and memory formation. Their dysfunction has 
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now been linked to cancer, neurodegeneration, epilepsy, memory impairment, reduced 
fertility, and developmental defects in mammals [2, 3, 5, 8, 12, 13, 15, 16, 18]. We 
anticipate that further elucidation of Pum function will facilitate better understanding of its 
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Materials and Methods 
 
Material in this chapter is currently being considered for publication, in which the 
co-authors are Joseph Buytendorp, Dr. Chung-Te Chang, Yevgen Levdansky, Dr. 
Eugene Valkov, Dr. Peter Freddolino and Dr. Aaron Goldstrohm. 
 
6.1 Plasmids and cloning   
All plasmid clones used in this study were verified by diagnostic restriction digests 
and DNA sequencing. All primer sequences used in this study are listed in Table 6.1. The 
pIZ plasmid (Invitrogen) used for effector expression contains OpIE2 promoter, 
Drosophila Kozak sequence, C-terminal V5 and His6 tags (H6), and SV40 
cleavage/poly(A) site. Functional assays and transcription shut off experiments used pIZ 
Pumilio V5H6 and pIZ Pumilio mut R7 V5H6 plasmids that were previously described [1]. 
The pIZ MS2-PumN V5H6, pIZ MS2-RD1 V5H6, pIZ MS2-RD2 V5H6, and pIZ MS2-RD3 
V5H6 plasmids used in tethered function assays were previously described [1]. The 
negative control pIZ MS2-EGFP plasmid was cloned by amplification of EGFP insert 
using oligos CW115 and CW116 (Table 6.1) and insertion into KpnI and XbaI sites of pIZ 
MS2CP vector [1]. Plasmid pIZ MS2-Dcp1 was cloned by amplification of Dcp1 coding 
sequence (NP_611842.1) from d.mel-2 cDNA using oligos RA 102 and RA 103 and 
insertion via SpeI and NotI sites into pIZ MS2CP vector. The plasmid pIZ Halotag V5 
StrepII was used to balance the total mass of transfected plasmid DNA in representative 
RNAi experiments (to demonstrate knockdown efficiency) and was created by inverse 
PCR using oligos RA 285 and RA 286 from pIZ Halotag V5H6 [2]. RNAi-mediated 
depletion of Pop2 was rescued using RNAi-resistant cDNA clone pIZ myc-Pop2, which 
contained the Pop2 coding sequence (NP_648538.1) generated by PCR from d.mel-2 
cDNA using CW 033 and CW 034 primers, with an N-terminal Myc tag, inserted into 
HindIII and XbaI sites of vector pIZ. The pIZ myc-Pop2 with active site mutations D52A 
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and E54A was generated from pIZ myc-Pop2 using quickchange site-directed 
mutagenesis (Agilent) using Pfusion DNA polymerase (Thermo Fisher) and primers CW 
161 and CW 162. The expression plasmid vector pUBKz 3x Flag contains the Drosophila 
ubiquitin 63E promoter, Kozak sequence, N-terminal 3x Flag, and SV40 cleavage and 
polyadenylation site in a pUC19 backbone (provided by Dr. Eric Wagner, University of 
Texas Medical Branch). pUbKz 3x Flag Dcp2 E361Q was cloned by PCR amplification of 
the Dcp2 coding sequence (NP_001246776.1) from d.mel-2 cDNA using oligos RA 086 
and RA 087 followed by insertion into SpeI and NotI sites in pUbKz 3x Flag vector. Point 
mutation of residue glutamate 361 to glutamine (E361Q) was made through quickchange 
mutagenesis using oligos RA 166 and RA 167. Nanos C-terminal mutants I376A, M378A 
and I382A were cloned in pIZ Nanos V5H6 vector via Quikchange PCR, as described in 
reference [2], using oligos indicated in Table 6.1. MS2-PCMa phosphomutants were 
cloned from pIZ MS2-PCMa-RD2-PCMb via inverse PCR using primers CW 037 and CW 
076, followed by blunt ligation. 
All reporter genes are based on vector pAc5 (Invitrogen) that contains the actin 
promoter. All reporter assays included the firefly luciferase (FFluc) internal control 
plasmid, pAc5.1 FFluc min 3'UTR, which was described previously [1]. The Nano-
luciferase reporter plasmid pAc5.4 Nluc2 control (multi-cloning site (MCS) 3'UTR, also 
referred to as ΔPRE) was cloned through amplification of Nano-luciferase coding 
sequence with C-terminal PEST sequence from pNL1.2 plasmid (Promega) using oligos 
CW 578 and RA 066, which was then inserted into the KpnI and XhoI sites of vector 
pAc5.4. Reporter plasmid pAc5.4 Nluc2 2xMS2 was cloned by inserting oligos AG 784 
and AG 785, encoding two copies of the binding site for MS2 coat protein (MS2), into 
pAc5.4 Nluc MCS 3'UTR vector via flanking XhoI and NotI sites. The pAc5.4 vector was 
described in Weidmann et al (2016) [2]. For the Histone Stem Loop (HSL) reporter, 
pAc5.4 Nluc2 2xMS2 HSL, was constructed using inverse PCR with oligos RA 255 and 
RA 256 using pAc5.4 Nluc2 2xMS2 as template, thereby replacing cleavage/p(A) element 
with HSL and Histone Downstream Element (HDE) sequences. To create the Pum 
reporter plasmid, first a unique XhoI site was inserted into pAc5.1 Rnluc [1] using inverse 
PCR with oligos RA 214 and RA 215. Next, the Nluc2 coding was inserted into KpnI and 




6.2 Cell Culture and Transfection   
D.mel-2 cells (Invitrogen) were cultured in Sf900III media (Thermo-Fisher, see 
Table 6.2 for reagents) at 25°C in 100 µg/ml penicillin and 100 µg/ml streptomycin. For 
transfection with Fugene (all except Figure 2.4 and C2)., 2 million d.mel-2 cells were 
plated in a 6-well plate and transfected with 3 µg effector DNA. FuGene HD (Promega) 
was used at a 4:1 ratio of FuGene HD volume (µl) to DNA molecular weight (µg) prepared 
in Sf900III media (150 µl total volume), and incubated for 15 minutes at room temperature 
prior to application to cells. For Figure 2.3, 100 ng of pIZ Nanos V5H6 plasmid, balanced 
to 3 µg with empty pIZ plasmid, was transfected with 10 ng of pAc5.1 Rnluc hb 3'UTR 
and 5 ng of pAc5.1 Ffluc min 3'UTR. For Figure 3.3, 5 ng of pAc5.4 Nluc 2xMS2 poly(A) 
reporter and pAc5.1 FFluc internal control plasmid were transfected. To boost signal for 
Northern blotting (dual luciferase assays in all other figures), 20 ng of pAc5.4 NLuc poly(A) 
or 100 ng Nluc HSL were transfected into cells along with 20 ng pAc5.1 FFluc.  
For Pop2 RNAi rescue experiment (Figure 3.2), 2.25 µg of tethered effector was 
transfected, along with 750 ng of either pIZ EGFP V5 or pIZ myc-Pop2 (WT or D52A and 
E54A double mutant). For experiments with Not1 RNAi and rescue with exogenous Pop2 
(Figure S3.5A and B), either 150 ng of pIZ EGFP V5 control, 100 ng myc-Pop2 (with 50 
ng pIZ EGFP V5), or 150 ng myc-Pop2 were transfected into cells along with 2.85 µg of 
the indicated tethered effectors. 
For analysis of decapping in Figure 4.3, 1.5 µg of the indicated tethered effectors 
and 1.5 µg of either pUbKz 3x Flag empty vector or pUbKz 3x Flag Dcp2 E361Q plasmid 
were transfected into cells that were also treated with non-targeting control (NTC) or Dcp2 
double stranded RNA, as described below. Importantly, the RNAi of the Dcp2 mRNA 
targeted the 3’UTR and thus did not affect expression of the Dcp2 E361Q. To measure 
repression by endogenous Pum in Figure 4.4, 1.5 µg total mass of transfected DNA, 
scaled to maintain 4:1 ratio of FuGene HD volume to mass of DNA, composed of either 
pUbKz 3x Flag empty vector or pUbKz 3x Flag Dcp2 E361Q was introduced into cells 
treated with Dcp2 dsRNA. 
For Figure 2.4 Nanos titration experiments and Figure C2 Pum transgene activity 
test, 1.6M d.mel-2 cells in 1.6 ml Sf900III media were transfected using Effectene 
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Transfection Reagent (Qiagen), as described in references [1, 3]. Each well was 
transfected with 10 ng of pAc5.1 Rnluc, 5 ng of pAc5.1 Ffluc min 3'UTR and 200 ng total 
pIZ effector DNA (balanced with empty pIZ plasmid for Nanos titrations). Used 43–44 µl 
of EC buffer, 1.6 µl of enhancer, and 2 µl of Effectene, delivering transfection mix to cells 
in 300 µl of new Sf-900 III SFM. 
 
6.3 RNA interference   
RNAi was induced by treating cells with gene-specific double stranded RNA 
(dsRNA), ranging from 133-601 bp, that were designed using the SnapDragon web-based 
tool (DRSC, URL: http://www.flyrnai.org/cgi-bin/RNAi_find_primers.pl) to prevent 
potential off-target regions. Templates were PCR-amplified to add opposing T7 promoters 
to each DNA strand (see Table 6.1 for T7 template primer sequences). dsRNAs were 
transcribed using HiScribe T7 high yield RNA synthesis kit (New England Biolabs). 
Reactions were treated with RQ1 RNase-free DNase (Promega) and purified using RNA 
Clean & Concentrator-25 (Zymo Research). Non-targeting control (NTC) dsRNA was 
described previously [1]. 
For all RNAi experiments, d.mel-2 cells were plated in 6-well plates with 24 µg 
dsRNA per well. For shorter RNAi experiments (Figures S3.4A-D, 4.1 A-B and 4.4), 1 
million cells were plated with dsRNA, incubated 24 hours, then reporters and effectors 
were transfected with FuGene HD as described above. After 48 hours, cells were 
harvested for luciferase assay, Western blotting, and RNA isolation. For all other RNAi 
experiments, 0.5 million cells were plated and incubated with dsRNAs for 72 hours, then 
reporters and effectors were transfected with FuGene HD as described above. After 48 
hours, cells were harvested for luciferase assay, Western blotting and RNA isolation. 
 
6.4 Reporter gene assays  
D.mel-2 cells were harvested from a 6-well plate and 100 µl of cell culture (~0.5-6 
x105 cells, depending on experimental conditions) was aliquoted into a 96-well plate. 
Luciferase assay was performed using Nano-Glo Dual-Luciferase Reporter Assay 
System (Promega) and a GloMax Discover luminometer (Promega) per manufacturer's 
instructions, except 10 µl/ml of Nluc substrate was used instead of 20 µl/ml. For each 
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sample, percent repression was calculated from the ratios of Nluc/FFluc to control for 
transfection efficiency as previously described [1, 4]. To measure repression by 
endogenous or over-expressed Pum, the Nluc 3xPRE was used. Where indicated the 
Nluc ΔPRE (MCS 3'UTR) served as a control reporter. To measure activity of tethered 
effectors, the Nluc 2xMS2 poly(A) or Nluc 2xMS2 HSL reporters were used. The internal 
control pAC5.1 FFluc 3'UTR poly(A) was used in all reporter experiments. In tethered 
assays, MS2-EGFP served as the negative control for effectors. In experiments analyzing 
full-length Pum, wild type or mutant W783G, the RNA-binding defective mutant Pum (mut 
R7) served as the negative control effector. For experiments measuring activity of 
endogenous Pum, relative response ratio for the Nluc 3xPRE reporter was normalized to 
the Nluc ΔPRE reporter within each RNAi condition. All normalized Relative Response 
Ratio (RRR) values were then expressed as fold change relative to the non-targeting 
control (NTC) negative control RNAi condition. All graphs represent mean values and 
standard error. All results were validated in independent experiments, each of which 
included multiple replicate measurements including four replicates for dual luciferase 
assays and three replicates for Northern blot detection.  
 
6.5 Pum antibody  
A custom anti-Pumilio rabbit polyclonal antibody (Life Technologies) was 
generated using the antigen containing Pum residues 1434-1533, fused to GST, which 
had been expressed and purified from E. coli.  Pum-specific antibodies were antigen-
affinity purified from the resulting serum using a column containing immobilized, 
recombinant, purified Halotag-Pum aa1434-1533 [5]. The Pum antigen sequence was: 
PITVGTGAGGVPAASSAAAVSSGATSASVTACTSGSSTTTTSTTNSLASPTICSVQENG
SAMVVEPSSPDASESSSSVVSGAVNSSLGPIGPPTNGNVVL. This antibody was 
validated using Pum RNAi in d.mel-2 cells (see Figure 4.4). 
 
6.6 Western blotting  
Cell lysates were prepared by adding 100 µl of lysis buffer containing 50 mM Tris-
HCl pH 8.0, 150 mM NaCl, 2x complete Mini, Ethylenediaminetetraacetic acid (EDTA)-
free protease inhibitor cocktail (Roche), and 0.5% Non-Idet P40 (NP40) to cells harvested 
146 
 
by centrifugation from 1 ml of cell culture containing between 0.5 to 6 x106 cells, 
dependent on experimental conditions (over-expression only versus RNAi and over-
expression, respectively). Cells were disrupted for 10 seconds using handheld cell 
disruptor, then centrifuged at 21,100 x g for 10 minutes to pellet debris. Supernatant was 
then collected as the lysate. Protein was quantitated using Lowry DC assay (BioRad) with 
a bovine serum albumin (BSA) standard curve. Lysate was then heated with SDS-PAGE 
loading dye and loaded on 4–20% Mini-PROTEAN TGX precast protein gel (BioRad). For 
the endogenous Pum experiment in Figure 4.4, 30 µg of total cellular protein per lane was 
analyzed alongside PageRuler Prestained Plus Molecular Weight Markers (Thermo 
Fisher). For Figure S3.5A, 20 µg of total protein was loaded. For all other experiments, 
10 µg of total protein was analyzed per lane. Gels were transferred onto Millipore 
Immobilon-P or Immobilon-PSQ (for Pop2 and EGFP detection) Polyvinylidene difluoride 
(PVDF) membrane at 30 V overnight or 65 V for 1.5 hours.  
Pop2 and Ccr4 blots were blocked in 3% BSA made in Tris-buffered saline (TBS) 
(20 mM Tris pH 7.5, 137 mM NaCl, 0.1% Tween 20 and then TBS+BSA was used in all 
subsequent steps. All other blots were blocked with Blotto (5% milk in 1x Phosphate-
buffered Saline (PBS) pH 7.4, containing 10 mM Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl 
and 137 mM NaCl) and 0.1% Tween 20. Blots were blocked either 1 hour at room 
temperature or overnight at 4°C. Primary antibody was used at the dilutions indicated in 
Table 6.3, and incubated with blot either for 1 hour at room temperature or overnight at 
4°C. Blot was then washed three times with Blotto or TBS+BSA for 5 minutes each wash. 
Secondary antibody was added at dilutions indicated in Table 6.3, and incubated for 1 
hour at room temperature. The blot was then washed an additional three times. For rabbit 
anti-V5 antibody, BSA was only used for primary antibody step, and Blotto for all other 
steps. Finally, blots were incubated with either Pierce or Immobilon enhanced 
chemiluminescent (ECL) substrates for 1 min followed by colorimetric and 
chemiluminescent detection using a ChemiDoc Touch imaging system (BioRad). Western 
blot images were processed using Image Lab 5.2.1 (BioRad); to analyze molecular 
weight, colorimetric and chemiluminescent images were merged. Images were exported 
to TIF files and processed for figures using Adobe Creative Suite. In figures, western blot 
147 
 
images from the same antibody, blot and exposure are surrounded by black boxes. In the 
event that lanes were cropped from a blot image, white space is made apparent. 
 
6.7 Immunoprecipitation  
D.mel-2 cells (2 million) were transfected with FuGene HD as described above and 
incubated for 3 days at 25°C to allow protein expression. Cells were lysed with a cell 
disruptor in Flag Buffer A containing 50 mM Tris-HCl pH 8.1, 200 mM NaCl, 1 mM EDTA, 
0.2% Triton X100 and 2x cOmplete Protease Inhibitor Cocktail (from tablets) (Roche) and 
cell debris was removed by centrifugation. Lysates were split into RNase treated (4 Units 
RNase One, Promega) and untreated (120 U  RNasin ribonuclease inhibitor, Promega) 
samples and incubated with 10 µl bed volume of EZview Red anti-FLAG M2 Affinity Gel 
(Sigma) overnight at 4°C. Beads were washed three times with Flag Buffer A, and three 
times with Flag Buffer B containing 50 mM Tris-HCl pH 8.1, 200 mM NaCl, and 1 mM 
EDTA, then resuspended in 60 µl Flag Buffer B. Bound proteins were eluted by heating 
in SDS-PAGE loading dye. Samples were prepared for SDS-PAGE as described above, 
with percentage of input and IP indicated in the Figure 3.3, panel C (top). 
 
6.8 Transcription shut off 
To measure RNA decay rates, a transcription shut off time course was performed. 
For Pum over-expression, 15.8 million d.mel-2 cells were seeded in a T75 flask containing 
15.8 ml of Sf900III media. For RNAi experiments, dsRNA was added to cell dilution to 
final concentration of 12 µg/ml. Cells were transfected using FuGene HD as described 
above (scaled proportionally from 6-well format by surface area) with 23.7 µg of pIZ Pum 
WT or mut R7 and 158 ng of pAc5.4 Nluc 3xNRE reporter. Three days post-transfection, 
transcription was inhibited by addition of Actinomycin D (Sigma) to the medium at a final 
concentration of 5 µg/ml. Prior to drug addition, two milliliters of cell culture was harvested 
(T=0 minutes). RNA was then purified from cells collected at time points including 2.5 ml 
of cell culture at each indicated time point, and 3.6 ml of cell culture at the final time point 





6.9 RNA purification and Northern blotting  
RNA was isolated from d.mel-2 cells using simplyRNA cells low elution volume kit 
and a Maxwell 16 instrument (Promega) following the manufacturer's instructions. RNA 
was quantitated using a NanoDrop One spectrophotometer (Thermo Scientific) and 
integrity was assessed by gel electrophoresis. For Northern blotting, total RNA (10 µg for 
Figures S3.1B, 3.1 and 3.5 transcription shut off experiments, 5 µg for all steady state 
Northern blots) was combined with 0.04 µg/µl Ethidium Bromide in sample buffer (23% 
formamide, 3% formaldehyde, 4.6 mM MOPS pH 7 (3-(N-morpholino)propanesulfonic 
acid), 1.1 mM sodium acetate, and 0.2 mM  EDTA), and loading dye (2.1% glycerol, 4.2 
mM EDTA, and 0.01% Bromophenol Blue and Xylene Cyanol). RNA was electrophoresed 
through a 1% denaturing agarose gel containing 1.48% formaldehyde and 1x MOPS 
buffer with 20 mM MOPS, 5 mM sodium acetate and 1mM EDTA. The gel was then 
blotted onto Immobilon-Ny+ membrane (Millipore) overnight using capillary transfer in 20x 
SSC buffer containing 3 M NaCl and 300 mM Sodium citrate, as previously described.[2] 
The blot was then crosslinked with 120 J/cm2 short wave UV (λ=254 nm) using a CL-1000 
ultraviolet crosslinker (UVP). Blot was either probed immediately or stored at 4°C. 
Transcription templates to produce antisense, radiolabeled RNA probes were 
generated by PCR (GoTaq Master Mix, Promega) using oligonucleotides with a promoter 
for T7 RNA polymerase appended to the reverse strand, described in Table 6.11. RNA 
probes for Northern blotting were generated for Nluc and FFluc by in vitro transcription 
using MAXIscript transcription kit (Thermo-Fisher). Transcription reactions were 
assembled in 25 µl total volume to include 2.5 µl of 10x Transcription Buffer, 1 µg of DNA 
template, 1 µl each of 10 mM ATP/CTP/GTP (0.4 mM each final), 2 µl of 800 Ci/mmol 10 
mCi/ml 12.5 µM UTP α-32P (1 µM, 10-20 µCi final per reaction) (PerkinElmer, see 6.2), 
0.2 µl of 1 mM non-radioactive UTP, and 2 µl enzyme mix containing 60 U T3, 30 U T7 
and 40 U SP6 RNA polymerases. Incubated transcription reactions for 10 min at 37°C. 
Next, 1 µl Turbo DNase (2 U) (Thermo-Fisher) was added to the reactions for 10 min at 
37°C to degrade template DNA. Divalent metal ions were chelated by addition of 1 µl of 
250 mM of EDTA and 250 mM EGTA to reaction. Next the probes were purified by size 
exclusion using a G25 sephadex (GE Life Sciences) spin-column and activity was 
quantitated with a Geiger counter. To detect stable 18S ribosome RNA, and antisense 
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1.7 µg of 18S rRNA deoxy-oligonucleotide probe (see Table 6.1) was phosphorylated 
using 2 µl of 6000 Ci/mmol, 150 mCi/ml, 25 µM ATP γ-32P (2.5 µM final, 25 to 100 µCi 
per reaction) (PerkinElmer) using 40 U of T4 Polynucleotide Kinase (New England 
Biolabs) in a 20 µl reaction incubated at 37°C for 40 minutes. The probe was then purified 
by size exclusion with G25 Sephadex column as described above. 
For anti-sense reporter probes, 2.5-7.5 x 106 total cpm was added to the blot that 
had been pre-hybridized for 45 min at 68°C in 6-8 ml (depending on size of blot) of 
ULTRAhyb hybridization buffer (Invitrogen). The blot was then incubated with probe at 
68°C overnight, washed two times sequentially with 2 ml each of 2x SSC, 0.1% SDS, and 
then two more times with 0.1x SSC, 0.1% SDS at 68°C for 15 minutes each wash. For 
18S rRNA probes, 5-6 x 106 cpm was added to the blot that had been pre-hybridized with 
6-8 ml ULTRAhyb-Oligo hybridization buffer (Invitrogen) at 42°C. The blot was incubated 
with probe overnight and then washed twice with 25 ml 2x SSC containing 0.5% SDS for 
30 minutes each wash at 42°C.  
Blots were then visualized using a Typhoon FLA phosphorimager (GE Life 
Sciences). Image and data analysis was performed using ImageQuant TL software (GE 
Life Sciences). Background signal was subtracted using “Rolling Ball” method. For steady 
state RNA analysis, percent repression was calculated as previously described [1, 4]. In 
tethered function assays, MS2-EGFP served as the negative control for normalization of 
the effectors. In the full-length Pum experiment, the RNA-binding defective mutant, Pum 
mut R7, served as the negative control effector. For the endogenous Pum experiment 
(Figure 4.4), relative response ratio was normalized that of the Nluc ΔPRE within each 
RNAi condition. All normalized values were then expressed at fold change relative to NTC 
negative control. All graphs represent mean values and standard error.  
To measure RNA decay rates, Nluc signal was normalized to stable 18S rRNA 
signal for each sample to adjust for variation in loading and transfer of RNA in each lane. 
Fraction of reporter mRNA remaining at each time point was plotted relative to time in 
minutes after Actinomycin D addition using Graphpad Prism 7 software. Half-lives were 
determined using a minimum of three biological replicates for each time point in each 
condition. Half-lives were calculated using non-linear regression analysis with curve fitting 
to first order exponential decay.  
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6.10 Poly(A) tail analysis  
High resolution Northern blots were performed to measure poly(A) tail length of 
reporter mRNAs. To do so, 3 µg of total RNA was heated at 70°C with 20 pmol of 
antisense Nluc cleavage oligo RA 296 (see Table 6.1) in 30 µl total volume containing 
200 mM KCl and 1 mM EDTA. In control reactions that remove the poly(A) tail (the A0 
control) 1500 ng oligo dT was also added. Reactions were then cooled at room 
temperature for 20 minutes to allow annealing of oligos to RNA. Next, 5 Units of RNase 
H (New England Biolabs) in 20 mM Tris-HCl pH 8.0, 28 mM MgCl2, and 48 U of RNasin 
(Promega) was added and reactions were incubated at 37°C for 1 hour. Next, 60 µl of 60 
mM EDTA (final 30 mM) was added to chelate metal ions, and reactions were incubated 
15 minutes at 37°C. RNA was then purified with Zymo Clean and Concentrator–25 kit, 
per manufacturer's instructions. 1.2 µg of purified RNA in 15 µl total volume was combined 
with 15 µl of RNA loading buffer (88% formamide, 0.025% Bromophenol blue, 0.025% 
Xylene cyanol, 10 mM EDTA, and 0.025% SDS) and heated for 10 minutes at 75°C. RNA 
was then loaded onto a 5% Criterion 1 x Tris-Borate-EDTA (TBE) - 8 M Urea 
Polyacrylamide Gel (BioRad) that had been pre-run to 20-25 mA in 1x TBE buffer (89 mM 
Tris, 89 mM Boric acid and 2 mM EDTA). Electrophoresis was carried out at 200 Volts 
until Xylene Cyanol dye ran off the bottom of the gel. Next, the RNA was transferred onto 
Immobilon-Ny+ Membrane (Millipore) for 45 minutes in 0.5 x TBE Buffer at 60 V at 4°C 
using a Trans-Blot Cell (BioRad). The blot was then crosslinked with 120 J/cm2 short 
wave UV (λ=254) using a CL-1000 Ultraviolet Crosslinker (UVP) and probed with a 2x 
MS2 antisense, radioactive riboprobe complementary to the 3'UTR (see Table 6.1 for 
primers) as described above. 
 
6.11 Reverse Transcription and Quantitative Polymerase Chain Reaction  
RT-qPCR parameters, including primer sequences, are reported according to 
MIQE (minimum information for publication of quantitative real-time PCR experiments) 
guidelines [6] (Tables 6.4 and 6.5). Primer efficiencies were determined for each primer 
set and the proper amplicon size was verified by gel electrophoresis, as reported in Tables 
6.4 and 6.5. Reverse transcription was performed using GoScript Reverse Transcriptase 
(Promega) per manufacturer's instructions. The purified RNA (4 µg) and 500 ng of random 
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hexamers were combined and heated in 10 µl volume of RNase free water at 70 °C for 5 
minutes and on ice for 5 minutes. Then, 10 µl of master mix containing 2x GoScript Buffer 
(1x final), 1 mM dNTPs (0.5 mM final), 4 mM MgCl2 (2 mM final),  20 U of RNAse inhibitors 
and 160 U Reverse Transcriptase (RT) in a 20 µl total reaction volume. RT reaction was 
then incubated at room temperature for 5 minutes, 42 °C for 45 minutes, and 70 °C for 
15 minutes. As a negative control for each primer set, mock “no RT” reaction was 
performed using 1 µg of RNA under identical conditions in the absence of reverse 
transcriptase (all components scaled proportionally). cDNA and no RT reactions were 
then diluted to 10 ng/µl of input RNA. Next, qPCR was performed using GoTaq qPCR 
Master Mix (Promega) with 100 ng of input RNA and 0.1 µM of each primer per reaction 
in 50 µl total volume. In addition, no template reactions were also performed wherein RNA 
was omitted, so as to assess potential false positive signal for each primer set. 
The following cycling parameters were performed using a CFX96 Real-Time PCR 
System thermocycler (BioRad): 1) 95°C for 3 minutes, 2) 95°C for 10 seconds, 3) 65°C 
(for Not1, Not2, Not3, Caf40 Dcp1, and Dcp2 reactions) or 62°C (for Pop2, Ccr4, Not10, 
Not11 and Ge-1 reactions) for 30 seconds, 4) 72°C for 40 seconds, 5) repeat steps 2-4 
for 40 cycles. Melt curve was generated with range 65-95°C at increments of 0.5°C. Data 
were analyzed using Pfaffl method[7], normalizing to the Rpl32 mRNA, with fold change 
calculated relative to the NTC negative control as previously described [1, 4]. 
 
6.12 Generation of transgenic Drosophila melanogaster 
The attB transgene plasmids contain nanos promoter and 5'UTR, Pum transgene 
(Pum TG) ORF, Pum 3'UTR, and the white marker. The pum 3' UTR (1.2 kb + ~600 bp 
downstream sequence to include polyadenylation elements) was amplified from d.mel-2 
genomic DNA (isolated using Promega SV Wizard Genomic DNA kit) using PCR with 
Phusion High Fidelity DNA Polymerase (NEB) and oligos RA 200 and RA 201. The PCR 
product was gel purified using Promega SV Wizard Gel purification and PCR Clean-up 
system; purified product was used in nested PCR for further amplification with Phusion. 
The Pum 3' UTR nested PCR product was then inserted into attB transgene vector via 
NotI and SbfI restriction sites. The Pum transgene ORFs were amplified from pIZ 
plasmids via PCR with Phusion, using reverse primer RA 197 and the appropriate forward 
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primer (Table 6.1). Pum transgene ORF PCR products were inserted into attB transgene 
vector containing Pum 3'UTR via SpeI and AscI restriction sites 
Transgene plasmids containing the white marker were introduced into nos-
phiC31\int.NLS}X; P{CaryP}attP40 Drosophila melanogaster (Bloomington stock center 
#25709; containing attP40 landing site on second chromosome, and PhiC31 integrase on 
the X chromosome) via PhiC31 mediated integration into the attP40 landing site; germline 
injections and initial crosses into the w118 were performed by Rainbow Transgenics. 
Positive transformants were screened for red or orange eye color. Transformant males 
were crossed with virgin females of yw;Pin/CyO balancer line; yw;PumTG/CyO males and 
virign female offspring (orange eyes and curly wing phenotype) were collected and mated 
to produce yw;PumTG/CyO stocks.  
For preparation of ovary lysates, female <1 day old w;PumTG/CyO Drosophila 
melanogaster were fed for 3 days at 25°C in bottles of corn meal agar food, supplemented 
with yeast (as in reference [8]). Ovaries were removed from flies in ice cold PBS (used 
10-22 ovaries per transgene). Ovaries were washed twice in ice-cold PBS, frozen on dry 
ice and stored at -80°C. Ovaries were resuspended in lysis buffer (section 6.6) (5 µl per 
ovary) and disrupted using handheld cell disruptor for 10-15 seconds. Lysates were 
incubated 20 minutes on ice, and centrifuged 5 minutes at 16,000 x g. Supernatant was 
collected as lysate. Western blotting was performed as described in section 6.6. 
 
6.13 Pum and CNOT in vitro pulldown 
Production and purification of Drosophila Pum fragments and human CNOT 
complex, as well as in vitro pulldowns were performed by Chung-Te Chang, Yevgen 
Levdansky, and Eugene Valkov. Plasmids for recombinant Drosophila Pum production 
were generated using Gibson assembly, inserting Pum cDNA sequences into the pnYC-
pM vector linearized with the NdeI restriction enzyme. This yielded Pum fusion constructs 
containing N-terminal Maltose Binding Protein (MBP) and human rhinovirus 3C protease 
site, and a C-terminal Strep II tag. Plasmids were validated using Sanger sequencing. 
E. coli BL21 (DE3) Star cells (Thermo Fisher Scientific) were used to express MBP-
tagged Pum fragments. Bacteria were grown in LB medium at 37°C overnight and lysed 
in lysis buffer comprised of 8 mM Na2HPO4, 137 mM NaCl, 2 mM KH2PO4, 2.7 mM KCl, 
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0.3% (v/v) Tween-20, pH 7.4. The lysates were cleared and incubated for 1 hour with 30 
µl (50% slurry) of Strep-Tactin sepharose resin (IBA). The beads were washed three 
times with lysis buffer and once with binding buffer comprised of 50 mM Tris-HCl (pH 7.5), 
150 mM NaCl. 50 µg of purified human CNOT complex or individual subcomplex modules 
were incubated with the beads for 1 hour. The beads were washed three times with 
binding buffer. The proteins were then eluted in binding buffer containing 2.5 mM D-
desthiobiotin. Purified proteins were separated by SDS-PAGE and visualized with 
Coomassie staining. 
Reconstitution of the full human CNOT complex will be described in Raisch et al.: 
“Reconstitution of recombinant human CCR4-NOT reveals molecular insights into 
regulated deadenylation” (in revision). Briefly, baculovirus containing sequences for each 
member of the NOT1-NOT2-NOT3-CAF40 tetramer was generated using the MultiBac 
system [9, 10]. Bacmid DNA was then transfected into Sf21 insect cells. The tetramer 
was purified using metal affinity purification via an N-terminal decahistidine tag on Not1. 
The CAF1-CCR4a heterodimer was expressed in E. coli BL21 (DE3) Star cells and 
purified via metal affinity purification, size exclusion chromatography and anion exchange. 
The NOT10-NOT11 heterodimer was expressed in E. coli BL21 (DE3) Star cells and 
purified via metal affinity purification and size exclusion chromatography. The full complex 
was then reconstituted using a 1:2:2 molar ratio of tetramer:CAF1-CCR4a:NOT10-
NOT11 and purified using size exclusion chromatography. The CNOT subcomplex 
modules were purified as described in references [11-13]. Stoichiometry and purity of 
complexes was verified using SDS-PAGE and Coomassie staining. 
 
6.14 List of plasmids   
The following plasmids were used in this study. The archive number is listed first, 
followed by the plasmid vector name. 
 
Effectors/Protein expression: 
ACG 864: pIZ Pumilio V5H6  
CAW 003: pIZ Pumilio mut R7 V5H6 
CAW 061: pIZ MS2-EGFP V5H6  
CAW 026: pIZ MS2-Pum N terminus V5H6  
CAW 039: pIZ MS2-RD1 V5H6  
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CAW 053: pIZ MS2-RD2 V5H6 
CAW 048: pIZ MS2-RD3 V5H6  
RMA 053: pIZ MS2-Dcp1 V5H6 
RMA 073: pUbKz 3xFlag Dcp2 E361Q V5H6  
CAW 108: pUbKz 3xFlag  
RMA 109: pIZ Halotag V5 StrepII  
CAW 014: pIZ myc-Pop2 
CAW 268: pIZ myc-Pop2 mutant D53A and E55A 
CAW 028: pIZ MS2-Pum N terminus W783G V5H6 
JBP 002: pIZ Pumilio W783G V5H6 
RMA 116: pUbKz 3xFlag GST V5H6 
CAW 419: pUbKz 3xFlag Pum N terminus V5H6 
CAW 379: pUbKz 3xFlag RBD V5H6 
CAW 214: pUbKz 3xFlag Nanos V5H6 
RMA 106: pUbKz 3xFlag Not2 V5H6 
RMA 107: pUbKz 3xFlag Not3 V5H6 
RMA 009 pIZ RD1-RBD V5H6 
RMA 069 pIZ RD2-RBD V5H6 
CAW 330 pIZ RBD-RD2 V5H6 
RMA 008 pIZ RD3-RBD V5H6 
ACG 866 pIZ RBD V5H6 
CAW 004 pIZ RBD mut R7 V5 H6 
CAW 413 pIZ Pumilio ∆RD1 V5H6 
CAW 415 pIZ Pumilio ∆RD2 V5H6 
CAW 391 pIZ Pumilio ∆RD3 V5H6 
RMA 088 AttB RD1-RBD V5 
RMA 089 AttB RD2-RBD V5 
RMA 90 AttB RD3-RBD V5 
RMA 084 AttB RBD V5 
RMA 083 AttB Pumilio  V5 
RMA 085 AttB Pumilio ∆RD1 V5 
RMA 086 AttB Pumilio ∆RD2 V5 
RMA 087 AttB Pumilio ∆RD3 V5 
CAW 018 pIZ Halotag V6H6 
CAW 225 pIZ HT-Nanos V5H6 
CAW 238 pIZ HT-Nanos Δ376-382 V5H6 
RMA 098 pIZ HT-Nanos I376A V5H6 
RMA 099 pIZ HT-Nanos M378A V5H6 
RMA 100 pIZ HT-Nanos I382A V5H6 
CAW 051 pIZ MS2-PCMa V5H6 
RMA 131 pIZ MS2-PCMa S to A V5H6  
RMA 132 pIZ MS2-PCMa S to D V5H6 
CAW 040 pIZ MS2-PCMa-RD2-PCMb V5H6 
CAW 318 pIZ MS2-PCMa-RD2-PCMb S to A V5H6 
CAW 319 pIZ MS2-PCMa-RD2-PCMb S to D V5H6 
CAW 308 pIZ Pum PCMa-RD2-PCMb Δhypphos V5H6 
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CAW 204 pIZ MS2-Nanos N-terminus V5H6 
 
Reporter plasmids: 
CAW 023: pAc5.1 FFluc min 3'UTR 
pBA 017: pAc5.4 Nluc2 2xMS2  
RMA 078: pAc5.4 Nluc2 2xMS2 HSL 
RMA 097: pAc5.1 Nluc2 3xPRE  
RMA 056: pAc5.4 Nluc2 ΔPRE (MCS 3'UTR) 
CAW 170 pAc5.1 Rnluc hb 3'UTR 
CAW 104 pAc5.1 Rnluc hb NRE1 
CAW 131 pAc5.1 Rnluc hb NRE2 
CAW 106 pAc5.1 Rnluc cycB NRE 
CAW 105 pAc5.1 Rnluc bcd NRE 
CAW 107 pAc5.1 Rnluc hb NRE2 +3G 
CAW 132 pAc5.1 Rnluc hb NRE2 ACA 
 











Table 6.1 List of DNA oligos 
Name Sequence Purpose Section 
CW 115 5'  
CGACGGTACCGGTGAGCAAGGGCGAGGA
GCTG 
Amplify EGFP insert (F), adding KpnI 
and XbaI sites 
Plasmids 
CW116 5'  
GCACTCTAGAGCCTTGTACAGCTCGTCCAT
GCCG 
Amplify EGFP insert (R), adding KpnI 
and XbaI sites 
Plasmids 
RA 102 5'  
GTTGACTAGTATGGCCGACGAGAGCATCA
C 
Amplify Dcp1 insert (F), adding SpeI 
and NotI sites 
Plasmids 
RA 103 5'  
GTTGGCGGCCGCTTTGATATGTGGAGCTG
GAGTCCAG 
Amplify Dcp1 insert (R), adding SpeI 
and NotI sites 
Plasmids 
RA 285 5'  CGGGTGGCTCCAaccggtacgcgtagaatcg Add StrepII tag via inverse PCR (R) Plasmids 
RA 286 5'  
CAATTTGAAAAAtgagtttatctgactaaatcttagtttgtat
tgtcatgt 
Add StrepII tag via inverse PCR (F) Plasmids 
RA 086 5'  
GTTGACTAGTcaaaATGGAAATCGCACCACT
GATCAAT 
Amplify Dcp2 ORF from Dmel-2 cDNA, 




RA 087 5'  
GTTGGCGGCCGCTTAGCAAAACACATTTGC
TATGAAGTTCTT 
Amplify Dcp2 ORF from Dmel-2 cDNA, 
adding SpeI and NotI sites (R) 
Plasmids 




E361Q point mut via Quickchange (F) Plasmids 
RA 167 5'  
CGATTAGGTCCGTGATATCGAACCCGGTCT
GCTCATAAACCTCTCTCGTTGCACAATGGG 
E361Q point mut via Quickchange (R) Plasmids 
AG 784 5'  
tcgagaaaacatgaggatcacccatgtctgcaggtcgactcta
gaaaacatgaggatcacccatgtctgc 
2xMS2 oligo with NotI and XhoI sites to 
insert into pAc5.4 Nluc  
Plasmids 
AG 785 5'  
ggccgcagacatgggtgatcctcatgttttctagagtcgacctg
cagacatgggtgatcctcatgttttc 
2xMS2 oligo with NotI and XhoI sites to 
insert into pAc5.4 Nluc  
Plasmids 
RA 255 5'  
cagattcaatgagataaaattttctgttgccgGTCGACCGA
TGCCCTTGAG 
Insert HSL and HDE via inverse PCR 
(F) 
Plasmids 
RA 256 5' 
gtttgtggtcctgaaaaggaccgattaGCGGCCAGCGG
C 
Insert HSL and HDE via inverse PCR 
(R) 
Plasmids 
RA 214 5'  CTCGAGTTCTAGGCGATCGCTCGAttg Insert XhoI site into pAc5.4 Rnluc, for 
replacing Rnluc with Nluc insert (F) 
Plasmids 
RA 215 5'  TTACTGCTCGTTCTTCAGCACG Insert XhoI site into pAc5.4 Rnluc, for 
replacing Rnluc with Nluc insert (R) 
Plasmids 
CW 578 5' 
GTTGGGTACCaaaATGGTCTTCACACTCGA
AGATTTCGTTG 
Amplify Nluc2 (+PEST) ORF from 
pNLP with KpnI and XhoI sites (F) 
Plasmids 
RA 066 5' 
CCAGCTCGAGTTAGACGTTGATGCGAGCT
GAAGC 
Amplify Nluc2 (+PEST) ORF from 
pNLP with KpnI and XhoI sites (R) 
Plasmids 
CW 033 5' 
gcacaagcttcaaaatggaacaaaaactcatctcagaagag
gatctgAAATGGACAATGCCCTCGGC 
Amplify Pop2 ORF from Dmel-2 cDNA 
adding HindIII site and myc tag F 
Plasmids 
CW 034 5' 
gccctctagacTGAAGCGCTGTTCGTCTCACCG 
Amplify Pop2 ORF from Dmel-2 cDNA 
with XbaI site and stop codon R 
Plasmids 
CW 161 5' 
GTACCACTATGTGGCCATGGCCACCGCGT
TTCCAGGCGTGGTAGC 
Pop2 mutations via Quickchange (F) Plasmids 
CW 162 5' 
GCTACCACGCCTGGAAACGCGGTGGCCAT
GGCCACATAGTGGTAC 
Pop2 mutations via Quickchange (R) Plasmids 
CW 013 5'  
ggatcctaatacgactcactataggGGACACCGAGTT
TCCAGGCG 
Pop2 ORF dsRNA T7 temp (F) 
(Weidmann et al. 2014) 
dsRNA T7 
temps 
CW 014 5'  
ggatcctaatacgactcactataggGAAGAAGGCCAT
GCCCGTCAGC 
Pop2 ORF dsRNA T7 temp (R) 
(Weidmann et al. 2014) 
dsRNA T7 
temps 
RA 299 5'  
ggatcctaatacgactcactatagggTCCAGCACTTGA
ATCGAAGAGC 
Pop2 5'UTR dsRNA T7 temp (F) dsRNA T7 
temps 
RA 300 5'  
ggatcctaatacgactcactatagggGACCGTGTAGGT
TTCGGCTATTTG 
Pop2 5'UTR dsRNA T7 temp (R) dsRNA T7 
temps 
RA 208 5' 
ggatcctaatacgactcactatagggCAAGGACTTCGC
CCTGGATG 
Not1 ORF dsRNA T7 temp (F) dsRNA T7 
temps 
RA 216 5' 
ggatcctaatacgactcactatagggcatttggctgagacaaat
ccgtcg 




RA 210 5'  
ggatcctaatacgactcactatagggCCTATACCACTG
CCAACGGC 
Not2 ORF dsRNA T7 temp (R) dsRNA T7 
temps 
RA 211 5' 
ggatcctaatacgactcactatagggCCGACGTCAGA
GCAATCGG 
Not2 ORF dsRNA T7 temp (F) dsRNA T7 
temps 
RA 202 5'  
ggatcctaatacgactcactatagggGATTGTCAGTTC
AACTCCCAGCA 
Not3 ORF dsRNA T7 temp (F) dsRNA T7 
temps 
RA 203 5'  
ggatcctaatacgactcactatagggGCAGCAAATGCA
ATTGTTGGTGTTG 
Not3 ORF dsRNA T7 temp (R) dsRNA T7 
temps 
CW 065 5'  
ggatcctaatacgactcactataggGCGTCCAGCCGC
TCTCCGTG 
Dcp1 ORF dsRNA T7 temp (F) dsRNA T7 
temps 
CW 066 5'  
ggatcctaatacgactcactataggGATATGTGGAGCT
GGAGTCCAGCAG 
Dcp1 ORF dsRNA T7 temp (R) dsRNA T7 
temps 
CW 067 5'  
ggatcctaatacgactcactataggCCTGCAGCACAT
GCCACAGCC 
Ge-1 ORF dsRNA T7 temp (F) dsRNA T7 
temps 
CW 068 5'  
ggatcctaatacgactcactataggCATTGTGATTGGT
CATGTCAGCGG 
Ge-1 ORF dsRNA T7 temp (R) dsRNA T7 
temps 
RA 084 5'  
ggatcctaatacgactcactataggAAGCGTAGCTTTA
AACCGCCCC 
Dcp2 3'UTR dsRNA T7 temp (F) dsRNA T7 
temps 
RA 085 5'  
ggatcctaatacgactcactataggCTTCACAATCCCA
TTCCCAAGTGG 
Dcp2 3'UTR dsRNA T7 temp (R) dsRNA T7 
temps 
RA 284 5' 
ggatcctaatacgactcactatagggCAACATGCTGAA
CCGCGTAATG 
Ccr4 dsRNA T7 temp (F) dsRNA T7 
temps 
CW 010 5' 
ggatcctaatacgactcactataggCGAACGTATAGTT
GGTGTGCGGCATT 
Ccr4 dsRNA T7 temp (R) dsRNA T7 
temps 
RA 241 5'  gtgtgcatggaacttgatcatccc Not1 qPCR (F) qPCR 
RA 242 5'  cgtgtttgcccagtgacg Not1 qPCR (R) qPCR 
RA 219 5'  GGTGGTAGCTCCCTGGC Not2 qPCR (F) qPCR 
RA 220 5'  CCTGTCCGTAGTTCGCCG Not2 qPCR (R) qPCR 
RA 237 5'  cgacgtctcattgaaacacaaatgg Not3 qPCR (F) qPCR 
RA 238 5'  gctggttaaccaattgcgtgc Not3 qPCR (R) qPCR 
RA 335  5'  GCGTGAGATGTTCTTCGAGGAC Pop2 qPCR (F) qPCR 
RA 336 5'  CTGTTCGTCTCACCGTTGC Pop2 qPCR (R) qPCR 
CW 119 5'  CTCGTCATACTCGGCCTCATGG Ccr4 qPCR (F) qPCR 
CW 120 5'  CGTAAAAATGCAGGCTGGTCG Ccr4 qPCR (R) qPCR 
RA 088 5'  TCAATGAGAACGAAGACCCAGCC Dcp2 qPCR (F) qPCR 
RA 089 5'  ACAGCCGCGTGTACTGGTAGTTG Dcp2 qPCR (R) qPCR 
CW 349 5'  CCAGCCGGCCAGCATATTC Dcp1 qPCR (F) qPCR 
CW350 5'  CACATTGCCGGCCGTTACG Dcp1 qPCR (R) qPCR 
RA 333 5'  CGCGTGAGAGCCAAAACC Ge-1 qPCR (F) qPCR 
RA 334 5'  CTGCAGTTCCATGTTGAGAACG Ge-1 qPCR (R) qPCR 
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RC 133  5'  GCCCAAGGGTATCGACAACA Rpl32 qPCR (internal ctrl) (F) qPCR 
RC 134 5'  GCGCTTGTTCGATCCGTAAC Rpl32 qPCR (internal ctrl) (R) qPCR 
RA 023 5' 
CGGAGAGGGAGCCTGAGAAACGGCTGCCA
CATCTAAGG 
18S oligo for Northern blot Northern 
blotting 
JB 172 5' 
ggatcctaatacgactcactatagggGATGCGAGCTG
AAGCACAAGC 




JB 173 5' CACTCGAAGATTTCGTTGGGGAC Nluc2 template for Northern probe (R) Northern 
blotting 
NB 111 5' CGAGATGAGCGTTCGGCTGGCAGAA FFluc  template for Northern probe (F) Northern 
blotting 
NB 112 5' 
ggatcctaatacgactcactatagggCCGAAGCCGTG
GTGAAATGGCA 








RA 306 5' 
ggatcctaatacgactcactatagggGCGGCCAGCGG
C 








RA 347 5' 
ggatcctaatacgactcactatagggTCATAAGCGTGC
ACGAGATTGC 
Caf40 3'UTR dsRNA T7 temp (F) dsRNA T7 
temps 
RA 348 5' 
ggatcctaatacgactcactatagggCGTATCGTCTGC
TCGAGGTTC 
Caf40 3'UTR dsRNA T7 temp (R) dsRNA T7 
temps 
RA 351 5' GGACAATACACGCGCTCG Caf40 qPCR (F) qPCR 
RA 352 5' CACTGCTTGGTCGACTTGTCC Caf40 qPCR (R) qPCR 
RA 353 5' 
ggatcctaatacgactcactatagggCGGGCGGTCAT
CTATTATCACC 
Not10 3'UTR dsRNA T7 temp (F) dsRNA T7 
temps 
RA 354 5' 
ggatcctaatacgactcactatagggGCATAAGCTGCT
TGGCGG 
Not10 3'UTR dsRNA T7 temp (R) dsRNA T7 
temps 
RA 355 5' CACAAGCGGGCACTATAACCC Not10 qPCR (F) qPCR 
RA 356 5' CCGAGGTTGTAAAGGATCTCGC Not10 qPCR (R) qPCR 
RA 359 5' 
ggatcctaatacgactcactatagggCCCCGCCCCTAA
TGGAC 
Not11 3'UTR dsRNA T7 temp (F) dsRNA T7 
temps 
RA 360 5' 
ggatcctaatacgactcactatagggGATCTCAATGGA
GATGAGAGGATTGC 
Not11 3'UTR dsRNA T7 temp (R) dsRNA T7 
temps 
RA 363 5' GGTCAACCGACTAACCACCTCC Not11 qPCR (F) qPCR 
RA 364 5' GCACCAGGCGAGACTGC Not11 qPCR (R) qPCR 
CW 069 5' 
ggatcctaatacgactcactataggGCGTATGCAGCA
GCTGGGACAG 
pAbp ORF dsRNA T7 temp (F) 
(Weidmann et al. 2014) 
dsRNA T7 
temps 
CW 070 5' 
ggatcctaatacgactcactataggCCTTGCAATTGCT
GTGGAATTGGC 
pAbp ORF dsRNA T7 temp (R) 
(Weidmann et al. 2014) 
dsRNA T7 
temps 
CW 357 5' CGTCGCTCGTTGGGCTATGC pAbp qPCR (F) (Weidmann et al. 
2014) 
qPCR 





CW 037 5' agtctagagggcccgcggttc Inverse cloning MS2-PCMa Plasmids 
CW 076 5' ctctgcaggtgatggttgacgtg Inverse cloning MS2-PCMa Plasmids 
RA 247 5' ccccaagaagccgatcgccaccatggaggatgcg Quikchange PCR for Nos mutagenesis 
(I376A) F 
Plasmids 
RA 248 5' cgcatcctccatggtggcgatcggcttcttgggg Quikchange PCR for Nos mutagenesis 
(I376A) R 
Plasmids 
RA 249 5' agaagccgatcatcaccgcggaggatgcgatcaagg Quikchange PCR for Nos mutagenesis 
(M378A) F 
Plasmids 
RA 250 5' ccttgatcgcatcctccgcggtgatgatcggcttct Quikchange PCR for Nos mutagenesis 
(M378A) R 
Plasmids 
RA 251 5' caccatggaggatgcggccaaggcggaatcgttc Quikchange PCR for Nos mutagenesis 
(I382A) F 
Plasmids 
RA 252 5' gaacgattccgccttggccgcatcctccatggtg Quikchange PCR for Nos mutagenesis 
(I382A) R 
Plasmids 
RA 186 5' 
GTGCGGCCGCACTAGTggcgcgccAGGAAAT
AAC 
Pum transgene 3' UTR F (+ AscI and 
NotI sites) 
Plasmids 
RA 200 5' 
GTCCTGCAGGCAAATGTTCAATGACTGGTA
TCCTTTGC 
Pum transgene 3' UTR R (+ SbfI site) Plasmids 
RA 197 5' 
GTGGCGCGCCTTAcgtagaatcgagaccgaggaga
gg 
Pum transgene ORF for all TG 
plasmids  (+AscI site) R 
Plasmids 
RA 196 5' GTACTAGTcaaaatgaagtttttgggtggtaacgatg Pum transgene ORF for WT, dRD2, 
dRD3, RD1-RBD  (+SpeI site) F 
Plasmids 
RA 243 5' 
GTACTAGTcaaaatgaagaaattgtgggagaaatccg 
Pum transgene ORF for dRD1  (+SpeI 
site) F 
Plasmids 
RA 244 5' GTACTAGTcaaaatggagtcccagccac Pum transgene ORF for RD2-RBD  
(+SpeI site) F 
Plasmids 
RA 245 5' GTACTAGTcaaaatggtgcccccgg Pum transgene ORF for RD3-RBD  
(+SpeI site) F 
Plasmids 






Table 6.2 List of reagents  
Name Manufacturer Catalog # 
cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail Roche 4693159001 
Immobilon-P PVDF transfer membrane Millipore IPVH00010 
Immobilon-PSQ PVDF transfer membrane Millipore ISEQ00010 
Pierce™ ECL Western Blotting Substrate Thermo-Fisher 32106 
Immobilon Western Chemiluminescent HRP Substrate Millipore WBKLS0500 
4–20% Mini-PROTEAN® TGX™ Precast Protein Gel BioRad 4561094 and 4561096 
GoTaq® qPCR Master Mix Promega A6001 
Nano-Glo® Dual-Luciferase® Reporter Assay System Promega N1610 
Ezview™ Red ANTI-FLAG® M2 Affinity Gel Sigma F2426 
HiScribe™ T7 High Yield RNA Synthesis Kit NEB E2040S 
RNA Clean & Concentrator – 25 Zymo Research R1018 
Maxwell® 16 LEV simplyRNA Cells kit Promega AS1270 
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GoScript™ Reverse Transcriptase Promega A5001 
Actinomycin D Sigma A1410 
Immobilon-Ny+ Membrane, charged Nylon, 0.45 µm Millipore INYC00010 
ULTRAhyb™ Ultrasensitive Hybridization Buffer Invitrogen/Thermo-fisher AM8670 
ULTRAhyb™-Oligo Invitrogen/Thermo-fisher AM8663 
Rnase H NEB M0279 
Rnasin® Ribonuclease Inhibitor Promega N2511 
5% Criterion™ TBE-Urea Polyacrylamide Gel BioRad 3450086 
Sephadex G-25 Fine GE Healthcare 17003202 
MAXIscript™ SP6/T7 Transcription Kit Thermo-Fisher AM1320 
UTP, [α-32P]- 800Ci/mmol 10mCi/ml , 250 µCi PerkinElmer BLU007X250UC 
ATP, [γ-32P]- 6000Ci/mmol 150mCi/ml Lead, 1 mCi PerkinElmer NEG035C001MC 
T4 Polynucleotide Kinase NEB M0201S 
T4 DNA Ligase NEB M0202S 
GoTaq® Green Master Mix Promega M712 
PageRuler™ Plus Prestained Protein Ladder, 10 to 250 
kDa 
Thermo-Fisher 26620 
Sf-900™ III SFM Thermo-Fisher 12658-035 
PhosSTOP Sigma-Aldrich 4906837001 
Lambda protein phosphatase NEB P0753S 
 
Table 6.3 List of antibodies 
Name Species Type Company/lab Catalog/ID # Dilution Blotto or BSA 
V5 Mouse Primary Invitrogen R960-25 1:5000 Blotto 
V5 (D3H8Q) Rabbit Primary CST 13202 1:1000  Antibody diluted in 
5% BSA in TBST, 
then blotto used for 
washes and 
secondary 
Not1 Mouse Primary Elmar Wahle CISS 2G5 1:500 Blotto 
Not2 (A) Rabbit Primary Elmar Wahle SA3858 1:1000 Blotto 
Not3 (B) Rabbit Primary Elmar Wahle SA4144 1:333 Blotto 
Pop2 Rabbit Primary Elmar Wahle SA1354 1:500 3% BSA in TBST 
Ccr4 Rabbit Primary Elmar Wahle SA2385 1:500 3% BSA in TBST 
Goat anti-
Mouse HRP 




Goat Secondary CST 7074 1:10,000 Depends on 
primary 
Pumilio Rabbit Primary Aaron 
Goldstrohm 
N/A 1:1000 Blotto 
Actin (C4) Mouse Primary MP Biomedicals 8691001 1:1000 Blotto 
Tubulin 
(DM1A) 
Mouse Primary CST 3873S 1:1000 Blotto 
 
Table 6.4 MIQE checklist 
 
Under Importance column, “E” indicates essential information for MIQE 








control  groups 
E Non-targeting control (NTC, dsRNA against LacZ) versus 
RNAi knockdown of Not1, Not2, Not3, Pop2, Ccr4, Ge-1, 
Dcp1, Dcp2, Caf40, Not10 and Not11 
Number within each 
group 
E 3 biological replicates and 3 technical replicates 
Assay carried out by 
core lab or 
investigator's lab? 
D Investigator's lab 
Acknowledgement of 
authors' contributions  
D   
SAMPLE 
Description E Dmel-2 cells (S2 derivative): knockdown and control samples 
treated with dsRNAs 
Volume/mass of 
sample processed 
D 1 ml Dmel-2 cells (0.5-6 x106 cells) used in RNA isolation 
 Microdissection or 
macrodissection 
E n/a (cell culture) 
Processing procedure E Promega Maxwell SimplyRNA cells kit  
If frozen - how and 
how quickly? 
E cells processed immediately after knockdown incubation using 
Maxwell RSC SimplyRNA Cells kit (Promega), and lysates 
either flash frozen in dry ice/EtOH bath and stored at -80 
degrees C, or immediately used in RNA isolation 
If fixed - with what, how 
quickly? 
E n/a  
Sample storage 
conditions and duration 
(especially for FFPE 
samples) 
E cells processed immediately after knockdown incubation using 
Maxwell RSC SimplyRNA Cells kit (Promega), and lysates 
either flash frozen in dry ice/EtOH bath and stored at -80 
degrees C, or immediately used in RNA isolation 
NUCLEIC ACID EXTRACTION 
Procedure and/or 
instrumentation 
E Maxwell Simply RNA cells (Promega) using Maxwell 16 
instrument 
Name of kit and details 
of any modifications 
E Maxwell Simply RNA cells (Promega) 
Source of additional 
reagents used  
D n/a  
Details of DNase or 
RNAse treatment 
E 10 µl of DnaseI used per sample from kit 
Contamination 
assessment (DNA or 
RNA) 
E NoRT control in qPCR 
Nucleic acid 
quantification  
E Nanodrop One 
Instrument and method E Nanodrop One 
Purity (A260/A280)  D   
Yield D   
RNA integrity 
method/instrument 
E RNA quality evaluated with electrophoresis 
RIN/RQI or Cq of 3' 
and 5' transcripts  
E N/A (used gel electrophoresis) 
Electrophoresis traces D   
Inhibition testing (Cq 
dilutions, spike or 
other)  






E GoScript (Promega) 
Amount of RNA and 
reaction volume 
E 4 µg RNA for RT and 1 µg noRT, 20 µl reaction volume RT 
and 5 µl noRT 
Priming oligonucleotide 
(if using GSP) and 
concentration 
E Random hexamers from 500 ng/µl stock - 50 ng/µl in 
annealing, 25 ng/µl final in 20 µl 
Reverse transcriptase 
and concentration 
E 8 U/µl 




D Promega, catalog #A5004 




Storage conditions of 
cDNA 
D stored at -20°C 
qPCR TARGET INFORMATION 
If multiplex, efficiency 





E Provided in Table 6.5 
Location of amplicon D   
Amplicon length E Provided in Table 6.5 
In silico specificity 
screen (BLAST, etc) 




D   
Sequence alignment D   
Secondary structure 
analysis of amplicon 
D   
Location of each 
primer by exon or 
intron (if applicable) 
E Provided in Table 6.5 
What splice variants 
are targeted? 
E Provided in Table 6.5 
qPCR OLIGONUCLEOTIDES 
Primer sequences E Provided in Table 6.5 
RTPrimerDB 
Identification Number  
D   
Probe sequences D**   










E Standard reaction conditions recommended by GoTaq qPCR 
Master Mix 
Reaction volume and 
amount of cDNA/DNA 
E 50 µl reaction volume, 100ng cDNA per reaction 
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Primer, (probe), Mg++ 
and dNTP 
concentrations 
E 0.1 µM each primer, MgCl2 and dNTP concentration 
proprietary (Promega) 
Polymerase identity 
and concentration  
E GoTaq polymerase (Taq, hot start), concentration proprietary 
(Promega, does not provide Unit definition) 
Buffer/kit identity and 
manufacturer  
E GoTaq qPCR master mix (Promega) 
Exact chemical 
constitution of the 
buffer 
D Exact buffer composition proprietary (Promega) 
Additives (SYBR 
Green I, DMSO, etc.) 



















D Standard curves initially performed with Ta 65°C, then 
gradient or alternative Ta performed if efficiency not between 
85-105% (data not shown) 
Specificity (gel, 
sequence,  melt, or 
digest) 
E Melt curves; amplicons were also evaluated using gel 
electrophoresis 
For SYBR Green I, Cq 
of the NTC 
E Below detection limit (N/A for all primers) 
Standard curves with 
slope and y-intercept 
E Performed standard curves for all primer sets; slope and y-
intercept provided in Table 6.5 
PCR efficiency 
calculated from slope 
E Efficiencies were between 84.7% and 103.9% and are 
provided in Table 6.5 
Confidence interval for 
PCR efficiency or 
standard error 
D   
r2 of standard curve E Provided in Table 6.5 
Linear dynamic range E All measurements made within the linear range of detection 
determined from standard curves 
Cq variation at lower 
limit 
E All assays were performed within the linear range of the 
standard curve for each primer set 
Confidence intervals 
throughout range 
D   
Evidence for limit of 
detection  
E All assays were performed within the linear range of the 
standard curve for each primer set 
If multiplex, efficiency 







E BioRad CFX Manager v 3.1; Fold change calculations done 
manually in Microsoft Excel 
Cq method 
determination 





Results of NTCs  E Below detection limit: Ct was "N/A" for all primer sets 
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Justification of number 
and choice of 
reference genes 




E RNAi conditions normalized to NTC. Fold change calculated 




D 3 biological replicates 
Number and stage (RT 
or qPCR) of technical 
replicates 
E 3 technical replicates, qPCR 
Repeatability (intra-
assay variation) 
E Triplicate measurements (technical reps), 3 independent trials, 
SEM 
Reproducibility (inter-
assay variation, %CV) 
D   
Power analysis D   
Statistical methods for 
result significance 
E Standard t-test (2-tailed, equal variance) 
Software (source, 
version) 
E BioRad CFX Manager v 3.1 






Table 6.5 qPCR primer information 
Gene Efficiency Ta 
(°C) 
ID Amplicon Spec. Slope Y-int. R2 Location Splice 
variants 
Not1 94.4% 65 FBgn0085436 141bp Only Not1 -3.4631 20.156 0.998
6 











-3.2322 23.484 0.987 Amplicon 
spans exon-
exon junction 2 
All 
Not3 94.8% 65 FBgn0033029 150bp Only Not3 -3.4526 21.106 0.999
2 




Pop2 94.5% 62 FBgn0036239 123bp Only Pop2 -3.4609 23.697 0.995
3 
F primer spans 
exon-exon 
junction 3 
A, B and C 





exon junction 4 
A, B, C, E 
and F 




exon junction 3 
All 
From Reference [6]: “MIQE checklist for authors, reviewers and editors. All essential information (E) must be 
submitted with the manuscript.  Desirable information (D) should be submitted if available. If using primers obtained 
from RTPrimerDB, information on qPCR target, oligonucleotides, protocols and validation is available from that 
source. 
*: Assessing the absence of DNA using a no RT assay is essential when first extracting RNA. Once the sample has 
been validated as RDNA-free, inclusion of a no-RT control is desirable, but no longer essential. 
**: Disclosure of the probe sequence is highly desirable and strongly encouraged. However, since not all 
commercial pre-designed assay vendors provide this information, it cannot be an essential requirement. Use of 












Ge-1 98.4% 62 FBgn0283682 113bp Only Ge-1 -3.3601 25.017 0.995
4 







(Ta 65°C)  
62 or 
65 




























Not10 87.10% 62 FBgn0260444 208bp Only Not10 -3.6768 23.233 0.998
5 




Not11 87.20% 62 FBgn0034963 119bp Only Not11 -3.6724 26.9 0.996
7 








exon junction 2 
All 
*no to very low expression of these genes in S2 cells (reference: Flybase) 
†amplicon >500bp 
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Tissue and Developmental Stage-Specific Expression of Deadenylases in 
Drosophila  
 
Pop2 and Ccr4 are expressed throughout development in Drosophila 
melanogaster (Figure A1); mRNA levels of each are roughly equal during early stages, 
with Ccr4 becoming more abundant beginning in the pupal stages and throughout 
adulthood (Flybase; modENCODE data). Tissue-specific RNA-seq (Figure A2, Flybase; 
FlyAtlas and modENCODE data) suggests that these differences may be most apparent 
in the germline, as Ccr4 is nearly six-fold more abundant in the testis. Ccr4 mRNA is more 
abundant than that of Pop2 in the ovary, with a 1.7-fold difference from the microarray 
data (panel A), and 1.2-fold (for virgin female) and 1.4-fold difference (mated female) from 
the RNA-seq data (panel B).  Tissue-specific microarray indicates that Pop2 mRNA is 





























Figure A1: Expression of  Pop2 and Ccr4 deadenylases over development in Drosophila melanogaster. 
Expression of Pop2 and Ccr4 mRNA over development, in Reads per Million Kilobases (RPKM). Graph generated 





Figure A2: Tissue-specific expression of  Pop2 and Ccr4 in Drosophila melanogaster. Expression of Pop2 
and Ccr4 mRNA in specific Drosophila tissues, in Reads per Million Kilobases (RPKM). Graph generated using 





Tissue and Developmental Stage-Specific Expression of Pumilio in Drosophila  
 
The pum mRNA is expressed broadly throughout development in Drosophila 
melanogaster (Figure B1, panel A), with its highest expression being during early 
embryogenesis (0-2 h). Analysis of pum mRNA expression in Drosophila melanogaster 
tissues (Figure B1, panel B) reveals higher pum expression in the developing central 







Figure B1: Developmental and tissue-specific expression of pum mRNA 
(A) Expression of pum mRNA throughout developmental stages in Drosophila from modENCODE RNA-seq 
(accessed from Flybase: https://flybase.org/). Expression data is in RPKM (Reads Per Kilobase of transcript, per 
Million mapped reads). (B) Tissue-specific expression of pum mRNA in Drosophila from modENCODE RNA-seq 
(accessed from Flybase: https://flybase.org/). Expression data is in RPKM (Reads Per Kilobase of transcript, per 





Establishing Transgenic Drosophila Expressing Pum RD Deletions 
 
This aim was done with Dr. Kelsey Hughes (University of Minnesota), in 
collaboration with Dr. Craig Smibert (University of Toronto) 
 
While Pum’s role in early embryogenesis is well established, the function of each 
Pum domain in vivo is not yet understood. While, the pum null embryo lacks abdominal 
segments, this phenotype can be fully rescued with expression of full-length Pum [1], but 
not that of the RBD [2]. This result indicates that the Pum N terminus is needed for 
regulation of hunchback during embryogenesis. Since the RDs confer the regulatory 
activity of the Pum N terminus, their roles in Pum repression activity during 
embryogenesis will be tested. The necessity of each Pum RD will be tested through 
constructs bearing deletions of each individual RD (Figure C1, panel A). In order to test 
whether each RD is sufficient for Pum activity, fusion constructs were made of each RD 
to the RBD (Figure D1, panel B). 
In preliminary experiments using Drosophila d.mel-2 cells, deletion constructs 
repress similarly to full-length Pum (Figure D2). Moreover, the RD-RBD fusions were all 
sufficient to confer repression activity equivalent to full-length Pum, while the RBD alone 
repressed very weakly (Figure D2). Based on these results, I hypothesize that each 
individual RD is sufficient to confer repression, but their activities are redundant.  
It is possible that the difference in regulatory landscape (i.e. expression of 
cofactors) between d.mel-2 cells and the early embryo will have an effect on Pum RD 
activity. Moreover, repression activity could vary by target mRNA; for example, 
hunchback mRNA is regulated by other RBPs which could affect how each RD functions 
in cells versus embryos. Indeed, subtle differences in Pum activity for the deletion 
constructs are observed between the Renilla and Nano luciferase reporters, where the 
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RD1 deletion exhibits impaired repression compared with full-length Pum (Figure D3). 
Thus, it will be necessary to evaluate RD activity in the context of embryogenesis and 
relevant targets. 
Transgenic Drosophila melanogaster were generated using PhiC31 mediated 
integration (Rainbow Transgenics) (see Chapter 6 for details) [3]. Flies carrying 
transgenes were then crossed to stocks carrying a balancer chromosome (Cyo) to 
suppress recombination. Figure D4 shows fly lines that were chosen for further crosses 
based on similar expression of the transgenes. Future work, in collaboration with Dr. Craig 
Smibert, will include crossing these transgenes into a pum loss-of-function mutant 
background. The extent of rescue of embryogenesis will be assessed through the number 





Figure C1 Pum RD transgene constructs 
Schematic of Pum transgene constructs used to study RD function in vivo. (A) Constructs bearing deletions in 
individual RDs to test necessary of each RD. Putative autoregulatory domains are represented by boxes. (B) 










Figure C2: Activity of transgene constructs in d.mel-2 cells on Renilla luciferase reporter 
Transgene constructs were tested in d.mel-2 cells before being subcloned into transgene vectors. (A) Repression 
activity of each construct. Percent repression was calculated based on relative response ratio of Renilla luciferase 
(RnLuc) expression to Firefly luciferase internal control expression. For fusion constructs, repression for each 
construct was normalized to RBD R7 mutant RNA binding negative control (mut R7). For deletion constructs, 
repression was normalized to Pum FL mut R7 (similar to Figure S2.1A). Mean percent repression values and 
standard error for four technical replicates are plotted for each effector.  (B) Western blot expression test of V5-
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Figure C4: Expression of Pum RD fusion and deletion constructs in transgenic Drosophila melanogaster 
Western blot using anti-V5 antibody was used to detect V5-tagged Pum constructs from Drosophila melanogaster 
ovary lysates from Pum transgene/CyO adult females. Tubulin was used as a loading control. 
Figure C3: Activity of deletion constructs on Nano luciferase reporter  
(A) Repression activity of each construct. Percent repression was calculated based on relative response ratio of 
Renilla luciferase (RnLuc) to Firefly luciferase internal control. Effector repression was normalized to Pum mut R7, 
as described in Figure C2. Mean percent repression values and standard error for four technical replicates are 
plotted for each effector. 
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Enriched GO Terms for PRE, BBS and NBS-Containing Messenger RNAs  
 
Table D1: Gene Ontology analysis for PRE, BBS and NBS-containing mRNAs 
Table lists the top 10 enriched Gene Ontology (GO) biological process terms for each 
binding site category of PRE, BBS, BBS-PRE, NBS-rPRE, NBS-PRE, BBS-NBS-rPRE, 
and NRE (BBS-NBS-PRE). GO term analysis was done using DAVID 
(https://david.ncifcrf.gov/). 
 




Transcription Regulation of transcription, DNA 
templated 
163 6.4 5.9E-27 
Transcription, DNA templated 139 5.4 1.1E-18 
Negative regulation of transcription 
from RNAPII promoter 
69 2.7 5.3E-15 
 
Positive regulation of transcription from 
RNAPII promoter 
91 3.6 1.3E-14 
Nervous system Axon guidance 81 3.2 9.0E-16 
Peripheral nervous system 
development 
44 1.7 4.6E-12 
Dendrite morphogenesis 71 2.8 8.5E-11 
Synapse organization* 33 1.3 2.0E-10 
Long-term memory 36 1.4 2.7E-9 
Development Imaginal disc-derived wing 
morphogenesis 
101 4.0 5.5E-22 
BBS 
Transcription Transcription, DNA templated 300 3.3 3.4E-16 
Positive regulation of transcription from 
RNAPII promoter 
192 2.1 6.0E-15 
Regulation of transcription, DNA 
templated 
308 3.4 1.4E-12 
Nervous system Axon guidance 167 1.9 1.4E-19 
Long-term memory 69 0.8 2.6E-11 
Dendrite morphogenesis 151 1.7 3.3E-10 
Neurotransmitter secretion* 81 0.9 3.9E-10 
Development Open tracheal system development 92 1.0 6.5E-11 
Imaginal disc-derived wing 
morphogenesis 
192 2.1 4.7E-20 





Transcription Transcription, DNA-templated 19 10.0 6.1E-6 
Regulation of transcription, DNA 
templated 
15 7.9 1.7E-3 
Negative regulation of gene expression 6 3.2 1.7E-3 
Positive regulation of transcription from 
RNAPII promoter 
10 5.3 5.2E-3 
Negative regulation of transcription 
from RNAPII 
8 4.2 5.3E-3 
Development Open tracheal system development 8 4.2 6.0E-4 
Imaginal disc-derived wing 
morphogenesis 
11 5.8 1.0E-3 
Morphogenesis of a branching 
structure 
3 1.6 4.0E-3 
Signaling Intracellular signal transduction 7 3.7 3.1E-3 
Misc. Molting cycle, chitin-based cuticle* 4 2.1 5.6E-4 
NBS-rPRE 
Transcription Transcription, DNA templated 273 3.9 3.4E-23 
Positive regulation of transcription from 
RNAPII promoter 
177 2.5 2.4E-20 
Regulation of transcription, DNA-
templated 
270 3.9 1.2E-15 
Positive regulation of transcription, 
DNA-templated 
97 1.4 9.5E-14 
Negative regulation of transcription 
from RNAPII promoter 
116 1.7 1.2E-13 
Nervous system Axon guidance 157 2.3 1.3E-25 
Long-term memory 67 1.0 1.7E-15 
Motor neuron axon guidance 61 0.9 8.9E-14 
Development Open tracheal system development 91 1.3 4.8E-18 
Imaginal disc-derived wing 
morphogenesis 
183 2.6 4.3E-29 
NBS-PRE 
Transcription Positive regulation of transcription from 
RNAPII promoter 
49 4.4 2.7E-10 
Negative regulation of transcription 
from RNAPII promoter 
35 3.2 1.3E-8 
Regulation of transcription, DNA 
templated 
64 5.8 1.0E-7 
Regulation of transcription of RNAPII 
promoter 
36 3.2 2.0E-7 
Transcription, DNA-templated 59 5.3 6.3E-7 
Nervous system Axon Guidance 39 3.5 4.0E-8 
Ventral cord development* 23 2.1 4.0E-7 
Motor neuron axon guidance 20 1.8 5.0E-7 
Long-term memory 20 1.8 2.2E-6 
Development Imaginal disc-derived wing 
morphogenesis 
46 4.1 1.6E-9 
BBS-NBS-rPRE 
Transcription Positive regulation of transcription from 
RNAPII promoter 
38 3.8 4.6E-6 
Nervous system Dendrite morphogenesis 36 3.6 1.8E-7 
Locomotor rhythm* 19 1.9 5.3E-7 
Axon guidance 35 3.5 6.3E-7 




Synaptic growth at neuromuscular 
junction* 
14 1.4 3.4E-6 
Long-term memory 18 1.8 1.5E-5 
Development Imaginal disc-derived wing 
morphogenesis 
50 5.0 9.5E-13 
Dorsal closure* 23 2.3 4.9E-6 
Metabolism Regulation of glucose metabolic 
process* 
31 3.1 1.5E-5 
Misc. Protein phosphorylation* 50 5.0 1.9E-9 
NRE 
Transcription Transcription, DNA templated 8 12.3 2.1E-3 
Negative regulation of gene expression 4 6.2 3.1E-3 
Positive regulation of transcription from 
RNAPII promoter 
6 9.2 4.7E-3 
Negative regulation of transcription 
from RNAPII promoter 
5 7.7 5.7E-3 
Development Open tracheal system development 5 7.7 1.4E-3 
Salivary gland development* 3 4.6 7.4E-3 
Epithelial cell migration, open tracheal 
system* 
3 4.6 1.2E-2 
Morphogenesis of a branching 
structure 
2 3.1 3.3E-2 
Zygotic determination of 
anterior/posterior axis, embryo * 
2 3.1 3.8E-2 
Misc. Negative regulation of programmed 
cell death* 
2 3.1 3.3E-2 
 




Independent Experiments for Key Results 
 
 Examples of independent experimental replicates are shown for key experiments 
in which only technical replicates were reported in Chapters 3 and 4. An additional 
independent experiment for Figure 3.2C is included that was performed under different 





Figure E1: The Pop2 subunit of the CNOT complex is necessary for repression by Pum RDs (corresponding 
to Figure 3.2C) 
Left panel: Pop2 RNAi, measuring tethered function of Pum N-terminus and RDs (Same conditions as 3.2C). Right 







Figure E2: Pop2 catalytic activity is necessary for repression by Pum RDs (corresponding to Figure 3.2D) 
Left panel: Rescue of tethered Pum N terminus and RD activity with wild-type Pop2 (same conditions as Figure 
3.2D). Right panel: Rescue of tethered Pum N terminus and RD activity with catalytic mutant of Pop2 (same 






Figure E3: The Not1 scaffold is required for repression activity of Pum RDs. (corresponding to Figure 3.3A) 






Figure E4: Decapping factors contribute to repression by the Pum N terminus (corresponding to Figure 
4.3C) 
Left panel: Decapping knockdown with tethered Pum N-terminus, measuring repression of the Nluc 2xMS2 poly(A) 
reporter (same conditions as Figure 4.3C). Right panel: Decapping knockdown with tethered Pum N-terminus, 
measuring repression of the Nluc 2xMS2 Histone Stem Loop (HSL) reporter (same conditions as Figure 4.3C). 
